

Nephrology and Urology

Denzel Diehl
Jamison Lyles

First Edition, 2012

ISBN 978-81-323-1418-9

© All rights reserved.

Published by:

College Publishing House
4735/22 Prakashdeep Bldg,
Ansari Road, Darya Ganj,
Delhi - 110002
Email: info@wtbooks.com

Table of Contents

Chapter 1 - Nephrology

Chapter 2 - Kidney

Chapter 3 - Acute Kidney Injury

Chapter 4 - Chronic Kidney Disease

Chapter 5 - Urinary Tract Infection

Chapter 6 - Kidney Stone

Chapter 7 - Hematuria

Chapter 8 - Biopsy

Chapter 9 - Angiography

Chapter 10 - Dialysis

Chapter 11 - Kidney Transplantation

Chapter 12 - Urology

Chapter 13 - Urogynecology

Chapter 14 - Development of the Urinary and Reproductive Organs

Chapter 15 - Bladder Cancer

Chapter 16 - Interstitial Cystitis

Chapter 17 - Prostate Cancer

Chapter 18 - Testicular Cancer

Chapter 19 - Hypospadias

Chapter 20 - Vasectomy

Chapter 21 - Vasectomy Reversal

Chapter 22 - Intersex Surgery

Chapter 1

Nephrology

Nephrologist

Occupation

Names	Doctor, Medical Specialist
Type	Specialty
Activity sectors	Medicine

Description

Education required	Doctor of Medicine
Fields of employment	Hospitals, Clinics

Nephrology (from Greek *νεφρός* - *nephros*, "kidney", combined with the suffix *-logy*, "the study of") is a branch of internal medicine and pediatrics dealing with the study of the function and diseases of the kidney.

Scope of the specialty

Nephrology concerns the diagnosis and treatment of kidney diseases, including electrolyte disturbances and hypertension, and the care of those requiring renal replacement therapy, including dialysis and renal transplant patients. Many diseases affecting the kidney are systemic disorders not limited to the organ itself, and may require special treatment. Examples include acquired conditions such as systemic vasculitides (e.g. ANCA vasculitis) and autoimmune diseases (e.g., lupus), as well as congenital or genetic conditions such as polycystic kidney disease.

Training

A nephrologist is a physician who has been trained in the diagnosis and management of kidney disease, by regulating blood pressure, regulating electrolytes, balancing fluids in the body, and administering dialysis. Nephrologists treat many different kidney disorders including acid-base disorders, electrolyte disorders, nephrolithiasis (kidney stones), hypertension (high blood pressure), acute kidney disease and end-stage renal disease. Nephrology is a subspecialty of internal medicine. In the United States, after medical

school nephrologists complete a three year residency in internal medicine followed by a two year (or longer) fellowship in nephrology.

Knowledge of internal medicine is required to obtain certification. To become a nephrologist requires many years of school and training. Nephrologists also must be approved by the board. To be approved, the physician must fulfill the requirements for education and training in nephrology in order to qualify to take the board's examination. If a physician passes the examination, then he or she can become a nephrology specialist. Typically, nephrologists also need two to three years of training in an ACGME or AOA accredited fellowship in nephrology.

Information that a nephrologist learns in training are fluid and acid base and electrolyte physiology, medical management of acute and chronic renal failure, glomerular and vascular disorders, tubular/interstitial disorders, mineral metabolism, clinical pharmacology, hypertension, epidemiology, and nutrition. Procedures a nephrologist may learn in a training program include native and transplant kidney biopsies, ultrasound guidance, placement of temporary dialysis catheters, placement of tunneled hemodialysis catheters and placement of peritoneal dialysis catheters. Nearly all programs train nephrologists in continuous renal replacement therapy; fewer than half train in the provision of plasmapheresis. Once training is satisfactorily completed, the physician is eligible to take the ABIM or AOBIM nephrology examination. Subspecialties within nephrology include interventional nephrology, dialytician, and transplant nephrology.

Only pediatric trained physicians are able to train in pediatric nephrology, and internal medicine (adult) trained physicians may enter general (adult) nephrology fellowships. Physicians that achieved training in both medicine and pediatrics may subspecialize in both adult and pediatric nephrology.

Conditions requiring a nephrologist

Patients are referred to nephrology specialists for various reasons, such as:

- Acute renal failure, a sudden loss of renal function
- Chronic kidney disease, declining renal function, usually with an inexorable rise in creatinine.
- Hematuria, blood in the urine
- Proteinuria, the loss of protein especially albumin in the urine
- Kidney stones, usually only recurrent stone formers.
- Chronic or recurrent urinary tract infections
- Hypertension that has failed to respond to multiple forms of anti-hypertensive medication or could have a secondary cause
- Electrolyte disorders or acid/base imbalance

Urologists are surgical specialists of the urinary tract. They are involved in renal diseases that might be amenable to surgery:

- Diseases of the Bladder and prostate such as malignancy, stones, or obstruction of the urinary tract.

Diagnosis

As with the rest of medicine, important clues as to the cause of any symptom are gained in the history and physical examination.

Laboratory tests are almost always aimed at: urea, creatinine, electrolytes, and urinalysis, which is frequently the key test in suggesting a diagnosis.

More specialized tests can be ordered to discover or link certain systemic diseases to kidney failure such as hepatitis b or hepatitis c, lupus serologies, paraproteinemias such as amyloidosis or multiple myeloma or various other systemic diseases that lead to kidney failure. Collection of a 24-hour sample of urine can give valuable information on the filtering capacity of the kidney and the amount of protein loss in some forms of kidney disease. However, 24-hour urine samples have recently, in the setting of chronic renal disease, been replaced by spot urine ratio of protein and creatinine.

Other tests often performed by nephrologists are:

- Renal biopsy, to obtain a *tissue diagnosis* of a disorder when the exact nature or stage remains uncertain.;
- Ultrasound scanning of the urinary tract and occasionally examining the renal blood vessels;
- CT scanning when mass lesions are suspected or to help diagnosis nephrolithiasis;
- Scintigraphy (nuclear medicine) for accurate measurement of renal function (rarely done), and MAG3 scans for diagnosis of renal artery disease or 'split function' of each kidney;
- Angiography or Magnetic resonance imaging angiography when the blood vessels might be affected

Therapy

Many kidney diseases are treated with medication, such as steroids, DMARDs (disease-modifying antirheumatic drugs), antihypertensives (many kidney diseases feature hypertension). Often erythropoietin and vitamin D treatment is required to replace these two hormones, the production of which stagnates in chronic kidney disease.

When chronic kidney disease progresses to stage five, dialysis or transplant is required.

Sub-specialties within nephrology include interventional nephrologists who focus on access placement and maintenance, a dialytician who focus upon ordering dialysis for patients, and transplant nephrologists who focus on the acute or sub-acute monitoring of immunosuppression in the transplant patient.


If patients proceed to transplant, nephrologists will continue to follow patients to monitor the immunosuppressive regimen and watch for the infection that can occur post transplant.

Organizations

The International Society of Nephrology is the largest global society representing medical professionals engaged in advancing kidney care worldwide. In the USA, the National Kidney Foundation is a national organization representing patients and professionals who treat kidney diseases. Founded in 1966, the American Society of Nephrology (ASN) is the world's largest professional society devoted to the study of kidney disease. In the United Kingdom, the National Kidney Federation represents patients, and the Renal Association represents renal physicians and works closely with the National Service Framework for kidney disease. The Renal Support Network (RSN) is a nonprofit, patient-focused, patient-run organization that provides non-medical services to those affected by chronic kidney disease (CKD). The American Association of Kidney Patients (AAKP) is a non-profit, patient-centric group focused on improving the health and well-being of CKD and dialysis patients.

Chapter 2

Kidney



Human kidneys viewed from behind with spine removed



Lamb kidneys

Latin	<i>ren</i>
Artery	renal artery
Vein	renal vein
Nerve	renal plexus


The **kidneys** are organs with several functions. They are seen in many types of animals, including vertebrates and some invertebrates. They are an essential part of the urinary system and also serve homeostatic functions such as the regulation of electrolytes, maintenance of acid-base balance, and regulation of blood pressure. They serve the body as a natural filter of the blood, and remove wastes which are diverted to the urinary bladder. In producing urine, the kidneys excrete wastes such as urea and ammonium; the kidneys also are responsible for the reabsorption of water, glucose, and amino acids. The kidneys also produce hormones including calcitriol, renin, and erythropoietin.

Located at the rear of the abdominal cavity in the retroperitoneum, the kidneys receive blood from the paired renal arteries, and drain into the paired renal veins. Each kidney excretes urine into a ureter, itself a paired structure that empties into the urinary bladder.

Renal physiology is the study of kidney function, while nephrology is the medical specialty concerned with kidney diseases. Diseases of the kidney are diverse, but individuals with kidney disease frequently display characteristic clinical features. Common clinical conditions involving the kidney include the nephritic and nephrotic syndromes, renal cysts, acute kidney injury, chronic kidney disease, urinary tract infection, nephrolithiasis, and urinary tract obstruction. Various cancers of the kidney exist; the most common adult renal cancer is renal cell carcinoma. Cancers, cysts, and some other renal conditions can be managed with removal of the kidney, or nephrectomy. When renal function, measured by glomerular filtration rate, is persistently poor, dialysis and kidney transplantation may be treatment options. Although they are not severely harmful, kidney stones can be a pain and a nuisance. The removal of kidney stones includes sound wave treatment, which breaks up the stones into smaller pieces which are then passed through the urinary tract. One common symptom of kidney stones is a sharp pain in the medial/lateral segments of the lower back.

Anatomy


Location



Surface projections of the organs of the trunk, showing kidneys at the level of T12 to L3

In humans the kidneys are located in the abdominal cavity, more specifically in the paravertebral gutter and lie in a retroperitoneal position at a slightly oblique angle. There are two, one on each side of the spine. The asymmetry within the abdominal cavity caused by the liver typically results in the right kidney being slightly lower than the left, and left kidney being located slightly more medial than the right. The left kidney is approximately at the vertebral level T12 to L3, and the right slightly lower. The right kidney sits just below the diaphragm and posterior to the liver, the left below the diaphragm and posterior to the spleen. Resting on top of each kidney is an adrenal gland. The upper (cranial) parts of the kidneys are partially protected by the eleventh and twelfth ribs, and each whole kidney and adrenal gland are surrounded by two layers of fat (the perirenal and pararenal fat) and the renal fascia. Each adult kidney weighs between 125 and 170 grams in males and between 115 and 155 grams in females. The left kidney is typically slightly larger than the right.

Structure



1. Renal pyramid • 2. Interlobular artery • 3. Renal artery • 4. Renal vein • 5. Renal hilum • 6. Renal pelvis • 7. Ureter • 8. Minor calyx • 9. Renal capsule • 10. Inferior renal capsule • 11. Superior renal capsule • 12. Interlobular vein • 13. Nephron • 14. Minor calyx • 15. Major calyx • 16. Renal papilla • 17. Renal column

The kidney has a bean-shaped structure, each kidney has concave and convex surfaces. The concave surface, the renal hilum, is the point at which the renal artery enters the organ, and the renal vein and ureter leave. The kidney is surrounded by tough fibrous tissue, the renal capsule, which is itself surrounded by perinephric fat, renal fascia (of Gerota) and paranephric fat. The anterior (front) border of these tissues is the peritoneum, while the posterior (rear) border is the transversalis fascia.


The superior border of the right kidney is adjacent to the liver; and the spleen, for the left border. Therefore, both move down on inhalation.

The kidney is approximately 11–14 cm in length, 6 cm wide and 4 cm thick.

The substance, or parenchyma, of the kidney is divided into two major structures: superficial is the renal cortex and deep is the renal medulla. Grossly, these structures take the shape of 8 to 18 cone-shaped renal lobes, each containing renal cortex surrounding a portion of medulla called a renal pyramid (of Malpighi). Between the renal pyramids are projections of cortex called renal columns (of Bertin). Nephrons, the urine-producing functional structures of the kidney, span the cortex and medulla. The initial filtering portion of a nephron is the renal corpuscle, located in the cortex, which is followed by a renal tubule that passes from the cortex deep into the medullary pyramids. Part of the renal cortex, a medullary ray is a collection of renal tubules that drain into a single collecting duct.

The tip, or papilla, of each pyramid empties urine into a minor calyx, minor calyces empty into major calyces, and major calyces empty into the renal pelvis, which becomes the ureter.

Blood supply



3D-rendered computed tomography, showing renal arteries and veins.


The kidneys receive blood from the renal arteries, left and right, which branch directly from the abdominal aorta. Despite their relatively small size, the kidneys receive approximately 20% of the cardiac output.

Each renal artery branches into segmental arteries, dividing further into interlobar arteries which penetrate the renal capsule and extend through the renal columns between the renal pyramids. The interlobar arteries then supply blood to the arcuate arteries that run through the boundary of the cortex and the medulla. Each arcuate artery supplies several interlobular arteries that feed into the afferent arterioles that supply the glomeruli.


The **interstitium** (or **interstitium**) is the functional space in the kidney beneath the individual filters (glomeruli) which are rich in blood vessels. The interstitium absorbs fluid recovered from urine. Various conditions can lead to scarring and congestion of this area, which can cause kidney dysfunction and failure.

After filtration occurs the blood moves through a small network of venules that converge into interlobular veins. As with the arteriole distribution the veins follow the same pattern, the interlobular provide blood to the arcuate veins then back to the interlobar veins which come to form the renal vein exiting the kidney for transfusion for blood.

Histology



Microscopic photograph of the renal medulla



Microscopic photograph of the renal cortex

Renal histology studies the structure of the kidney as viewed under a microscope. Various distinct cell types occur in the kidney, including:

- Kidney glomerulus parietal cell
- Kidney glomerulus podocyte
- Kidney proximal tubule brush border cell
- Loop of Henle thin segment cell
- Thick ascending limb cell
- Kidney distal tubule cell
- Kidney collecting duct cell
- Interstitial kidney cells

Innervation

The kidney and nervous system communicate via the renal plexus, whose fibers course along the renal arteries to reach the kidney. Input from the sympathetic nervous system triggers vasoconstriction in the kidney, thereby reducing renal blood flow. The kidney is not thought to receive input from the parasympathetic nervous system. Sensory input from the kidney travels to the T10-11 levels of the spinal cord and is sensed in the corresponding dermatome. Thus, pain in the flank region may be referred from the kidney.

Functions

The kidney participates in whole-body homeostasis, regulating acid-base balance, electrolyte concentrations, extracellular fluid volume, and regulation of blood pressure. The kidney accomplishes these homeostatic functions both independently and in concert with other organs, particularly those of the endocrine system. Various endocrine hormones coordinate these endocrine functions; these include renin, angiotensin II, aldosterone, antidiuretic hormone, and atrial natriuretic peptide, among others.

Many of the kidney's functions are accomplished by relatively simple mechanisms of filtration, reabsorption, and secretion, which take place in the nephron. Filtration, which takes place at the renal corpuscle, is the process by which cells and large proteins are filtered from the blood to make an ultrafiltrate that will eventually become urine. The kidney generates 180 liters of filtrate a day, while reabsorbing a large percentage, allowing for only the generation of approximately 2 liters of urine. Reabsorption is the transport of molecules from this ultrafiltrate and into the blood. Secretion is the reverse process, in which molecules are transported in the opposite direction, from the blood into the urine.

Excretion of wastes

The kidneys excrete a variety of waste products produced by metabolism. These include the nitrogenous wastes urea, from protein catabolism, and uric acid, from nucleic acid metabolism.

Acid-base homeostasis

Two organ systems, the kidneys and lungs, maintain acid-base homeostasis, which is the maintenance of pH around a relatively stable value. The kidneys contribute to acid-base homeostasis by regulating bicarbonate (HCO_3^-) concentration. The kidneys have two important roles in the maintaining of the acid-base balance: to reabsorb bicarbonate from and to excrete hydrogen ions into urine

Osmolality regulation

Any significant rise in plasma osmolality is detected by the hypothalamus, which communicates directly with the posterior pituitary gland. An increase in osmolality causes the gland to secrete antidiuretic hormone (ADH), resulting in water reabsorption by the kidney and an increase in urine concentration. The two factors work together to return the plasma osmolality to its normal levels.

ADH binds to principal cells in the collecting duct that translocate aquaporins to the membrane allowing water to leave the normally impermeable membrane and be reabsorbed into the body by the vasa recta, thus increasing the plasma volume of the body.

There are two systems that create a hyperosmotic medulla and thus increase the body plasma volume: Urea recycling and the 'single effect.'

Urea is usually excreted as a waste product from the kidneys. However, when plasma blood volume is low and ADH is released the aquaporins that are opened are also permeable to urea. This allows urea to leave the collecting duct into the medulla creating a hyperosmotic solution that 'attracts' water. Urea can then re-enter the nephron and be excreted or recycled again depending on whether ADH is still present or not.

The 'Single effect' describes the fact that the ascending thick limb of the loop of Henle is not permeable to water but is permeable to NaCl. This means that a countercurrent system is created whereby the medulla becomes increasingly concentrated setting up an osmotic gradient for water to follow should the aquaporins of the collecting duct be opened by ADH.

Blood pressure regulation

Long-term regulation of blood pressure predominantly depends upon the kidney. This primarily occurs through maintenance of the extracellular fluid compartment, the size of which depends on the plasma sodium concentration. Although the kidney cannot directly sense blood pressure, changes in the delivery of sodium and chloride to the distal part of the nephron alter the kidney's secretion of the enzyme renin. When the extracellular fluid compartment is expanded and blood pressure is high, the delivery of these ions is increased and renin secretion is decreased. Similarly, when the extracellular fluid compartment is contracted and blood pressure is low, sodium and chloride delivery is decreased and renin secretion is increased in response.

Renin is the first in a series of important chemical messengers that comprise the renin-angiotensin system. Changes in renin ultimately alter the output of this system, principally the hormones angiotensin II and aldosterone. Each hormone acts via multiple mechanisms, but both increase the kidney's absorption of sodium chloride, thereby expanding the extracellular fluid compartment and raising blood pressure. When renin levels are elevated, the concentrations of angiotensin II and aldosterone increase, leading to increased sodium chloride reabsorption, expansion of the extracellular fluid compartment, and an increase in blood pressure. Conversely, when renin levels are low, angiotensin II and aldosterone levels decrease, contracting the extracellular fluid compartment, and decreasing blood pressure.

Hormone secretion

The kidneys secrete a variety of hormones, including erythropoietin, and the enzyme renin. Erythropoietin is released in response to hypoxia (low levels of oxygen at tissue level) in the renal circulation. It stimulates erythropoiesis (production of red blood cells) in the bone marrow. Calcitriol, the activated form of vitamin D, promotes intestinal absorption of calcium and the renal reabsorption of phosphate. Part of the renin-

angiotensin-aldosterone system, renin is an enzyme involved in the regulation of aldosterone levels.

Development

The mammalian kidney develops from intermediate mesoderm. Kidney development, also called *nephrogenesis*, proceeds through a series of three successive phases, each marked by the development of a more advanced pair of kidneys: the pronephros, mesonephros, and metanephros.

Evolutionary adaptation

Kidneys of various animals show evidence of evolutionary adaptation and have long been studied in ecophysiology and comparative physiology. Kidney morphology, often indexed as the relative medullary thickness, is associated with habitat aridity among species of mammals.

Etymology

Medical terms related to the kidneys commonly use terms such as *renal* and the prefix *nephro-*. The adjective *renal*, meaning related to the kidney, is from the Latin *rēnēs*, meaning kidneys; the prefix *nephro-* is from the Ancient Greek word for kidney, *nephros* (*νεφρός*). For example, surgical removal of the kidney is a *nephrectomy*, while a reduction in kidney function is called *renal dysfunction*.


Diseases and disorders

Congenital

- Congenital hydronephrosis
- Congenital obstruction of urinary tract
- Duplex kidneys, or double kidneys, occur in approximately 1% of the population. The normally cause no complications, but, occasionally, can cause urine infections.
- Duplicated ureter occurs in approximately one in 100 live births
- Horseshoe kidney occurs in approximately one in 400 live births
- Polycystic kidney disease
 - Autosomal dominant polycystic kidney disease afflicts patients later in life. Approximately one in 1000 people will develop this condition
 - Autosomal recessive polycystic kidney disease is far less common, but more severe, than the dominant condition. It is apparent *in utero* or at birth.
- Renal agenesis. Failure of one kidney to form occurs in approximately one in 750 live births. Failure of both kidneys to form is invariably fatal.
- Renal dysplasia
- Unilateral small kidney

- Multicystic dysplastic kidney occurs in approximately one in every 2400 live births
- Ureteropelvic Junction Obstruction or UPJO; although most cases appear congenital, some appear to be an acquired condition

Acquired



Drawing of an enlarged kidney by John Hunter

- Diabetic nephropathy
- Glomerulonephritis
- Hydronephrosis is the enlargement of one or both of the kidneys caused by obstruction of the flow of urine.
- Interstitial nephritis


- Kidney stones (nephrolithiasis) are a relatively common and particularly painful disorder.

- Kidney tumors
 - Wilms tumor
 - Renal cell carcinoma
- Lupus nephritis
- Minimal change disease
- In nephrotic syndrome, the glomerulus has been damaged so that a large amount of protein in the blood enters the urine. Other frequent features of the nephrotic syndrome include swelling, low serum albumin, and high cholesterol.
- Pyelonephritis is infection of the kidneys and is frequently caused by complication of a urinary tract infection.
- Renal failure
 - Acute renal failure
 - Stage 5 Chronic Kidney Disease

Kidney failure

Generally, humans can live normally with just one kidney, as one has more functioning renal tissue than is needed to survive. Only when the amount of functioning kidney tissue is greatly diminished will chronic kidney disease develop. Renal replacement therapy, in the form of dialysis or kidney transplantation, is indicated when the glomerular filtration rate has fallen very low or if the renal dysfunction leads to severe symptoms.

In other animals



A pig's kidney opened

In the majority of vertebrates, the mesonephros persists into the adult, albeit usually fused with the more advanced metanephros; only in amniotes is the mesonephros restricted to the embryo. The kidneys of fish and amphibians are typically narrow, elongated organs, occupying a significant portion of the trunk. The collecting ducts from each cluster of nephrons usually drain into an *archinephric duct*, which is homologous with the vas deferens of amniotes. However, the situation is not always so simple; in cartilaginous fish and some amphibians, there is also a shorter duct, similar to the amniote ureter, which drains the posterior (metanephric) parts of the kidney, and joins with the archinephric duct at the bladder or cloaca. Indeed, in many cartilaginous fish, the anterior portion of the kidney may degenerate or cease to function altogether in the adult.

In the most primitive vertebrates, the hagfish and lampreys, the kidney is unusually simple: it consists of a row of nephrons, each emptying directly into the archinephric duct. Invertebrates may possess excretory organs that are sometimes referred to as "kidneys", but, even in *Amphioxus*, these are never homologous with the kidneys of vertebrates, and are more accurately referred to by other names, such as nephridia.

The kidneys of reptiles consist of a number of lobules arranged in a broadly linear pattern. Each lobule contains a single branch of the ureter in its centre, into which the collecting ducts empty. Reptiles have relatively few nephrons compared with other amniotes of a similar size, possibly because of their lower metabolic rate.

Birds have relatively large, elongated kidneys, each of which is divided into three or more distinct lobes. The lobes consist of several small, irregularly arranged, lobules, each centred on a branch of the ureter. Birds have small glomeruli, but about twice as many nephrons as similarly sized mammals.

The human kidney is fairly typical of that of mammals. Distinctive features of the mammalian kidney, in comparison with that of other vertebrates, include the presence of the renal pelvis and renal pyramids, and of a clearly distinguishable cortex and medulla. The latter feature is due to the presence of elongated loops of Henle; these are much shorter in birds, and not truly present in other vertebrates (although the nephron often has a short *intermediate segment* between the convoluted tubules). It is only in mammals that the kidney takes on its classical "kidney" shape, although there are some exceptions, such as the multilobed reticulate kidneys of cetaceans.

History

The Latin term *renes* is related to the English word "reins", a synonym for the kidneys in Shakespearean English (e.g. *Merry Wives of Windsor* 3.5), which was also the time the King James Version was translated. Kidneys were once popularly regarded as the seat of the conscience and reflection, and a number of verses in the Bible (e.g. Ps. 7:9, Rev. 2:23) state that God searches out and inspects the kidneys, or "reins", of humans. Similarly, the Talmud (*Berakhoth* 61.a) states that one of the two kidneys counsels what is good, and the other evil.

Animal kidneys as food




Hökarpanna, Swedish pork and kidney stew

The kidneys of animals can be cooked and eaten by humans (along with other offal).

Kidneys are usually grilled or sautéed, but in more complex dishes they are stewed with a sauce that will improve their flavor. In many preparations, kidneys are combined with pieces of meat or liver, as in mixed grill or *meurav Yerushalmi*. Among the most reputed kidney dishes, the British steak and kidney pie, the Swedish *hökarpanna* (pork and kidney stew), the French *rognons de veau sauce moutarde* (veal kidneys in mustard sauce) and the Spanish *riñones al Jerez* (kidneys stewed in sherry sauce), deserve special mention.

Chapter 3

Acute Kidney Injury



Pathologic kidney specimen showing marked pallor of the cortex, contrasting to the darker areas of surviving medullary tissue. The patient died with acute kidney injury.

ICD-10	N17.
ICD-9	584
DiseasesDB	11263
MedlinePlus	000501
eMedicine	med/1595
MeSH	D007675

Acute kidney injury (AKI), previously called **acute renal failure (ARF)**, is a rapid loss of kidney function. Its causes are numerous and include low blood volume, exposure to toxins, and urinary obstruction (e.g. prostate enlargement). AKI is diagnosed on the basis of clinical history, such as decreased urine production, and characteristic laboratory

findings, such as elevated blood urea nitrogen and creatinine. Depending on its severity, AKI may lead to a number of complications, including metabolic acidosis, high potassium levels, uremia, changes in body fluid balance, and effects to other organ systems. Management includes supportive care, such as renal replacement therapy, as well as treatment of the underlying disorder.

Epidemiology

Acute kidney injury is common among hospitalized patients. It affects some 3-7% of patients admitted to the hospital and approximately 25-30% of patients in the intensive care unit.

Causes

Classic laboratory findings in AKI

Type	U_{Osm}	U_{Na}	Fe_{Na}	BUN/Cr
Prerenal	>500	<10	<1%	>20
Intrinsic	<350	>20	>2%	<15
Postrenal	<350	>40	>4%	>15

The myriad causes of acute kidney injury are commonly categorised into *prerenal*, *intrinsic*, and *postrenal*.

Prerenal

Prerenal causes of AKI are those that decrease effective blood flow to the kidney. These include systemic causes, such as low blood volume, low blood pressure, and heart failure, as well as local changes to the blood vessels supplying the kidney. The latter include renal artery stenosis, which is a narrowing of the renal artery that supplies the kidney, and renal vein thrombosis, which is the formation of a blood clot in the renal vein that drains blood from the kidney. Renal ischaemia ultimately results in functional disorder, depression of GFR, or both. These causes the inadequate cardiac output and hypovolemia or vascular diseases causing reduced perfusion of both kidneys.

Intrinsic

Sources of damage to the kidney itself are dubbed *intrinsic*. Intrinsic AKI can be due to damage to the glomeruli, renal tubules, or interstitium. Common causes of each are glomerulonephritis, acute tubular necrosis (ATN), and acute interstitial nephritis (AIN), respectively.

Postrenal

Postrenal AKI is a consequence of urinary tract obstruction. This may be related to benign prostatic hyperplasia, kidney stones, obstructed urinary catheter, bladder stone,

bladder, ureteral or renal malignancy. It is useful to perform a bladder scan or a post void residual to rule out urinary retention. In post void residual, a catheter is inserted immediately after urinating to measure fluid still in the bladder. 50-100ml suggests neurogenic bladder. A renal ultrasound will demonstrate hydronephrosis if present. A CT scan of the abdomen will also demonstrate bladder distension or hydronephrosis, however, in case of acute renal failure, the use of IV contrast is contraindicated. On the basic metabolic panel, the ratio of BUN to creatinine may indicate post renal failure.

Diagnosis

Acute kidney injury is diagnosed on the basis of clinical history and laboratory data. A diagnosis is made when there is rapid reduction in kidney function, as measured by serum creatinine, or based on a rapid reduction in urine output, termed oliguria.

Definition

Introduced by the Acute Kidney Injury Network (AKIN), specific criteria exist for the diagnosis of AKI:

1. Rapid time course (less than 48 hours)
2. Reduction of kidney function
 - Rise in serum creatinine
 - Absolute increase in serum creatinine of ≥ 0.3 mg/dl (≥ 26.4 $\mu\text{mol/l}$)
 - Percentage increase in serum creatinine of $\geq 50\%$
 - Reduction in urine output, defined as < 0.5 ml/kg/hr for more than 6 hours

Staging

The *RIFLE criteria*, proposed by the Acute Dialysis Quality Initiative (ADQI) group, aid in the staging of patients with AKI:

- Risk: serum creatinine increased 1.5 times or urine production of < 0.5 ml/kg for 6 hours
- Injury: doubling of creatinine or urine production < 0.5 ml/kg for 12 hours
- Failure: tripling of creatinine or creatinine > 355 $\mu\text{mol/l}$ (with a rise of > 44) (> 4 mg/dl) OR urine output below 0.3 ml/kg for 24 hours
- Loss: persistent AKI or complete loss of kidney function for more than 4 weeks
- End-stage renal disease: complete loss of kidney function for more than 3 months

Further testing

Once the diagnosis of AKI is made, further testing is often required to determine the underlying cause. These may include urine sediment analysis, renal ultrasound and/or kidney biopsy. Indications for renal biopsy in the setting of AKI include:

1. Unexplained AKI

2. AKI in the presence of the nephritic syndrome
3. Systemic disease associated with AKI

Treatment

The management of AKI hinges on identification and treatment of the underlying cause. In addition to treatment of the underlying disorder, management of AKI routinely includes the avoidance of substances that are toxic to the kidneys, called nephrotoxins. These include NSAIDs such as ibuprofen, iodinated contrasts such as those used for CT scans, and others.

Monitoring of renal function, by serial serum creatinine measurements and monitoring of urine output, is routinely performed. In the hospital, insertion of a urinary catheter helps monitor urine output and relieves possible bladder outlet obstruction, such as with an enlarged prostate.

Specific therapies

In prerenal AKI without fluid overload, administration of intravenous fluids is typically the first step to improve renal function. Volume status may be monitored with the use of a central venous catheter to avoid over- or under-replacement of fluid.

Should low blood pressure prove a persistent problem in the fluid-replete patient, inotropes such as norepinephrine and dobutamine may be given to improve cardiac output and hence renal perfusion. While a useful pressor, there is no evidence to suggest that dopamine is of any specific benefit, and may be harmful.

The myriad causes of intrinsic AKI require specific therapies. For example, intrinsic AKI due to Wegener's granulomatosis may respond to steroid medication. Toxin-induced prerenal AKI often responds to discontinuation of the offending agent, such as aminoglycoside, penicillin, NSAIDs, or acetaminophen.

If the cause is obstruction of the urinary tract, relief of the obstruction (with a nephrostomy or urinary catheter) may be necessary.

Diuretic agents

The use of diuretics such as furosemide, while widespread and sometimes convenient in ameliorating fluid overload, does not reduce the risk of complications or death.

Renal replacement therapy

Renal replacement therapy, such as with hemodialysis, may be instituted in some cases of AKI. A systematic review of the literature in 2008 demonstrated no difference in outcomes between the use of intermittent hemodialysis and continuous venovenous hemofiltration (CVVH). Among critically ill patients, intensive renal replacement therapy

with CVVH does not appear to improve outcomes compared to less intensive intermittent hemodialysis.

Complications

Metabolic acidosis, hyperkalemia, and pulmonary edema may require medical treatment with sodium bicarbonate, antihyperkalemic measures, and diuretics.

Lack of improvement with fluid resuscitation, therapy-resistant hyperkalemia, metabolic acidosis, or fluid overload may necessitate artificial support in the form of dialysis or hemofiltration. Depending on the cause, a proportion of patients will never regain full renal function, thus having end-stage renal failure requiring lifelong dialysis or a kidney transplant.

History

Before the advancement of modern medicine, acute kidney injury might be referred to as *uremic poisoning*. Uremia was the term used to describe the contamination of the blood with urine. Starting around 1847 this term was used to describe reduced urine output, now known as oliguria, which was thought to be caused by the urine's mixing with the blood instead of being voided through the urethra.

Acute kidney injury due to acute tubular necrosis (ATN) was recognised in the 1940s in the United Kingdom, where crush injury victims during the London Blitz developed patchy necrosis of renal tubules, leading to a sudden decrease in renal function. During the Korean and Vietnam wars, the incidence of AKI decreased due to better acute management and administration of intravenous fluids.

Chapter 4

Chronic Kidney Disease

Chronic kidney disease

ICD-10	N03.
ICD-9	585 403
DiseasesDB	11288
MedlinePlus	000471
eMedicine	med/374
MeSH	D007676

Chronic kidney disease (CKD), also known as **chronic renal disease**, is a progressive loss in renal function over a period of months or years. The symptoms of worsening kidney function are unspecific, and might include feeling generally unwell and experiencing a reduced appetite. Often, chronic kidney disease is diagnosed as a result of screening of people known to be at risk of kidney problems, such as those with high blood pressure or diabetes and those with a blood relative with chronic kidney disease. Chronic kidney disease may also be identified when it leads to one of its recognized complications, such as cardiovascular disease, anemia or pericarditis.

Chronic kidney disease is identified by a blood test for creatinine. Higher levels of creatinine indicate a falling glomerular filtration rate and as a result a decreased capability of the kidneys to excrete waste products. Creatinine levels may be normal in the early stages of CKD, and the condition is discovered if urinalysis (testing of a urine sample) shows that the kidney is allowing the loss of protein or red blood cells into the urine. To fully investigate the underlying cause of kidney damage, various forms of medical imaging, blood tests and often renal biopsy (removing a small sample of kidney tissue) are employed to find out if there is a reversible cause for the kidney malfunction. Recent professional guidelines classify the severity of chronic kidney disease in five stages, with stage 1 being the mildest and usually causing few symptoms and stage 5 being a severe illness with poor life expectancy if untreated. Stage 5 CKD is also called **established chronic kidney disease** and is synonymous with the now outdated terms

end-stage renal disease (ESRD), chronic kidney failure (CKF) or chronic renal failure (CRF).

There is no specific treatment unequivocally shown to slow the worsening of chronic kidney disease. If there is an underlying cause to CKD, such as vasculitis, this may be treated directly with treatments aimed to slow the damage. In more advanced stages, treatments may be required for anemia and bone disease. Severe CKD requires one of the forms of renal replacement therapy; this may be a form of dialysis, but ideally constitutes a kidney transplant.

Signs and symptoms

CKD is initially without specific symptoms and can only be detected as an increase in serum creatinine or protein in the urine. As the kidney function decreases:

- blood pressure is increased due to fluid overload and production of vasoactive hormones, increasing one's risk of developing hypertension and/or suffering from congestive heart failure
- Urea accumulates, leading to azotemia and ultimately uremia (symptoms ranging from lethargy to pericarditis and encephalopathy). Urea is excreted by sweating and crystallizes on skin ("uremic frost").
- Potassium accumulates in the blood (known as hyperkalemia with a range of symptoms including malaise and potentially fatal cardiac arrhythmias)
- Erythropoietin synthesis is decreased (potentially leading to anemia, which causes fatigue)
- Fluid volume overload - symptoms may range from mild edema to life-threatening pulmonary edema
- Hyperphosphatemia - due to reduced phosphate excretion, associated with hypocalcemia (due to vitamin D₃ deficiency). The major sign of hypocalcemia is tetany.
 - Later this progresses to tertiary hyperparathyroidism, with hypercalcaemia, renal osteodystrophy and vascular calcification that further impairs cardiac function.
- Metabolic acidosis, due to accumulation of sulfates, phosphates, uric acid etc. This may cause altered enzyme activity by excess acid acting on enzymes and also increased excitability of cardiac and neuronal membranes by the promotion of hyperkalemia due to excess acid (acidemia)

People with chronic kidney disease suffer from accelerated atherosclerosis and are more likely to develop cardiovascular disease than the general population. Patients afflicted with chronic kidney disease and cardiovascular disease tend to have significantly worse prognoses than those suffering only from the latter.

Causes

The most common causes of CKD are diabetes mellitus, hypertension, and glomerulonephritis. Together, these cause approximately 75% of all adult cases. Certain geographic areas have a high incidence of HIV nephropathy.

Historically, kidney disease has been classified according to the part of the renal anatomy that is involved, as:

- Vascular, includes large vessel disease such as bilateral renal artery stenosis and small vessel disease such as ischemic nephropathy, hemolytic-uremic syndrome and vasculitis
- Glomerular, comprising a diverse group and subclassified into
 - Primary Glomerular disease such as focal segmental glomerulosclerosis and IgA nephritis
 - Secondary Glomerular disease such as diabetic nephropathy and lupus nephritis
- Tubulointerstitial including polycystic kidney disease, drug and toxin-induced chronic tubulointerstitial nephritis and reflux nephropathy
- Obstructive such as with bilateral kidney stones and diseases of the prostate
- On rare cases, pin worms infecting the kidney can also cause idiopathic nephropathy.

Diagnosis

In many CKD patients, previous renal disease or other underlying diseases are already known. A small number presents with CKD of unknown cause. In these patients, a cause is occasionally identified retrospectively.

It is important to differentiate CKD from acute renal failure (ARF) because ARF can be reversible. Abdominal ultrasound is commonly performed, in which the size of the kidneys are measured. Kidneys with CKD are usually smaller (< 9 cm) than normal kidneys with notable exceptions such as in diabetic nephropathy and polycystic kidney disease. Another diagnostic clue that helps differentiate CKD and ARF is a gradual rise in serum creatinine (over several months or years) as opposed to a sudden increase in the serum creatinine (several days to weeks). If these levels are unavailable (because the patient has been well and has had no blood tests) it is occasionally necessary to treat a patient briefly as having ARF until it has been established that the renal impairment is irreversible.

Additional tests may include nuclear medicine MAG3 scan to confirm blood flows and establish the differential function between the two kidneys. DMSA scans are also used in renal imaging; with both MAG3 and DMSA being used chelated with the radioactive element Technetium-99.

In chronic renal failure treated with standard dialysis, numerous uremic toxins accumulate. These toxins show various cytotoxic activities in the serum, have different molecular weights and some of them are bound to other proteins, primarily to albumin. Such toxic protein bound substances are receiving the attention of scientists who are interested in improving the standard chronic dialysis procedures used today.

Stages

All individuals with a Glomerular filtration rate (GFR) <60 mL/min/1.73 m² for 3 months are classified as having chronic kidney disease, irrespective of the presence or absence of kidney damage. The rationale for including these individuals is that reduction in kidney function to this level or lower represents loss of half or more of the adult level of normal kidney function, which may be associated with a number of complications.

All individuals with kidney damage are classified as having chronic kidney disease, irrespective of the level of GFR. The rationale for including individuals with GFR 60 mL/min/1.73 m² is that GFR may be sustained at normal or increased levels despite substantial kidney damage and that patients with kidney damage are at increased risk of the two major outcomes of chronic kidney disease: loss of kidney function and development of cardiovascular disease.

The loss of protein in the urine is regarded as an independent marker for worsening of renal function and cardiovascular disease. Hence, British guidelines append the letter "P" to the stage of chronic kidney disease if there is significant protein loss.

Stage 1

Slightly diminished function; Kidney damage with normal or relatively high GFR (≥ 90 mL/min/1.73 m²). Kidney damage is defined as pathologic abnormalities or markers of damage, including abnormalities in blood or urine test or imaging studies.

Stage 2

Mild reduction in GFR ($60-89$ mL/min/1.73 m²) with kidney damage. Kidney damage is defined as pathologic abnormalities or markers of damage, including abnormalities in blood or urine test or imaging studies.

Stage 3

Moderate reduction in GFR ($30-59$ mL/min/1.73 m²). British guidelines distinguish between stage 3A (GFR $45-59$) and stage 3B (GFR $30-44$) for purposes of screening and referral.

Stage 4

Severe reduction in GFR (15-29 mL/min/1.73 m²) Preparation for renal replacement therapy

Stage 5

Established kidney failure (GFR <15 mL/min/1.73 m², or permanent renal replacement therapy (RRT))

Treatment

The goal of therapy is to slow down or halt the otherwise relentless progression of CKD to stage 5. Control of blood pressure and treatment of the original disease, whenever feasible, are the broad principles of management. Generally, angiotensin converting enzyme inhibitors (ACEIs) or angiotensin II receptor antagonists (ARBs) are used, as they have been found to slow the progression of CKD to stage 5. Although the use of ACE inhibitors and ARBs represents the current standard of care for patients with CKD, patients progressively lose kidney function while on these medications, as seen in the IDNT and RENAAL studies, which reported a decrease over time in estimated glomerular filtration rate (an accurate measure of CKD progression, as detailed in the K/DOQI guidelines) in patients treated by these conventional methods.

Currently, several compounds are in development for CKD. These include, but are not limited to, bardoxolone methyl, olmesartan medoxomil, sulodexide, and avosentan.

Replacement of erythropoietin and calcitriol, two hormones processed by the kidney, is often necessary in patients with advanced CKD. Phosphate binders are also used to control the serum phosphate levels, which are usually elevated in advanced chronic kidney disease.

When one reaches stage 5 CKD, renal replacement therapy is required, in the form of either dialysis or a transplant.

The normalization of hemoglobin has not been found to be of any benefit.

Prognosis

The prognosis of patients with chronic kidney disease is guarded as epidemiological data has shown that all cause mortality (the overall death rate) increases as kidney function decreases. The leading cause of death in patients with chronic kidney disease is cardiovascular disease, regardless of whether there is progression to stage 5.

While renal replacement therapies can maintain patients indefinitely and prolong life, the quality of life is severely affected. Renal transplantation increases the survival of patients with stage 5 CKD significantly when compared to other therapeutic options; however, it

is associated with an increased short-term mortality (due to complications of the surgery). Transplantation aside, high intensity home hemodialysis appears to be associated with improved survival and a greater quality of life, when compared to the conventional three times a week hemodialysis and peritoneal dialysis.

Epidemiology

In Canada 1.9 to 2.3 million people have chronic kidney disease.

UK estimates suggest that 8.8% of the population of Great Britain and Northern Ireland have symptomatic CKD.

Organizations


In the USA, the National Kidney Foundation is a national organization representing patients and professionals who treat kidney diseases. The American Kidney Fund (AKF) is a national non-profit organization providing treatment-related financial assistance to 1 out of every 5 dialysis patients each year. The Renal Support Network (RSN) is a nonprofit, patient-focused, patient-run organization that provides non-medical services to those affected by CKD. The American Association of Kidney Patients (AAKP) is a non-profit, patient-centric group focused on improving the health and well-being of CKD and dialysis patients. The Renal Physicians Association (RPA) is an association representing nephrology professionals.

In the United Kingdom, the UK National Kidney Federation represents patients, and the Renal Association represents renal physicians and works closely with the National Service Framework for kidney disease.

Chapter 5

Urinary Tract Infection

Urinary tract infection



Multiple white cells at urinary microscopy from a patient with urinary tract infection.

ICD-10	N39.0
ICD-9	599.0
DiseasesDB	13657
MedlinePlus	000521
eMedicine	emerg/625 emerg/626
MeSH	D014552

Urinary tract infection (UTI) is a bacterial infection that affects any part of the urinary tract. Symptoms include frequent feeling and/or need to urinate, pain during urination,

and cloudy urine. The main causal agent is *Escherichia coli*. Although urine contains a variety of fluids, salts, and waste products, it does not usually have bacteria in it. When bacteria get into the bladder or kidney and multiply in the urine, they may cause a UTI.

The most common type of UTI is acute cystitis often referred to as a bladder infection. An infection of the upper urinary tract or kidney is known as pyelonephritis, and is potentially more serious. Although they cause discomfort, urinary tract infections can usually be easily treated with a short course of antibiotics with all no significant difference between the classes of antibiotics commonly used.

Signs and symptoms

The most common symptoms of a bladder infection are burning with urination (dysuria), frequency of urination, an urge to urinate, no vaginal discharge, and no significant pain. An upper urinary tract infection or pyelonephritis may also present with flank pain and a fever. Healthy women have an average of 5 days of symptoms.

The symptoms of urinary tract infections may vary with age and the part of the urinary system that was affected. In young children, urinary tract infection symptoms may include diarrhea, loss of appetite, nausea and vomiting, fever, and excessive crying that cannot be resolved by typical measures. Older children on the other hand may experience abdominal pain, or incontinence. Lower urinary tract infections in adults may manifest with symptoms including hematuria (blood in the urine), inability to urinate despite the urge, and malaise.

Other signs of urinary tract infections include foul-smelling urine and urine that appears cloudy.

Depending on the site of infection, urinary tract infections may cause different symptoms. Urethritis, meaning only the urethra has been affected, does not usually cause any other symptoms besides dysuria. However, if the bladder is affected (cystitis), the patient is likely to experience more symptoms, including lower abdomen discomfort, low-grade fever, pelvic pressure, and frequent urination, all together with dysuria.

Whereas in newborns the condition may cause jaundice and hypothermia, in the elderly, symptoms of urinary tract infections may include lethargy and a change in mental status, signs that are otherwise nonspecific.

Risk factors

Intercourse

In young sexually active women, sex is the cause of 75–90% of bladder infections, with the risk of infection related to the frequency of sex. The term "honeymoon cystitis" has been applied to this phenomenon of frequent UTIs during early marriage. In post

menopausal women sexual activity does not affect the risk of developing a UTI. Spermicide use, independent of sexual frequency, increases the risk of UTIs.

Sex

Women are more prone to UTIs than men because, in females, the urethra is much closer to the anus than in males, and women lack the bacteriostatic properties of prostatic secretions. UTIs also more commonly progress to bladder infections in females due to the much shorter length of the female urethra. Among the elderly, UTI frequency is roughly equal proportions in women and men. This is due, in part, to an enlarged prostate in older men. As the gland grows, it obstructs the urethra, leading to increased difficulty in micturition. Because there is less urine flushing the urethra, there is a higher incidence of colonization.

Urinary catheters

Urinary catheters are a risk factor for urinary tract infections. The risk of an associated infection can be decreased by only catheterizing when necessary, using aseptic technique for insertion, and maintaining unobstructed closed drainage of the catheter.

Genetics

A predisposition for bladder infections may run in families.

Others

Other risk factors include diabetes, sickle-cell disease, or anatomical malformations of the urinary tract such as prostate enlargement.

While ascending infections are, in general, the rule for lower urinary tract infections and cystitis, the same is not necessarily true for upper urinary tract infections like pyelonephritis, which may originate from a blood-born infection.

Pathogenesis

The most common organism implicated in UTIs (80–85%) is *E. Coli*, while *Staphylococcus saprophyticus* is the cause in 5–10%.

The bladder wall, in common with most epithelia is coated with a variety of cationic antimicrobial peptides such as the defensins and cathelicidin which disrupt the integrity of bacterial cell walls. In addition, there are also mannosylated proteins present, such as Tamm-Horsfall proteins (THP), which interfere with the binding of bacteria to the uroepithelium. As binding is an important factor in establishing pathogenicity for these organisms, its disruption results in reduced capacity for invasion of the tissues. Moreover, the unbound bacteria are more easily removed when voiding. The use of urinary catheters

(or other physical trauma) may physically disturb this protective lining, thereby allowing bacteria to invade the exposed epithelium.

During cystitis, uropathogenic *Escherichia coli* (UPEC) subvert innate defenses by invading superficial umbrella cells and rapidly increasing in numbers to form intracellular bacterial communities (IBCs). By working together, bacteria in biofilms build themselves into structures that are more firmly anchored in infected cells and are more resistant to immune-system assaults and antibiotic treatments. This is often the cause of chronic urinary tract infections.


Prevention

The following are measures that studies suggest may reduce the incidence of urinary tract infections.

- A prolonged course (six months to a year) of low-dose antibiotics (usually nitrofurantoin or TMP/SMX) is effective in reducing the frequency of UTIs in those with recurrent UTIs.
- Cranberry (juice or capsules) may decrease the incidence of UTI in those with frequent infections. Long-term tolerance, however, is an issue. Subsequent research has questioned these findings.
- For post-menopausal women intravaginal application of topical estrogen cream can prevent recurrent cystitis. This however is not as useful as low dose antibiotics.
- Studies have shown that breastfeeding can reduce the risk of UTIs in infants.

A number of measures have not been confirmed to affect UTI frequency including: the use of birth control pills or condoms, voiding after sex, the type of underwear used, personal hygiene methods used after voiding or defecating, and whether one takes a bath instead of a shower.

Diagnosis



Multiple bacilli (rod-shaped bacteria, here shown as black and bean-shaped) shown between white cells at urinary microscopy. This is called bacteriuria and pyuria, respectively. These changes are indicative of a urinary tract infection.

In straight-forward cases, a diagnosis may be made and treatment given based on symptoms alone without further laboratory confirmation. In complicated or questionable cases, confirmation via urinalysis, looking for the presence of nitrites, leukocytes, or leukocyte esterase, or via urine microscopy, looking for the presence of red blood cells, white blood cells, and bacteria, may be useful.

Urine culture showing a quantitative count of greater than or equal to 10^3 colony-forming units (CFU) per mL of a typical urinary tract organism along with antibiotic sensitivities is useful to guide antibiotic choice. However, women with negative cultures may still improve with antibiotic treatment.

Most cases of lower urinary tract infections in females are benign and do not need exhaustive laboratory work-ups. However, UTI in young infants may receive some imaging study, typically a retrograde urethrogram, to ascertain the presence/absence of congenital urinary tract anomalies.

Differential

If the urine culture is negative:

- Symptoms of urethritis may point at *Chlamydia trachomatis* or *Neisseria gonorrhoeae* infection.
- Symptoms of cystitis may point at interstitial cystitis.
- In men, prostatitis may present with dysuria.

The presence of bacteria in the urinary tract of older adults, without symptoms or signs of infection, is a well-recognized phenomenon that may not require antibiotics. This is usually referred to as asymptomatic bacteriuria. The overuse of antibiotics in the context of bacteriuria among the elderly is an issue of concern.

Treatment

Uncomplicated

Uncomplicated UTIs can be diagnosed and treated based on symptoms alone. Oral antibiotics such as trimethoprim, cephalosporins, nitrofurantoin, or a fluoroquinolone substantially shorten the time to recovery. All are equally effective for both short and long term cure rates. About 50% of people will recover without treatment within a few days or weeks. The Infectious Diseases Society of America recommends a combination of trimethoprim and sulfamethoxazole as a first-line agent in uncomplicated UTIs rather than fluoroquinolones. Fluoroquinolones are not recommended first line due to their cost and concern that over use will increase resistance and thus decrease the utility of this class for those with severe infections. Resistance has developed in the community to all of these medications due to their widespread use.

A three-day treatment with trimethoprim, TMP/SMX, or a fluoroquinolone is usually sufficient, whereas nitrofurantoin requires 7 days. Trimethoprim is often recommended to be taken at night to ensure maximal urinary concentrations to increase its effectiveness. While trimethoprim/sulfamethoxazole was previously internationally used (and continues to be used in the U.S. and Canada), the addition of the sulfonamide gives little additional benefit compared to the trimethoprim component alone. However, it is responsible for a high incidence of mild allergic reactions and rare but potentially serious complications. For simple UTIs, children often respond well to a three-day course of antibiotics.

Pyelonephritis

Pyelonephritis is treated more aggressively than a simple bladder infection using either a longer course of oral antibiotics or intravenous antibiotics. Regimens vary, and include SMX/TMP and fluoroquinolones. In the past, they have included aminoglycosides (such as gentamicin) used in combination with a beta-lactam (such as ampicillin or ceftriaxone). These are continued for 48 hours after fever subsides.

If there is a poor response to IV antibiotics (marked by persistent fever, worsening renal function), then imaging is indicated to rule out formation of an abscess either within or around the kidney, or the presence of an obstructing lesion such as a stone or tumor.

Recurrent

Women with recurrent simple UTIs may benefit from self-treatment upon occurrence of symptoms with medical follow-up only if the initial treatment fails. Effective treatment can also be delivered over the phone.

Epidemiology

Bladder infections are most common in young women with 10% of women getting an infection yearly and 60% having an infection at some point in their life. Pyelonephritis occurs between 18–29 times less frequently.

According to the 1997 National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey, urinary tract infection accounted for nearly 7 million office visits and 1 million emergency department visits, resulting in 100,000 hospitalizations.

Nearly 1 in 3 women will have had at least 1 episode of urinary tract infections requiring antimicrobial therapy by the age of 24 years. The risk of urinary tract infection increases with increasing duration of catheterization. In non-institutionalized elderly populations, urinary tract infections are the second-most-common form of infection, accounting for nearly 25% of all infections.

The condition rarely occurs in men who are younger than 50 years old and who did not undergo any genitourinary procedure. However, the incidence of urinary tract infections in men tends to rise after the age of 50.

According to statistics from 1990, the prevalence of urinary tract infections in pre-school and school girls was 1% to 3%, nearly 30-fold higher than that in boys. Also, the statistics from the same year show that approximately 5% of girls will develop at least one urinary tract infection in their school years.

In what concerns the symptoms of the condition, bacteriuria appears to increase in prevalence with age in women, still being 50 times greater than the one in males. It is estimated that bacteriuria will be experienced by 20 to 50% of older women and 5 to 20% of older men.

In children

Children with recurrent UTIs may be treated with preventative antibiotics that decrease the rate of microbiological recurrence but not symptomatic recurrence. These conclusion must be viewed in light of the poor quality of evidence available.

In pregnancy

Urinary tract infections are more concerning in pregnancy. If urine testing shows signs of infection even in the absence of symptoms (known as asymptomatic bacteriuria) women are treated. Treatment is typically with cephalexin or nitrofurantoin as while there are no adequate studies of these antibiotics in pregnant women, many women have safely used them during pregnancy.

Chapter 6

Kidney Stone

Kidney stone



An 8-mm kidney stone.

ICD-10	N20.0
ICD-9	592.0
DiseasesDB	11346
MedlinePlus	000458
eMedicine	med/1600
MeSH	D007669

Kidney stones (ureterolithiasis) result from **stones** or **renal calculi** (from Latin *ren*, *renes*, "kidney" and *calculi*, "pebbles") in the ureter. The stones are solid concretions or calculi (crystal aggregations) formed in the kidneys from dissolved urinary minerals. **Nephrolithiasis** (from Greek νεφρός (*nephros*, "kidney") and λίθος (*lithos*, "stone")) refers to the condition of having kidney stones. Urolithiasis refers to the condition of having calculi in the urinary tract (which also includes the kidneys), which may form or pass into the urinary bladder. Ureterolithiasis is the condition of having a calculus in the ureter, the tube connecting the kidneys and the bladder. The term bladder stones usually applies to urolithiasis of the bladder in non-human animals such as dogs and cats.


Kidney stones typically leave the body by passage in the urine stream, and many stones are formed and passed without causing symptoms. If stones grow to sufficient size before passage on the order of at least 2-3 millimeters they can cause obstruction of the ureter. The resulting obstruction causes dilation or stretching of the upper ureter and renal pelvis (the part of the kidney where the urine collects before entering the ureter) as well as muscle spasm of the ureter, trying to move the stone. This leads to pain, most commonly felt in the flank, lower abdomen and groin (a condition called renal colic). Renal colic can be associated with nausea and vomiting. There can be blood in the urine, visible with the naked eye or under the microscope (macroscopic or microscopic hematuria) due to damage to the lining of the urinary tract.

There are several types of kidney stones based on the type of crystals of which they consist. The majority are calcium oxalate stones, followed by calcium phosphate stones. More rarely, struvite stones are produced by urea-splitting bacteria in people with urinary tract infections, and people with certain metabolic abnormalities may produce uric acid stones or cystine stones.

The diagnosis of a kidney stone can be confirmed by radiological studies and/or ultrasound examination; urine tests and blood tests are also commonly performed. When a stone causes no symptoms, watchful waiting is a valid option. In other cases, pain control is the first measure, using for example non-steroidal anti-inflammatory drugs or opioids. Using soundwaves, some stones can be shattered into smaller fragments (this is called extracorporeal shock wave lithotripsy). Sometimes a procedure is required, which can be through a tube into the urethra, bladder and ureter (ureteroscopy), or a keyhole or open surgical approach from the kidney's side. Sometimes, a tube may be left in the ureter (a ureteric stent) to prevent the recurrence of pain. Preventive and structive measures are often advised such as drinking sufficient amounts of water and milk although the effect of many dietary interventions has not been rigorously studied.

Signs and symptoms

Symptoms of kidney stones include:



Localization of kidney stone pain

- Colicky pain: "loin to groin". Often described as "the worst pain [...] ever experienced." This can also occur in the lower back. The pain is elicited by contractions of the ureter in response to the stone, causing severe, crampy pain in the flank or lower back, often radiating to the groin or, in men, to the testes. The pain typically comes in waves, with a typical wave lasting 20 to 60 minutes.
- Nausea/vomiting: embryological link with intestine– stimulates the vomiting center.
- Hematuria: blood in the urine, due to minor damage to inside wall of kidney, ureter and/or urethra.
- Pyuria: pus in the urine.
- Dysuria: burning on urination when passing stones (rare). More typical of infection.
- Oliguria: reduced urinary volume caused by obstruction of the bladder or urethra by stone, or extremely rarely, simultaneous obstruction of both ureters by a stone.
- Postrenal azotemia: the blockage of urine flow through a ureter.
- Hydronephrosis: the distension and dilation of the renal pelvis and calyces.

Causes

Kidney stones do not have single, well-defined cause, but are the result of a combination of factors. A stone is created when the urine does not have the correct balance of fluid and a combination of minerals and acids. When the urine contains more crystal-forming substances than the fluid can dilute, crystals can form. Normally the urine contains components that prevent these crystals from attaching to each other. However, when

these substances fall below their normal proportions, stones can form out of an accumulation of crystals.

Kidney stones or calcium oxalate crystals in the kidney can be due to underlying metabolic conditions, such as renal tubular acidosis, Dent's disease, hyperparathyroidism, primary hyperoxaluria and medullary sponge kidney. Kidney stones are also more common in patients with Crohn's disease. Patients with recurrent kidney stones should be screened for these disorders. This is typically done with a 24 hour urine collection that is chemically analyzed for deficiencies and excesses that promote stone formation.

There has been some evidence that water fluoridation may increase the risk of kidney stone formation. In one study, patients with symptoms of skeletal fluorosis were 4.6 times as likely to develop kidney stones.

A 1998 paper in the Archives of Internal Medicine examined the sources of a widely-held belief in the medical community that vitamin C can cause kidney stones, and found it to be based on several circular references, ultimately attributing the belief to a wider pattern of skepticism regarding efficacy of vitamin supplements. A more recent study suggested a causal relationship may exist, but it was not conclusive.

The American Urological Association has projected that increasing global temperatures will lead to greater future prevalence of kidney stones, notably by expanding the "kidney stone belt" of the southern United States. Astronauts seem to show a higher risk of developing kidney stones during or after long duration space flights.

Calcium oxalate stones

The most common type of kidney stone is composed of calcium oxalate crystals, occurring in about 75 to 80% of cases, and the factors that promote the precipitation of crystals in the urine are associated with the development of these stones.

Perhaps counter-intuitively, current evidence suggests that the consumption of diets low in calcium is associated with a higher overall risk for the development of kidney stones. This is perhaps related to the role of calcium in binding ingested oxalate in the gastrointestinal tract. As the amount of calcium intake decreases, the amount of oxalate available for absorption into the bloodstream increases; this oxalate is then excreted in greater amounts into the urine by the kidneys. In the urine, oxalate is a very strong promoter of calcium oxalate precipitation, about 15 times stronger than calcium.

Uric acid (urate)

About 5–10% of all stones are formed from uric acid. A risk factor is obesity. Uric acid stones form in association with conditions that cause hyperuricosuria with or without high blood serum uric acid levels (hyperuricemia); and with acid/base metabolism disorders where the urine is excessively acidic (low pH) resulting in uric acid

precipitation. A diagnosis of uric acid nephrolithiasis is supported if there is a radiolucent stone, a persistent undue urine acidity, and uric acid crystals in fresh urine samples.

Other types

Other types of kidney stones are composed of struvite (magnesium, ammonium and phosphate); calcium phosphate; and cystine.

Struvite stones are also known as infection stones, urease or triple-phosphate stones. About 10–15% of urinary calculi consist of struvite stones. The formation of struvite stones is associated with the presence of urea-splitting bacteria, most commonly *Proteus mirabilis* (but also *Klebsiella*, *Serratia*, *Providencia* species). These organisms are capable of splitting urea into ammonia, decreasing the acidity of the urine and resulting in favorable conditions for the formation of struvite stones. Struvite stones are always associated with urinary tract infections.

The formation of calcium phosphate stones is associated with conditions such as hyperparathyroidism and renal tubular acidosis.

Formation of cystine stones is uniquely associated with people suffering from cystinuria, who accumulate cystine in their urine. Cystinuria can be caused by Fanconi's syndrome.

Urolithiasis has also been noted to occur in the setting of therapeutic drug use, with crystals of drug forming within the renal tract in some patients currently being treated with Indinavir, Sulfadiazine or Triamterene.

Diagnosis

Clinical diagnosis is usually made on the basis of the location and severity of the pain, which is typically colicky in nature (comes and goes in spasmodic waves). Pain in the back occurs when calculi produce an obstruction in the kidney.

Imaging is used to confirm the diagnosis and a number of other tests can be undertaken to help establish both the possible cause and consequences of the stone.

X-rays

The relatively dense calcium renders these stones radio-opaque and they can be detected by a traditional X-ray of the abdomen that includes the kidneys, ureters and bladder—KUB. This may be followed by an IVP (intravenous pyelogram—intravenous urogram (IVU) is the same test by another name) which requires about 50 ml of a special dye to be injected into the bloodstream that is excreted by the kidneys and by its density helps outline any stone on a repeated X-ray. These can also be detected by a retrograde pyelogram where similar "dye" is injected directly into the ureteral opening in the bladder by a surgeon, usually a urologist.

About 10% of stones do not have enough calcium to be seen on standard X-rays (radiolucent stones).

Computed tomography

Computed tomography without contrast is considered the gold standard diagnostic test for the detection of kidney stones. All stones are detectable by CT except very rare stones composed of certain drug residues in the urine. If positive for stones, a single standard X-ray of the abdomen (KUB) is recommended. This gives a clearer idea of the exact size and shape of the stone as well as its surgical orientation. Further, it makes it simple to follow the progress of the stone by doing another X-ray in the future.

Drawbacks of CT scans include radiation exposure and cost.

Ultrasound

Ultrasound imaging is useful as it gives details about the presence of hydronephrosis (swelling of the kidney—suggesting the stone is blocking the outflow of urine). It can also be used to detect stones during pregnancy when x-rays or CT are discouraged. Radiolucent stones may show up on ultrasound however they are also typically seen on CT scans.

Some recommend that US be used as the primary diagnostic technique with CT being reserved for those with negative US result and continued suspicion of a kidney stone. This is due to its lesser cost and avoidance of radiation.

Other

Other investigations typically carried out include:

- Microscopic study of urine, which may show proteins, red blood cells, bacteria, cellular casts and crystals.
- Culture of a urine sample to exclude urine infection (either as a differential cause of the patient's pain, or secondary to the presence of a stone).
- Blood tests: Full blood count for the presence of a raised white cell count (Neutrophilia) suggestive of infection, a check of renal function and to look for abnormally high blood calcium blood levels (hypercalcaemia).
- 24 hour urine collection to measure total daily urinary volume, magnesium, sodium, uric acid, calcium, citrate, oxalate and phosphate.
- Catching of passed stones at home (usually by urinating through a tea strainer or stonescreen) for later examination and evaluation by a doctor.




Staghorn calculus



Multiple kidney stones composed of uric acid and a small amount of calcium oxalate




Star-shaped bladder urolith on an X-ray of the pelvis




A kidney stone at the tip of an ultrasonic instrument



Bilateral kidney stones on abdominal X-ray. Not to be confused with phleboliths seen in the pelvis.



CT of abdomen without contrast showing right proximal ureteric stone causing mild obstruction and hydronephrosis (marked by an arrow)



Three-dimensional reconstructed CT scan image of a ureteral stent in the left kidney (indicated by yellow arrow). There is a kidney stone in the pyelum of the lower pole of the kidney (highest red arrow) and one in the ureter beside the stent (lower red arrow).

Prevention

Preventive strategies may include dietary modifications and medication with the goal of reducing excretory load on the kidneys:

- Drinking enough water to make 2 to 2.5 liters of urine per day. A failure to intake sufficient liquids will mean the urine is concentrated and the substances that create kidney stones are more likely to clump together.
- A diet low in protein, nitrogen and sodium intake. The National Institutes of Health website disputes the notion that specific foods can cause formation of kidney stones in everyone, although "in some people, a diet high in protein may lead to kidney stones because extra protein causes calcium to be excreted from the body, raising calcium levels in the urine."

People with urinary tract infections, kidney disorders such as cystic kidney diseases, and certain rare, inherited metabolic disorders are also more likely to develop kidney stones.

In some of these susceptible people, the foods they eat can have an influence on the development of their kidney stones. Prevention strategies include:

- Restriction of oxalate-rich foods, or consumption of more calcium
- Taking drugs such as thiazides, potassium citrate, magnesium citrate and allopurinol, depending on the cause of stone formation.
- Some fruit juices, such as orange, blackcurrant, and cranberry, may be useful for lowering the risk factors for specific types of stones. Orange juice may help prevent calcium oxalate stone formation, blackcurrant may help prevent uric acid stones, and cranberry may help with UTI-caused stones. Lemons have the highest concentration of citrate of any citrus fruit, and daily consumption of lemonade has been shown to decrease the rate of stone formation. Beer is also recommended, but grapefruit juice has been known to increase the risk of stones.
- One study indicated that intake of caffeinated beverages increases risk of kidney stones, a finding which was soon taken up in the popular press. While it may be advised to avoid cola beverages, whether artificially sweetened or not because of their high phosphate content, this does not include coffee or tea. Prospective cohort studies of coffee and tea actually indicate that they may prevent kidney stones, while apple juice and grapefruit juice may cause them.
- Avoiding large doses of vitamin C.
- In South Asia, there is a popular cultural belief that spinach should not be cooked along with tomatoes, since spinach is rich in calcium and oxalates, and reacts with the chemicals in tomatoes, causing deposits in those prone to kidney stone formation. However, this theory is not scientifically proven and is controversial.

For those patients interested in optimizing their kidney stone prevention options, a 24 hour urine test can be a useful diagnostic.

Oxalate and calcium balance

Since oxalates form the basis of one type of kidney stone, one prevention strategy is to restrict consumption of oxalate-rich foods such as chocolate, nuts, soybeans, rhubarb, and spinach. However, this is only helpful in those patients who are absorbing excess oxalate - a minority of patients as most oxalate excreted in the urine is actually made by the liver.

Stones are formed when oxalates bind with calcium, but calcium plays a vital role in body chemistry and limiting calcium may be unhealthy. Recent research has actually shown that a diet that includes recommended calcium levels prevents kidney stones in men better than a low-calcium diet appears to. Since calcium in the intestinal tract will bind with available oxalate, thereby preventing its absorption into the blood stream, some nephrologists and urologists recommend chewing calcium tablets during meals containing oxalate foods. Calcium citrate should be taken with food if dietary calcium cannot be increased.

Diuretics

Although it has been claimed that the diuretic effects of alcohol can result in dehydration, which is important for kidney stone sufferers to avoid, there are no conclusive data demonstrating any cause and effect regarding kidney stones. However, some have theorized that frequent and binge drinkers create situations that set up dehydration: alcohol consumption, hangovers, and poor sleep and stress habits. In this view, it is not the alcohol that creates a kidney stone but it is the alcohol drinker's associated behavior that sets it up.

One of the recognized medical therapies for prevention of stones is thiazides, a class of drugs usually thought of as diuretics. These drugs prevent calcium stones through an effect independent of their diuretic properties: they reduce urinary calcium excretion. Nonetheless, their diuretic property does not preclude their efficacy as stone preventive. Sodium restriction is necessary for clinical effect of thiazides, as sodium excess promotes calcium excretion. Thiazides work best for renal leak hypercalciuria - a condition in which the high urinary calcium levels are from a primary kidney defect. They work well initially for absorptive hypercalciuria - a condition in which high urinary calcium is a result of excess absorption from the GI tract. With this condition they lose effectiveness over time, typically around 2 years, and patients need a period off treatment to regain effectiveness. Thiazides will cause hypokalemia and reduced urinary citrate levels so should be given with supplements for each, usually as a potassium citrate preparation.

Allopurinol

Allopurinol (*Zyloprim*) is another drug with proven benefits in some calcium kidney stone formers. Allopurinol interferes with the liver's production of uric acid. Hyperuricosuria, too much uric acid in the urine, is a risk factor for calcium stones. Allopurinol reduces calcium stone formation in such patients. The drug is also used in patients with gout or hyperuricemia. However, hyperuricemia is not the critical feature of uric acid stones, which can occur in the presence of *hypouricemia*. Uric acid stones are more often caused by a combination of high urine uric acid and low urine pH. Even relatively high uric acid excretion will not be associated with uric acid stone formation if the urine pH is alkaline. Therefore prevention of uric acid stones relies on alkalinization of the urine with citrate (in the form of Shohl's solution (sodium citrate), sodium bicarbonate, potassium citrate, potassium bicarbonate or acetazolamide, a carbonic anhydrase inhibitor).

Allopurinol is reserved for patients in whom alkalinization is difficult. For patients with increased uric acid levels and calcium stones, allopurinol is one of the few treatments that has been shown in double-blinded placebo controlled studies to actually reduce kidney stone recurrences. Dosage is adjusted to maintain a reduced urinary excretion of uric acid. Serum uric acid level at or below 6 mg/dL is often the goal of the drug's use in patients with gout or hyperuricemia.

Decreased-protein diet

American diets typically contain more animal protein than the body can use, and the excess is broken down into uric acid and excreted, increasing the risk of uric acid stones. Red meat also contains acids that need to be excreted and these acids constitute another risk factor for kidney stones because the body will balance urinary pH by leaching calcium from the bones and this free calcium is subject to combining with any available oxalate to form stones.

Other modifications

Potassium citrate is also used in kidney stone prevention. This is available as both a tablet and liquid preparation. The medication increases urinary pH (makes it more alkaline), as well as increases the urinary citrate level, which helps reduce calcium oxalate crystal aggregation. Optimal 24 hour urine levels of citrate are thought to be over 320 mg/liter of urine or over 600 mg per day. There are urinary dipsticks available that allow patients to monitor and measure urinary pH so patients can optimize their urinary citrate level.

Though caffeine does acutely increase urinary calcium excretion, several independent epidemiologic studies have shown that coffee intake overall is protective against the formation of stones.

Measurements of food oxalate content have been difficult and issues remain about the proportion of oxalate that is bio-available, versus a proportion that is not absorbed by the intestine. Oxalate-rich foods are usually restricted to some degree, particularly in patients with high urinary oxalate levels, but no randomized controlled trial of oxalate restriction has been performed to test that hypotheses.

Calgranulin

Crystallization of calcium oxalate (CaOx) appears to be reduced by molecules in the urine that retard the formation, growth, aggregation, and renal cell adherence of calcium oxalate. By purifying urine using salt precipitation, preparative isoelectric focusing, and sizing chromatography, some researchers have found that the molecule calgranulin is able to inhibit calcium oxalate crystal growth. Calgranulin is a protein formed in the kidney. Given the large amounts of calcium oxalate in the urine, and considering its potency, calgranulin could become an important contribution to the normal urinary inhibition of crystal growth and aggregation. If so, it will be an important tool in the renal defense against kidney stones.

Medical management

There has been some debate regarding the usefulness of medical management overall in the treatment of stone forming patients. Despite this debate, it is clear that repeat stone formers do benefit from more intense management, including proper hydration and use of certain medications. Additionally, it is also clear that careful surveillance is required in

order to maximize the clinical course for patients who are unlucky enough to be stone formers.

Management

Conservative

85% of the time, it is possible to pass the stone with urination. Usually this will occur within 72 hours of the start of symptoms. Stones larger than 6 mm will almost always require some form of intervention, however. There are various measures that can be used to encourage the passage of a stone. These can include increased hydration.

Straining the urine allows collection of the stone when it passes and analysis of the stone can help establish preventative options.

In most cases, interventions are not needed especially for smaller stones, unless a month goes by and the stone has not moved. Prompt surgery may nonetheless be required with persons who have only one working kidney, bilateral obstructing stones, a urinary tract infection and thus presumably an infected kidney, or intractable pain.

Analgesia

Management of pain often requires intravenous administration of NSAIDs or opioids in an emergency room setting. Orally-administered medications are often effective for less severe discomfort (NSAIDs or opioids). Intravenous acetaminophen also appears to be effective.

After treatment, the pain may return if the stone moves but re-obstructs in another location.

Alpha adrenergic blockers

Alpha adrenergic blockers such as tamsulosin (Flomax) may increase the spontaneous passage of the stone by 30%. Recent studies have, however, questioned this claim, finding no benefit from these medications.

Lithotripsy

Extracorporeal shock wave lithotripsy (ESWL) was the most common form of intervention in 1990s and 2000s and is still very common for stones that are 10 mm or smaller as it is the least invasive form of intervention. This involves breaking up the stone by projecting sonic waves into the area.

A single retrospective study at the Mayo Clinic suggested that lithotripsy may increase subsequent incidence of diabetes and hypertension, but the clinic did not believe the treatment should be abandoned. Although shock wave lithotripsy may involve some

bruising and provoke internal bleeding, the benefits of SWL outweigh the risk for many patients. A shock wave firing rate of 60 waves per minute represents a lower risk of renal injury than 120 per minute.

Surgery

Percutaneous nephrolithotomy or, rarely, open surgery may ultimately be necessary for large or complicated stones or stones which fail other less invasive attempts at treatment. Surgery is typically done from the back, through the ureter.

Ureteral stents

One modern medical technique uses a ureteral stent (a small tube between the bladder and the inside of the kidney) to provide immediate relief of a blocked kidney. This is especially useful in saving a failing kidney due to swelling and infection from the stone. Ureteral stents vary in length and width but most have the same shape usually called a "double-J" or "double pigtail", because of the curl at both ends. They are designed to allow urine to drain around any stone or obstruction. They can be retained for some length of time as infections recede and as stones are dissolved or fragmented with ESWL or other treatment. The stents will gently dilate or stretch the ureters which can facilitate instrumentation and they will also provide a clear landmark to help surgeons see the stones on x-ray. Most stents can be removed easily during a final office visit. Discomfort levels from stents typically range from minimal associated pain to moderate discomfort. However, it isn't uncommon for patients to experience severe discomfort too, especially upon removal of said stent.

The use of ureteral stents is of particular significance in the treatment of ureteral stones. Their use, non use, and circumstances peculiar to stents should be well understood in order to maximize the benefits.

Ureteroscopy

Ureteroscopy has become increasingly popular as ureteroscopes have gotten smaller. Typically, a ureteroscope will use a laser to destroy or at least fragment encountered stones.

Epidemiology

Within the United States, about 12% of men and 7% of women will be diagnosed with a kidney stone, and the total cost for treating this condition was US\$2 billion in 2003. The incidence rate increases to 20–25% in the Middle East, because of increased risk of dehydration in hot climates (the typical Middle Eastern diet is also 50% lower in calcium and 250% higher in oxalates compared to Western diets, increasing the net risk). Recurrence rates are estimated at about 10% per year, totalling 50% over a 5–10 year period and 75% over 20 years. Recent evidence has shown an increase in pediatric cases.

History

The existence of kidney stones has been recorded since the beginning of civilization, and lithotomy for the removal of stones is one of the earliest known surgical procedures. In 1901, a stone was discovered in the pelvis of an ancient Egyptian mummy, and was dated to 4,800 BC. Medical text from ancient Mesopotamia, India, China, Persia, Greece and Rome all mentioned calculous disease. Part of the Hippocratic oath suggests that there were practicing surgeons in Ancient Greece to whom physicians should defer for lithotomies. The Roman medical treatise *De Medicina* by Cornelius Celsus contained a description of lithotomy, and this work served as the basis for this procedure up until the 18th century.

Among the famous leaders who were kidney stone formers are Emperor Napoleon Bonaparte, Emperor Napoleon III, Peter the Great, Louis XIV, George IV, Oliver Cromwell, and former U.S. President Lyndon B. Johnson. Other notable individuals who endured stones include Benjamin Franklin, the philosophers Michel de Montaigne and Sir Francis Bacon, the scientist Sir Isaac Newton, the civil servant and diarist Samuel Pepys, the physicians William Harvey and Herman Boerhaave, and the anatomist Antonio Scarpa. Interestingly, astronauts seem to have a higher risk of developing kidney stones during or after long duration space flights.


New techniques in lithotomy began to emerge starting in 1520, but the operation remained risky. It was only after Henry Jacob Bigelow popularized the technique of litholapaxy in 1878 that the mortality rate dropped from about 24% down to 2.4%. However, other treatment techniques were developed that continued to produce a high level of mortality, especially among inexperienced urologists. In 1980, Dornier MedTech introduced extracorporeal shock wave lithotripsy for breaking up stones via acoustical pulses, and this technique has come into widespread use.

Kidney stones were once referred to as gravel or *gravel disease* during the 1800s in the United States. One such example is documented in the Oak Ridge Cemetery records for Charles Muir Campbell who died 13 Oct 1874 in Springfield, Sangamon, Illinois, USA.

Chapter 7

Hematuria

Hematuria



Microscopic hematuria

ICD-10 N02., R31.

ICD-9 599.7, 791.2

DiseasesDB 19635

eMedicine ped/951

MeSH D006417

In medicine, **hematuria**, or **haematuria**, is the presence of red blood cells (erythrocytes) in the urine. It may be idiopathic and/or benign, or it can be a sign that there is a kidney stone or a tumor in the urinary tract (kidneys, ureters, urinary bladder, prostate, and urethra), ranging from trivial to lethal. If white blood cells are found in addition to red blood cells, then it is a signal of urinary tract infection.

Occasionally "hemoglobinuria" is used synonymously, although more precisely it refers only to hemoglobin in the urine.

Types

Red discoloration of the urine can have various causes:

- Red blood cells
 - Microscopic hematuria (small amounts of blood, can be seen only on urinalysis or light microscopy)
 - Macroscopic hematuria (or "frank" or "gross") hematuria
- Hemoglobin (only the red pigment, not the red blood cells)
- Other pigments
 - Myoglobin in myoglobinuria
 - Porphyrins in porphyria
 - Betanin, after eating beets
 - Drugs such as Rifampicin and Phenazopyridine

Diagnosis



Gross hematuria due to trauma

Often, the diagnosis is made on the basis of the medical history and some blood tests—especially in young people in whom the risk of malignancy is negligible and the symptoms are generally self-limited.

Ultrasound investigation of the renal tract is often used to distinguish between various sources of bleeding. X-rays can be used to identify kidney stones, although CT scanning is more precise.

In older patients, cystoscopy with biopsy of suspected lesions is often employed to investigate for bladder cancer.

If combined with pain, it may be *loin pain hematuria syndrome*.

Per AUA (American Urologic Association) guidelines, the following should be performed for high risk patients with significant microhematuria (greater than three red blood cells per high powered field):

1. Upper tract imaging of which a CT urogram is the gold standard
2. Urine cytology
3. Cystoscopy

Causes

The most common causes of hematuria/haematuria are:

- Urinary tract infection with viruses, other sexually transmitted diseases (particularly in women) or some bacterial species including strains of EPEC and *Staphylococcus saprophyticus*
- Kidney stones or ureter stones
- Benign prostatic hyperplasia, in older men, especially those over 50

Other, less common causes of hematuria include:

- IgA nephropathy ("Berger's disease") - occurs during viral infections in predisposed patients
- Trauma (e.g., a blow to the kidneys)
- Tumours and/or cancer in the urinary system, for example bladder cancer or renal cell carcinoma
- Kidney diseases
- Urinary Schistosomiasis (caused by *Schistosoma haematobium*) - a major cause for hematuria in many African and Middle-Eastern countries;
- Prostate infection or inflammation (prostatitis)

Rare causes include:

- Benign familial hematuria

- Paroxysmal nocturnal hemoglobinuria - a rare disease where hemoglobin of hemolysed cells is passed into the urine.
- Sickle cell trait can precipitate large amounts of red blood cell discharge, but only a small number of individuals endure this problem
- Arteriovenous malformation of the kidney (rare, but may impress like renal cell carcinoma on scans as both are highly vascular)
- Nephritic syndrome (a condition associated with post-streptococcal and rapidly progressing glomerulonephritis).
- Fibrinoid necrosis of the Glomeruli (as a result of malignant hypertension)
- Bladder vesicle varices may rarely develop secondary to obstruction of the inferior vena cava.
- Allergy may rarely cause episodic gross hematuria in children.
- Left renal vein hypertension, also called "nutcracker phenomenon" or "nutcracker syndrome," is a rare vascular abnormality responsible for gross hematuria.
- Ureteral Pelvic Junction Obstruction (UPJ) is a rare condition beginning from birth in which the ureter is blocked between the kidney and bladder. This condition may cause blood in the urine.
- March hematuria - Very prolonged exercise, such as long-distance horseback riding and bicycle riding.
- Medications can cause red discoloration of the urine, but not haematuria. Some examples include: sulfonamides, quinine, rifampin, phenytoin

Chapter 8

Biopsy



Brain biopsy

A **biopsy** is a medical test involving the removal of cells or tissues for examination. It is the medical removal of tissue from a living subject to determine the presence or extent of a disease. The tissue is generally examined under a microscope by a pathologist, and can also be analyzed chemically. When an entire lump or suspicious area is removed, the procedure is called an *excisional biopsy*. When only a sample of tissue is removed with preservation of the histological architecture of the tissue's cells, the procedure is called an *incisional biopsy* or *core biopsy*. When a sample of tissue or fluid is removed with a needle in such a way that cells are removed without preserving the histological architecture of the tissue cells, the procedure is called a needle aspiration biopsy.

Etymology

Biopsy is of Greek origin, coming from the words bio, meaning life, and opsia, meaning to see.


Breast biopsy

Several methods for a breast biopsy now exist. The most appropriate method of biopsy for a patient depends upon a variety of factors, including the size, location, appearance and characteristics of the abnormality.

Fine needle aspiration

Fine needle aspiration (FNA) is a percutaneous ("through the skin") procedure that uses a fine needle and a syringe to sample fluid from a breast cyst or remove clusters of cells from a solid mass. With FNA, the cellular material taken from the breast is usually sent to the pathology laboratory for analysis. A technique similar to FNA can also be used by the radiologist or surgeon to drain fluid from a benign cyst. This procedure is called cyst aspiration. A fine needle aspiration procedure is generally almost painless and takes only a few minutes to perform. Technically, this FNA procedure is not a biopsy as the material retrieved is made of fluid coming either from a cyst or from the intercellular space and a few cells, when a biopsy is bringing back a piece of tissue where the architecture of the tissue is preserved.

Core needle biopsy



Liver core needle biopsy

A core needle biopsy is a procedure that removes small but solid samples of tissue using a hollow "core" needle. For palpable ("able to be felt") lesions, the physician fixes the lesion with one hand and performs a freehand needle biopsy with the other. In case of non-palpable lesions stereotactic mammography, or ultrasound, or PEM guidance is used. With stereotactic mammography it is possible to pinpoint the exact location of a mass based on images taken from two different angles of the x-ray machine. With ultrasound, the radiologist or surgeon can watch the needle on the ultrasound monitor to help guide it to the area of concern. With PEM (positron emission mammography), the lesion is targeted in 3D based on a positron emission tomography (PET) image of the breast. The needle used during core needle biopsy is larger than the needle used with FNA. The core biopsy needle also has a special cutting edge allowing removal of a bigger sample of tissue. With core needle biopsy a relatively large sample can be removed through a small single incision in the skin. Typically, the breast area is first locally anesthetized with a small amount of anesthetic fluid. Then, the needle is placed into the breast. As with FNA, the radiologist or surgeon will guide the needle into the area of concern by palpating the lump. If the lesion can't be felt the core needle biopsy is performed under image-guidance using either stereotactic mammography, ultrasound or even magnetic resonance imaging (MRI). A core needle biopsy procedure takes a few minutes to perform and is almost painless.

Vacuum assisted biopsy

Vacuum assisted biopsy is a version of core needle biopsy using a vacuum technique to assist the collection of the tissue sample. The needle normally has a lateral ("from the side") opening and can be rotated allowing multiple samples to be collected through a single skin incision. The Vacuum assisted biopsy procedure is similar to normal core needle biopsy. The vacuum assisted biopsy category also includes automated rotational core devices.

Direct & frontal biopsy

Recent innovations in tissue acquisition for the human breast have led to the development of unique direct frontal systems. Efficacy is considered optimal if the diagnosis by transcutaneous biopsy is identical to the surgical specimen in case of malignancy or in line with clinical follow-up when benign. The direct and frontal biopsy systems are safe for the patient, and the procedure can even be considered relatively painless. The quality of the sample is sufficient for research on molecular biology. The direct frontal tissue-acquisition systems can be added to the list of safe and efficient macrobiopsy methods to be used in the early detection of breast cancer.

Open surgical biopsy



Surgeon doing a surgical breast biopsy

Open surgical biopsy means that a large mass or lump is removed during a surgical procedure. Surgical biopsy requires an approximately 3 to 5 centimeters incision and is normally performed in an operating room in sterile conditions. Open surgical biopsy in some cases can be performed with local anesthesia but in most cases general anesthesia may be necessary. Ten years ago, most breast biopsies were open surgical procedures. Today most patients are candidates for less invasive biopsy procedures such as core needle biopsy. Depending on the location of the lesion to be biopsied, a radiologist will often perform needle localization beforehand to guide the surgeon to the site being biopsied.

Skin biopsy

Multiple methods for skin biopsy exist. Each has its own limitation and problems. Most are done under local anesthesia in a doctor's office. The result is very dependent on the clinical history presented to the pathologist, and also the method utilized. A shave biopsy is absolutely useless in diagnosing vasculitis, whereas an excisional biopsy might be excessive in diagnosing a possible basal cell carcinoma

Shave biopsy

This is done with either a small scalpel blade, a curved razor blade, or a broken piece of "safety" razor. The technique is very much user skill dependent, as some surgeons can

remove a small fragment of skin with minimal blemish using any one of the above tools, while others have great difficulty securing the devices. Ideally, the razor will shave only a small fragment of protruding tumor and leaving the skin relatively flat after the procedure. Hemostasis is obtained using light electrocautery, Monsel solution, or aluminum chloride. This is the ideal method of diagnosis for basal cell cancer. It can be used to diagnose squamous cell carcinoma and melanoma-in-situ, however, the doctor's understanding of the growth of these last two cancers should be considered before one uses the shave method. The punch or incisional method is better for the latter two cancers as false negative is less likely to occur (i.e. calling a squamous cell cancer an actinic keratosis or keratinous debris). Hemostasis for the shave technique can be difficult if one relied on electrocautery alone. A small "shave" biopsy often ends up being a large burn defect when the surgeon tries to control the bleeding with electrocautery alone. Pressure dressing or chemical astringent can help in hemostasis in patients taking anticoagulants.

Punch biopsy

This is done with a round shaped knife ranging in size from 1mm to 8 mm. Some punch biopsies are shaped like an ellipse, although one can accomplish the same desired shape with a standard scalpel. The 1 mm and 1.5 mm punch are ideal for locations where cosmetic appearance is difficult to accomplish with the shave method. Minimal bleeding is noted with the 1 mm punch, and often the wound is left to heal without stitching for the smaller punch biopsies. Disadvantage of the 1 mm punch is that the tissue obtained is almost impossible to see at times due to small size, and the 1.5 mm biopsy is preferred in most cases. The common punch size use to diagnose most inflammatory skin condition is the 3.5 or 4 mm punch. Ideally, the punch biopsy include the full thickness skin and subcutaneous fat in the diagnosis of skin diseases. The punch biopsy is preferred over the shave biopsy for the diagnosis of squamous cell carcinoma and for melanomas. One or two sutures are required to close most punch biopsies with the exception of the smallest punches. Two "dog ear" defects can result in punch biopsies much larger than 5 mm, thus an incisional biopsy is preferred on larger lesions.

Incisional biopsy

When a cut is made through the entire dermis down to the subcutaneous fat. A punch biopsy is essentially an incisional biopsy, except it is round rather than elliptical as in most incisional biopsies done with a scalpel. Incisional biopsies can include the whole lesion (excisional), part of a lesion, or part of the affected skin plus part of the normal skin (to show the interface between normal and abnormal skin). Incisional biopsy often yield better diagnosis for deep pannicular skin diseases and more subcutaneous tissue can be obtained than a punch biopsy. Long and thin deep incisional biopsy are excellent on the lower extremities as they allow a large amount of tissue to be harvested with minimal tension on the surgical wound. Advantage of the incisional biopsy over the punch method is that hemostasis can be done more easily due to better visualization. Dog ear defects are rarely seen in incisional biopsies with length at least twice as long as the width.

Excisional biopsy

This is essentially the same as incision biopsy, except the entire lesion or tumor is included. This is the ideal method of diagnosis of small melanomas (when performed as an excision). Ideally, an entire melanoma should be submitted for diagnosis if it can be done safely and cosmetically. This "excisional" biopsy is often done with a narrow margin to make sure the deepest thickness of the melanoma is given before prognosis is decided. However, as many melanoma-in-situ are large and on the face, a physician often chose to do multiple small punch biopsies before committing to a large excision for diagnostic purpose alone. Many prefer the small punch method for initial diagnostic value before resorting to the excisional biopsy. An initial small punch biopsy of a melanoma might say "severe cellular atypia, recommend wider excision". At this point, the clinician can be confident that an excisional biopsy can be performed without risking committing a "false positive" clinical diagnosis.

Curettage biopsy

This can be done on the surface of tumors or on small epidermal lesions with minimal to no topical anesthetic using a round curette blade. Diagnosis of basal cell cancer can be made with some limitation, as morphology of the tumor is often disrupted. The pathologist must be informed about the type of anesthetic used, as topical anesthetic can cause artifact in the epidermal cells.

Fine needle aspirate

This is done with the rapid stabbing motion of the hand guiding a needle tipped syringe and the rapid sucking motion applied to the syringe. It is a method used to diagnose tumor deep in the skin or lymphnodes under the skin. The cellular aspirate is mounted on a glass slide and immediate diagnosis can be made with proper staining or submitted to a laboratory for final diagnosis. A fine needle aspirate can be done with simply a large bore needle and a small syringe (1 cc) that can generate rapid changes in suction pressure. Fine needle aspirate can be used to distinguish a cystic lesion from a lipoma. Both the surgeon and the pathologist must be familiar with the method of procuring, fixing, and reading of the slide. Many center have dedicated team used in the harvest of fine needle aspirate.

"Scoop", "scallop", or "shave" excision


A trend has occurred in dermatology over the last 10 years with the advocacy of a deep shave excision of a pigmented lesion. An author published the result of this method and advocated it as better than standard excision and less time consuming. The added economic benefit is that many surgeons bill the procedure as an excision, rather than a shave biopsy. This save the added time for hemostasis, instruments, and suture cost. The great disadvantage, seen years later is the numerous scallop scars, and a very difficult to deal with lesion called a "recurrent melanocytic nevus". What has happened is that many "shave" excisions does not adequately penetrate the dermis or subcutaneous fat enough to include the entire melanocytic lesion. Residual melanocytes regrow into the scar. The

combination of scarring, inflammation, blood vessels, and atypical pigmented streaks seen in these recurrent nevus gives the perfect dermatoscopic picture of a melanoma. When a second physicians re-examine the patient, he or she has no choice but to recommend the reexcision of the scar. If one does not have access to the original pathology report, it is impossible to tell a recurring nevus from a severely dysplastic nevus or a melanoma. As the procedure is widely practiced, it is not unusual to see a patient with dozens of scallop scars, with as many as 20% of the scar showing residual pigmentation. The second issue with the shave excision is fat herniation, iatrogenic anetoderma, and hypertrophic scarring. As the deep shave excision either completely remove the full thickness of the dermis or greatly diminishing the dermal thickness, subcutaneous fat can herniate outward or pucker the skin out in an unattractive way. In areas prone to friction, this can result in pain, itching, or hypertrophic scarring.

History

One of the earliest diagnostic biopsies was developed by the Arab physician Abulcasim (1013-1107 AD). A needle was used to puncture a goiter, and the material issuing was characterized.

Cancer



Lung biopsy in a case of suspected lung cancer under control of computertomography

When cancer is suspected, a variety of biopsy techniques can be applied. An *excisional biopsy* is an attempt to remove an entire lesion. When the specimen is evaluated, in addition to diagnosis, the amount of uninvolved tissue around the lesion, the *surgical margin* of the specimen is examined to see if the disease has spread beyond the area biopsied. "Clear margins" or "negative margins" means that no disease was found at the edges of the biopsy specimen. "Positive margins" means that disease was found, and a

wider excision may be needed, depending on the diagnosis. When intact removal is not indicated for a variety of reasons, a wedge of tissue may be taken in an *incisional biopsy*. In some cases, a sample can be collected by devices that "bite" a sample. A variety of sizes of needle can collect tissue in the lumen ("core biopsy"). Smaller diameter needles collect cells and cell clusters, fine needle aspiration biopsy. Pathologic examination of a biopsy can determine whether a lesion is benign or malignant, and can help differentiate between different types of cancer. In contrast to a biopsy that merely samples a lesion, a larger excisional specimen called a resection may come to a pathologist, typically from a surgeon attempting to eradicate a known lesion from a patient. For example, a pathologist would examine a mastectomy specimen, even if a previous nonexcisional breast biopsy had already established the diagnosis of breast cancer. Examination of the full mastectomy specimen would confirm the exact nature of the cancer (subclassification of tumor and histologic "grading") and reveal the extent of its spread (pathologic "staging").

Precancerous conditions

For easily detected and accessed sites, any suspicious lesions may be assessed. Originally, this was skin or superficial masses. X-ray, then later CT, MRI, and ultrasound along with endoscopy extended the range.

Inflammatory conditions

A biopsy of the temporal arteries is often performed for suspected vasculitis. In inflammatory bowel disease (Crohn's disease and ulcerative colitis), frequent biopsies are taken to assess the activity of disease and to assess changes that precede malignancy.

Biopsy specimens are often taken from part of a lesion when the cause of a disease is uncertain or its extent or exact character is in doubt. Vasculitis, for instance, is usually diagnosed on biopsy.

Kidney disease

Biopsy and fluorescence microscopy are key in the diagnosis of alterations of renal function. The immunofluorescence plays vital role in the diagnosis of Crescentic glomerulonephritis.

Infectious disease

Lymph node enlargement may be due to a variety of infectious or autoimmune diseases.

Metabolic disease

Some conditions affect the whole body, but certain sites are selectively biopsied because they are easily accessed. Amyloidosis is a condition where degraded proteins accumulate in body tissues. In order to make the diagnosis, the gingival.

Transplantation

Biopsies of transplanted organs are performed in order to determine that they are not being rejected or that the disease that necessitated transplant has not recurred.

Fertility

A testicular biopsy is used for evaluating the fertility of men and find out the cause of a possible infertility, e.g. when sperm quality is low, but hormone levels still are within normal ranges.

Commonly biopsied sites

Bone marrow

Since blood cells are formed in the bone marrow, a bone marrow biopsy is employed in the diagnosis of abnormalities of blood cells when the diagnosis cannot be made from the peripheral blood alone. In malignancies of blood cells (leukemia and lymphoma) a bone marrow biopsy is used in staging the disease. The procedure involves taking a core of trabecular bone using a trephine, and then aspirating material.

Gastrointestinal tract

Flexible endoscopy enables access to the upper and lower gastrointestinal tract, such that biopsy of the esophagus, stomach and duodenum via the mouth and the rectum, colon and terminal ileum are commonplace. A variety of biopsy instruments may be introduced through the endoscope and the visualized site biopsied. Until recently, the majority of the small intestine could not be visualized for biopsy. The double-ballon “push-pull” technique allows visualization and biopsy of the entire gastrointestinal tract.

Needle core biopsies or aspirates of the pancreas may be made through the duodenum or stomach.

Lung

Biopsies of the lung can be performed in a variety of ways depending on the location.

Liver

In hepatitis, most biopsies are not used for diagnosis, which can be made by other means. Rather, it is used to determine response to therapy which can be assessed by reduction of inflammation and progression of disease by the degree of fibrosis or, ultimately, cirrhosis.


In Wilson's disease, the biopsy is used to determine the quantitative copper level.

Analysis of biopsied material

After the biopsy is performed, the sample of tissue that was removed from the patient is sent to the pathology laboratory. A pathologist is a physician who specializes in diagnosing diseases (such as cancer) by examining tissue under a microscope. When the laboratory receives the biopsy sample, the tissue is processed and an extremely thin slice of tissue is removed from the sample and attached to a glass slide. Any remaining tissue is saved for use in later studies, if required. The slide with the tissue attached is treated with dyes that stain the tissue, which allows the individual cells in the tissue to be seen more clearly. The slide is then given to the pathologist, who examines the tissue under a microscope, looking for any abnormal findings. The pathologist then prepares a report that lists any abnormal or important findings from the biopsy. This report is sent to the physician who originally performed the biopsy on the patient.

Chapter 9

Angiography



Angiogram showing a transverse projection of the vertebrobasilar and posterior cerebral circulation

Angiography or **arteriography** is a medical imaging technique used to visualize the inside, or lumen, of blood vessels and organs of the body, with particular interest in the arteries, veins and the heart chambers. This is traditionally done by injecting a radio-opaque contrast agent into the blood vessel and imaging using X-ray based techniques such as fluoroscopy. The word itself comes from the Greek words *angeion*, "vessel", and *graphein*, "to write or record". The film or image of the blood vessels is called an *angiograph*, or more commonly, an *angiogram*.

The term *angiography* is strictly defined as based on projectional radiography; however, the term has been applied to newer vascular imaging techniques such as CT angiography and MR angiography. The term *isotope angiography* has also been used, although this more correctly is referred to as isotope perfusion scanning.

History

The technique was first developed in 1927 by the Portuguese physician and neurologist Egas Moniz at the University of Lisbon to provide contrasted x-ray cerebral angiography in order to diagnose several kinds of nervous diseases, such as tumors, coronary heart disease and arteriovenous malformations. He is usually recognized as one of the pioneers in this field. Moniz performed the first cerebral angiogram in Lisbon in 1927, and Reynaldo Cid dos Santos performed the first aortogram in the same city in 1929. With the introduction of the Seldinger technique in 1953, the procedure became markedly safer as no sharp introductory devices needed to remain inside the vascular lumen.

Technique



Mobile X-ray machine

Depending on the type of angiogram, access to the blood vessels is gained most commonly through the femoral artery, to look at the left side of the heart and the arterial system or the jugular or femoral vein, to look at the right side of the heart and the venous system. Using a system of guide wires and catheters, a type of contrast agent (which shows up by absorbing the x-rays), is added to the blood to make it visible on the x-ray images.

The X-ray images taken may either be still images, displayed on a image intensifier or film, or motion images. For all structures except the heart, the images are usually taken

using a technique called digital subtraction angiography (DSA). Images in this case are usually taken at 2 - 3 frames per second, which allows the radiologist to evaluate the flow of the blood through a vessel or vessels. This technique "subtracts" the bones and other organs so only the vessels filled with contrast agent can be seen. The heart images are taken at 15-30 frames per second, not using a subtraction technique. Because DSA requires the patient to remain motionless, it cannot be used on the heart. Both these techniques enable the radiologist or cardiologist to see stenosis (blockages or narrowings) inside the vessel which may be inhibiting the flow of blood and causing pain.

Uses

Coronary angiography

One of most common angiograms performed is to visualize the blood in the coronary arteries. A long, thin, flexible tube called a catheter is used to administer the x-ray contrast agent at the desired area to be visualized. The catheter is threaded into an artery in the forearm, and the tip is advanced through the arterial system into the major coronary artery. X-ray images of the transient radiocontrast distribution within the blood flowing within the coronary arteries allows visualization of the size of the artery openings. Presence or absence of atherosclerosis or atheroma within the walls of the arteries cannot be clearly determined.

Microangiography

Microangiography is commonly used to visualize tiny blood vessels.

Neuro-vascular angiography

Another increasingly common angiographic procedure is neuro-vascular digital subtraction angiography in order to visualise the arterial and venous supply to the brain. Intervention work such as coil-embolisation of aneurysms and AVM gluing can also be performed.

Peripheral angiography

Angiography is also commonly performed to identify vessel narrowing in patients with leg claudication or *cramps*, caused by reduced blood flow down the legs and to the feet; in patients with renal stenosis (which commonly causes high blood pressure) and can be used in the head to find and repair stroke. These are all done routinely through the femoral artery, but can also be performed through the brachial or axillary (arm) artery. Any stenoses found may be treated by the use of atherectomy.

Other

Other angiographic uses include the diagnosis of retinal vascular disorders, such as diabetic retinopathy and macular degeneration.

Complications

Coronary angiography

Coronary angiographies are common and major complications are rare. These include Cardiac arrhythmias, kidney damage, blood clots (which can cause heart attack or stroke), hypotension and pericardial effusion. Minor complications can include bleeding or bruising at the site where the contrast is injected, blood vessel damage on the route to the heart from the catheter (rare) and allergic reaction to the contrast.

Cerebral angiography

Major complications in Cerebral Angiography are also rare but include stroke, an allergic reaction to the anaesthetic other medication or the contrast medium, blockage or damage to one of the access veins in the leg, or thrombosis and embolism formation. Bleeding or bruising at the site where the contrast is injected are minor complications, delayed bleeding can also occur but is rare.

Chapter 10

Dialysis



A hemodialysis machine

In medicine, **dialysis** (from Greek "dialysis", meaning dissolution, "dia", meaning through, and "lysis", meaning loosening) is primarily used to provide an artificial replacement for lost kidney function in people with renal failure. Dialysis may be used for those with an acute disturbance in kidney function (acute kidney injury, previously acute renal failure) or for those with progressive but chronically worsening kidney function—a state known as chronic kidney disease stage 5 (previously chronic renal failure or end-stage kidney disease). The latter form may develop over months or years, but in contrast to acute kidney injury is not usually reversible, and dialysis is regarded as a

"holding measure" until a renal transplant can be performed, or sometimes as the only supportive measure in those for whom a transplant would be inappropriate.

The kidneys have important roles in maintaining health. When healthy, the kidneys maintain the body's internal equilibrium of water and minerals (sodium, potassium, chloride, calcium, phosphorus, magnesium, sulfate). Those acidic metabolism end products that the body cannot get rid of via respiration are also excreted through the kidneys. The kidneys also function as a part of the endocrine system producing erythropoietin and calcitriol. Erythropoietin is involved in the production of red blood cells and calcitriol plays a role in bone formation. Dialysis is an imperfect treatment to replace kidney function because it does not correct the endocrine functions of the kidney. Dialysis treatments replace some of these functions through diffusion (waste removal) and ultrafiltration (fluid removal).

History

Dr. Willem Kolff, a Dutch physician, constructed the first working dialyzer in 1943 during the Nazi occupation of the Netherlands. Due to the scarcity of available resources, Kolff had to improvise and build the initial machine using sausage casings, beverage cans, a washing machine and various other items which were available at the time. Over the following two years, Kolff used his machine to treat 16 patients who suffered from acute kidney failure, but the results were unsuccessful. Then, in 1945, a 67-year-old woman in uremic coma regained consciousness following 11 hours of hemodialysis with the dialyzer, and lived for another seven years before dying of an unrelated condition. She was the first-ever patient successfully treated with dialysis.

Principle

Dialysis works on the principles of the diffusion of solutes and ultrafiltration of fluid across a semi-permeable membrane. Diffusion describes a property of substances in water. Substances in water tend to move from an area of high concentration to an area of low concentration. Blood flows by one side of a semi-permeable membrane, and a dialysate, or special dialysis fluid, flows by the opposite side. A semipermeable membrane is a thin layer of material that contains various sized holes, or pores. Smaller solutes and fluid pass through the membrane, but the membrane blocks the passage of larger substances (for example, red blood cells, large proteins).

The two main types of dialysis, hemodialysis and Peritoneal dialysis, remove wastes and excess water from the blood in different ways. Hemodialysis removes wastes and water by circulating blood outside the body through an external filter, called a dialyzer, that contains a semipermeable membrane. The blood flows in one direction and the dialysate flows in the opposite. The counter-current flow of the blood and dialysate maximizes the concentration gradient of solutes between the blood and dialysate, which helps to remove more urea and creatinine from the blood. The concentrations of solutes (for example potassium, phosphorus, and urea) are undesirably high in the blood, but low or absent in the dialysis solution and constant replacement of the dialysate ensures that the


concentration of undesired solutes is kept low on this side of the membrane. The dialysis solution has levels of minerals like potassium and calcium that are similar to their natural concentration in healthy blood. For another solute, bicarbonate, dialysis solution level is set at a slightly higher level than in normal blood, to encourage diffusion of bicarbonate into the blood, to act as a pH buffer to neutralize the metabolic acidosis that is often present in these patients. The levels of the components of dialysate are typically prescribed by a nephrologist according to the needs of the individual patient.

In peritoneal dialysis, wastes and water are removed from the blood inside the body using the *peritoneal membrane* of the peritoneum as a natural semipermeable membrane. Wastes and excess water move from the blood, across the peritoneal membrane, and into a special dialysis solution, called dialysate, in the abdominal cavity which has a composition similar to the fluid portion of blood.

Types

There are two primary and two secondary types of dialysis: hemodialysis, peritoneal dialysis, hemofiltration, hemodiafiltration, and intestinal dialysis.


Hemodialysis



Hemodialysis schematic

In hemodialysis, the patient's blood is pumped through the blood compartment of a dialyzer, exposing it to a partially permeable membrane. The dialyzer is composed of thousands of tiny synthetic hollow fibers. The fiber wall acts as the semipermeable membrane. Blood flows through the fibers, dialysis solution flows around the outside the fibers, and water and wastes move between these two solutions. The cleansed blood is then returned via the circuit back to the body. Ultrafiltration occurs by increasing the hydrostatic pressure across the dialyzer membrane. This usually is done by applying a negative pressure to the dialysate compartment of the dialyzer. This pressure gradient causes water and dissolved solutes to move from blood to dialysate, and allows the removal of several litres of excess fluid during a typical 3 to 5 hour treatment. In the US, hemodialysis treatments are typically given in a dialysis center three times per week (due in the US to Medicare reimbursement rules); however, as of 2007 over 2,500 people in the US are dialyzing at home more frequently for various treatment lengths. Studies have demonstrated the clinical benefits of dialyzing 5 to 7 times a week, for 6 to 8 hours. This type of hemodialysis is usually called "nocturnal daily hemodialysis", which a study has shown a significant improvement in both small and large molecular weight clearance and decrease the requirement of taking phosphate binders. These frequent long treatments are often done at home while sleeping, but home dialysis is a flexible modality and schedules can be changed day to day, week to week. In general, studies have shown that both increased treatment length and frequency are clinically beneficial.

Peritoneal dialysis



Schematic diagram of peritoneal dialysis

In peritoneal dialysis, a sterile solution containing glucose is run through a tube into the peritoneal cavity, the abdominal body cavity around the intestine, where the peritoneal membrane acts as a semipermeable membrane. The peritoneal membrane or peritoneum is a layer of tissue containing blood vessels that lines and surrounds the peritoneal, or abdominal, cavity and the internal abdominal organs (stomach, spleen, liver, and intestines). The dialysate is left there for a period of time to absorb waste products, and

then it is drained out through the tube and discarded. This cycle or "exchange" is normally repeated 4-5 times during the day, (sometimes more often overnight with an automated system). Each time the dialysate fills and empties from the abdomen is called one exchange. A dwell time means that the time of dialysate stay in patient's abdominal cavity - wastes, chemicals and extra fluid move from patient's blood to the dialysate across the peritoneum. A drain process is the process after the dwell time, the dialysate full with waste products and extra fluid is drained out of patient's blood. Ultrafiltration occurs via osmosis; the dialysis solution used contains a high concentration of glucose, and the resulting osmotic pressure causes fluid to move from the blood into the dialysate. As a result, more fluid is drained than was instilled. Peritoneal dialysis is less efficient than hemodialysis, but because it is carried out for a longer period of time the net effect in terms of removal of waste products and of salt and water are similar to hemodialysis. Peritoneal dialysis is carried out at home by the patient. Although support is helpful, it is not essential. It does free patients from the routine of having to go to a dialysis clinic on a fixed schedule multiple times per week, and it can be done while travelling with a minimum of specialized equipment.

Hemofiltration

Hemofiltration is a similar treatment to hemodialysis, but it makes use of a different principle. The blood is pumped through a dialyzer or "hemofilter" as in dialysis, but no dialysate is used. A pressure gradient is applied; as a result, water moves across the very permeable membrane rapidly, "dragging" along with it many dissolved substances, importantly ones with large molecular weights, which are cleared less well by hemodialysis. Salts and water lost from the blood during this process are replaced with a "substitution fluid" that is infused into the extracorporeal circuit during the treatment. Hemodiafiltration is a term used to describe several methods of combining hemodialysis and hemofiltration in one process.

Hemodiafiltration

Hemodiafiltration is a combination of hemodialysis and hemofiltration. In theory, this technique offers the advantages of both hemodialysis and hemofiltration.

Intestinal dialysis

In intestinal dialysis, the diet is supplemented with soluble fibres such as acacia fibre, which is digested by bacteria in the colon. This bacterial growth increases the amount of nitrogen that is eliminated in fecal waste. An alternative approach utilizes the ingestion of 1 to 1.5 liters of non-absorbable solutions of polyethylene glycol or mannitol every fourth hour.

Starting indications


The decision to initiate dialysis or hemofiltration in patients with renal failure depends on several factors. These can be divided into acute or chronic indications.

- Indications for dialysis in the patient with acute kidney injury are:
 1. Metabolic acidosis in situations where correction with sodium bicarbonate is impractical or may result in fluid overload.
 2. Electrolyte abnormality, such as severe hyperkalemia, especially when combined with AKI.
 3. Fluid overload not expected to respond to treatment with diuretics.
 4. Complications of uremia, such as pericarditis, encephalopathy, or gastrointestinal bleeding.
 5. Intoxication, that is, acute poisoning with a dialyzable substance. These substances can be represented by the mnemonic SLIME: salicylic acid, lithium, isopropanol, Magnesium-containing laxatives, and ethylene glycol.

- Chronic indications for dialysis:
 1. Symptomatic renal failure
 2. Low glomerular filtration rate (GFR) (RRT often recommended to commence at a GFR of less than 10-15 mls/min/1.73m²). In diabetics dialysis is started earlier.
 3. Difficulty in medically controlling fluid overload, serum potassium, and/or serum phosphorus when the GFR is very low

Chapter 11

Kidney Transplantation



The donor kidney is typically placed inferior of the normal anatomical location

Kidney transplantation or **renal transplantation** is the organ transplant of a kidney into a patient with end-stage renal disease. Kidney transplantation is typically classified as deceased-donor (formerly known as cadaveric) or living-donor transplantation depending on the source of the donor organ. Living-donor renal transplants are further characterized as genetically related (living-related) or non-related (living-unrelated) transplants, depending on whether a biological relationship exists between the donor and recipient.

History

The first cadaveric kidney transplantation in the United States was performed June 17, 1950, on Ruth Tucker, a 44-year-old woman with polycystic kidney disease, at Little Company of Mary Hospital in Evergreen Park, Illinois. Although the donated kidney was rejected ten months later because no immunosuppressive therapy was available at the time—the development of effective antirejection drugs was years away—the intervening time gave Tucker's remaining kidney time to recover and she lived another five years.

The first kidney transplants between living patients were undertaken in 1954 in Boston and Paris. The Boston transplantation, performed on December 23, 1954, at Brigham Hospital was performed by Joseph Murray, J. Hartwell Harrison, John Merrill and others. The procedure was done between identical twins to eliminate any problems of an immune reaction. For this and later work, Dr. Murray received the Nobel Prize for Medicine in 1990. The recipient died eight years after the transplantation.

The first kidney transplantation in the United Kingdom did not occur until 1960, when Michael Woodruff performed one between identical twins in Edinburgh. Until the routine use of medications to prevent and treat acute rejection, introduced in 1964, deceased donor transplantation was not performed. The kidney was the easiest organ to transplant: tissue typing was simple, the organ was relatively easy to remove and implant, live donors could be used without difficulty, and in the event of failure, kidney dialysis was available from the 1940s. Tissue typing was essential to the success: early attempts in the 1950s on sufferers from Bright's disease had been very unsuccessful.

The major barrier to organ transplantation between genetically non-identical patients lay in the recipient's immune system, which would treat a transplanted kidney as a "non-self" and immediately or chronically, reject it. Thus, having medications to suppress the immune system was essential. However, suppressing an individual's immune system places that individual at greater risk of infection and cancer (particularly skin cancer and lymphoma), in addition to the side effects of the medications.

The basis for most immunosuppressive regimens is prednisolone, a corticosteroid. Prednisolone suppresses the immune system, but its long-term use at high doses causes a multitude of side effects, including glucose intolerance and diabetes, weight gain, osteoporosis, muscle weakness, hypercholesterolemia, and cataract formation. Prednisolone alone is usually inadequate to prevent rejection of a transplanted kidney. Thus other, non-steroid immunosuppressive agents are needed, which also allow lower doses of prednisolone.

Indications

The indication for kidney transplantation is end-stage renal disease (ESRD), regardless of the primary cause. This is defined as a drop in the glomerular filtration rate (GFR) to 20–25% of normal. Common diseases leading to ESRD include malignant hypertension, infections, diabetes mellitus, and focal segmental glomerulosclerosis; genetic causes

include polycystic kidney disease, a number of inborn errors of metabolism, and autoimmune conditions such as lupus and Goodpasture's syndrome. Diabetes is the most common cause of kidney transplantation, accounting for approximately 25% of those in the US. The majority of renal transplant recipients are on some form of peritoneal dialysis, or the similar process of hemofiltration—at the time of transplantation. However, individuals with chronic renal failure who have a living donor available may undergo pre-emptive transplantation before dialysis is needed.

Contraindications and Requirements

Contraindications include both cardiac and pulmonary insufficiency, as well as hepatic disease. Concurrent tobacco use and morbid obesity are also among the indicators putting a patient at a higher risk for surgical complications.

Kidney transplant requirements vary from program to program and country to country. Many programs place limits on age (e.g. the person must be under a certain age to enter the waiting list) and require that one must be in good health (aside from the kidney disease). Significant cardiovascular disease, incurable terminal infectious diseases and cancer often are transplant exclusion criteria. In addition, candidates are typically screened to determine if they will be compliant with their medications, which is essential for survival of the transplant. People with mental illness and/or significant on-going substance abuse issues may be excluded.

HIV was at one point considered to be a complete contraindication to transplantation. There was fear that immunosuppressing someone with a depleted immune system would result in the progression of the disease. However, some research seem to suggest that immunosuppressive drugs and antiretrovirals may work synergistically to help both HIV viral loads/CD4 cell counts and prevent active rejection.

Sources of kidneys

Since medication to prevent rejection is so effective, donors do not need to be genetically similar to their recipient. Most donated kidneys come from deceased donors, however the utilization of living donors in the United States is on the rise. In 2006, 47% of donated kidneys were from living donors. This varies by country: for example, only 3% of kidneys transplanted during 2006 in Spain came from living donors.

Living donors

More than one in three donations in the UK is now from a live donor and almost one in three in Israel. The percentage of transplants from living donors is increasing. Potential donors are carefully evaluated on medical and psychological grounds. This ensures that the donor is fit for surgery and has no disease which brings undue risk or likelihood of a poor outcome for either the donor or recipient. The psychological assessment is to ensure the donor gives informed consent and is not coerced. In countries where paying for organs is illegal, the authorities may also seek to ensure that a donation has not resulted

from a financial transaction. In the UK, the Human Tissue Act 2004 (HTA) dictated that donors must prove a familial or long term relationship or enduring friendship, for instance by providing photographs of themselves together spread over a period of time, or a birth or wedding certificate. Purely altruistic donation to strangers has recently been accepted by the Human Tissue Authority in the United Kingdom, and as of December 2007 only four people had been given permission to do this under the HTA. The decision must be approved by a panel, whereas the typical donation based on relationship is required only to go through an executive. There is good evidence that kidney donation is not associated with long term harm to the donor.

So called "daisy chain" transplants in the US involve one altruistic donor who donates a kidney to someone who has a family member willing to donate, who isn't a match. That family member then donates to a recipient who is a match. This "chain" can be continued with several more pairs of donors/recipients.

Traditionally, the donor procedure has been through a single incision of 4–7 inches (10–18 cm), but live donation is being increasingly performed by laparoscopic surgery. This reduces pain and accelerates recovery for the donor. Operative time and complications decreased significantly after a surgeon performed 150 cases. Live donor kidney grafts tend to perform better than those from deceased donors. Since the increase in the use of laparoscopic surgery, the number of live donors has increased. Any advance which leads to a decrease in pain and scarring and swifter recovery has the potential to boost donor numbers. In January 2009, the first all-robotic kidney transplant was performed at Saint Barnabas Medical Center through a two-inch incision. In the following six months, the same team performed eight more robotic-assisted transplants.

In 2004 the FDA approved the Cedars-Sinai High Dose IVIG therapy which reduces the need for the living donor to be the same blood type (ABO compatible) or even a tissue match. The therapy reduced the incidence of the recipient's immune system rejecting the donated kidney in highly sensitized patients.

In 2009 at the Johns Hopkins Medical Center, a healthy kidney was removed through the donor's vagina. Vaginal donations promise to speed recovery and reduce scarring. The first donor was chosen as she had previously had a hysterectomy. The extraction was performed using natural orifice transluminal endoscopic surgery, where an endoscope is inserted through an orifice, then through an internal incision, so that there is no external scar. The recent advance of single port access surgery requiring only one entry point at the navel is another advance with potential for more frequent use.

Organ trade

In the developing world some people sell their organs. Such people are often in grave poverty, or exploited by salespersons. People travelling to make use of such kidneys, sometimes known as "transplant tourists", are not looked upon favorably by organizations such as the US National Kidney Foundation. These patients may have increased complications due to poor infection control and lower medical and surgical standards.

One surgeon has said organ trade could be legalized in the UK to prevent such tourism, but this is not seen by the National Kidney Research Fund as the answer to a deficit in donors.

Deceased donors

Deceased donors can be divided in two groups:

- Brain-dead (BD) donors
- Donation after Cardiac Death (DCD) donors

Although brain-dead (or "beating heart") donors are considered dead, the donor's heart continues to pump and maintain the circulation. This makes it possible for surgeons to start operating while the organs are still being perfused. During the operation, the aorta will be cannulated, after which the donor's blood will be replaced by an ice-cold storage solution, such as UW (Viaspan), HTK, or Perfadex. Depending on which organs are transplanted, more than one solution may be used simultaneously. Due to the temperature of the solution, and since large amounts of cold NaCl-solution are poured over the organs for a rapid cooling, the heart will stop pumping.

"Donation after Cardiac Death" donors are patients who do not meet the brain-dead criteria but, due to the small chance of recovery, have elected via a living will or through family to withdraw support. In this procedure, treatment is discontinued (mechanical ventilation is shut off). After a time of death has been pronounced, the patient is rushed to the operating room where the organs are recovered. Storage solution is flushed through the organs. Since the blood is no longer being circulated, coagulation must be prevented with large amounts of anti-coagulation agents such as heparin. Several ethical and procedural guidelines must be followed; most importantly, the organ recovery team should not participate in the patient's care in any manner until after death has been declared.

Compatibility

If plasmapheresis or IVIG is not performed, the donor and recipient have to be ABO blood group compatible. Also, they should ideally share as many HLA and "minor antigens" as possible. This decreases the risk of transplant rejection and the need for another transplant. The risk of rejection may be further reduced if the recipient is not already sensitized to potential donor HLA antigens, and if immunosuppressant levels are kept in an appropriate range. In the United States, up to 17% of all deceased donor kidney transplants have no HLA mismatch. However, HLA matching is a relatively minor predictor of transplant outcomes. In fact, living non-related donors are now almost as common as living (genetically)-related donors.

In the 1980s, experimental protocols were developed for ABO-incompatible transplants using increased immunosuppression and plasmapheresis. Through the 1990s these techniques were improved and an important study of long-term outcomes in Japan was

published (). Now, a number of programs around the world are routinely performing ABO-incompatible transplants.

Procedure

In most cases the barely functioning existing kidneys are not removed, as this has been shown to increase the rates of surgical morbidities. Therefore the kidney is usually placed in a location different from the original kidney, often in the iliac fossa, so it is often necessary to use a different blood supply:

- The renal artery of the kidney, previously branching from the abdominal aorta in the donor, is often connected to the external iliac artery in the recipient.
- The renal vein of the new kidney, previously draining to the inferior vena cava in the donor, is often connected to the external iliac vein in the recipient.

There is disagreement in surgical textbooks regarding which side of the recipient's pelvis to use in receiving the transplant. Campbell's Urology (2002) recommends placing the donor kidney in the recipient's contralateral side (i.e. a left sided kidney would be transplanted in the recipient's right side) to ensure the renal pelvis and ureter are anterior in the event that future surgeries are required. In an instance where there is doubt over whether there is enough space in the recipient's pelvis for the donor's kidney the textbook recommends using the right side because the right side has a wider choice of arteries and veins for reconstruction. Smith's Urology (2004) states that either side of the recipient's pelvis is acceptable, however the right vessels are "more horizontal" with respect to each other and therefore easier to use in the anastomoses. It is unclear what is meant by the words "more horizontal". Glen's Urological Surgery (2004) recommends putting the kidney in the contralateral side in all circumstances. No reason is explicitly put forth however one can assume the rationale is similar to that of Campbell's- to ensure the renal pelvis and ureter are most anterior in the event that future surgical correction are necessary.

Kidney-pancreas transplant

Occasionally, the kidney is transplanted together with the pancreas. This is done in patients with diabetes mellitus type 1, in whom the diabetes is due to destruction of the beta cells of the pancreas and in whom the diabetes has caused renal failure (diabetic nephropathy). This is almost always a deceased donor transplant. Only a few living donor (partial) pancreas transplants have been done. For individuals with diabetes and renal failure, the advantages of earlier transplant from a living donor (if available) are far superior to the risks of continued dialysis until a combined kidney and pancreas are available from a deceased donor. A patient can either receive a living kidney followed by a donor pancreas at a later date (PAK, or pancreas-after-kidney) or a combined kidney-pancreas from a donor (SKP, simultaneous kidney-pancreas).

Transplanting just the islet cells from the pancreas is still in the experimental stage, but shows promise. This involves taking a deceased donor pancreas, breaking it down, and

extracting the islet cells that make insulin. The cells are then injected through a catheter into the recipient and they generally lodge in the liver. The recipient still needs to take immunosuppressants to avoid rejection, but no surgery is required. Most people need two or three such injections, and many are not completely insulin-free.

Post operation

The transplant surgery takes about three hours. The donor kidney will be placed in the lower abdomen and its blood vessels connected to arteries and veins in the recipient's body. When this is complete, blood will be allowed to flow through the kidney again. The final step is connecting the ureter from the donor kidney to the bladder. In most cases, the kidney will soon start producing urine.

Depending on its quality, the new kidney usually begins functioning immediately. Living donor kidneys normally require 3–5 days to reach normal functioning levels, while cadaveric donations stretch that interval to 7–15 days. Hospital stay is typically for 4–7 days. If complications arise, additional medications (diuretics) may be administered to help the kidney produce urine.

Immunosuppressant drugs are used to suppress the immune system from rejecting the donor kidney. These medicines must be taken for the rest of the patient's life. The most common medication regimen today is a cocktail of tacrolimus, mycophenolate, and prednisone. Some patients may instead take cyclosporine, sirolimus, or azathioprine. Cyclosporine, considered a breakthrough immunosuppressive when first discovered in the 1980s, ironically causes nephrotoxicity and can result in iatrogenic damage to the newly transplanted kidney. Blood levels must be monitored closely and if the patient seems to have declining renal function, a biopsy may be necessary to determine whether this is due to rejection or cyclosporine intoxication.

Post operation diet

Grapefruit can decrease the proper metabolism of many drugs, and therefore decrease/or almost cancel out the effect of many critical drugs given after kidney transplants. Therefore, grapefruit products and certain other citrus products must be avoided.

Acute rejection occurs in 10–25% of people after transplant during the first sixty days. Rejection does not necessarily mean loss of the organ, but may require additional treatment and medication adjustments.

Complications

Problems after a transplant may include:

- Transplant rejection (hyperacute, acute or chronic)
- Infections and sepsis due to the immunosuppressant drugs that are required to decrease risk of rejection

- Post-transplant lymphoproliferative disorder (a form of lymphoma due to the immune suppressants)
- Imbalances in electrolytes including calcium and phosphate which can lead to bone problems amongst other things
- Other side effects of medications including gastrointestinal inflammation and ulceration of the stomach and esophagus, hirsutism (excessive hair growth in a male-pattern distribution), hair loss, obesity, acne, diabetes mellitus type 2, hypercholesterolemia, and others.

The average lifetime for a donated kidney is ten to fifteen years. When a transplant fails, a patient may opt for a second transplant, and may have to return to dialysis for some intermediary time.

Prognosis

Kidney transplantation is a life-extending procedure. The typical patient will live ten to fifteen years longer with a kidney transplant than if kept on dialysis. The years of life gained is greater for younger patients, but even 75 year-old recipients (the oldest group for which there is data) gain an average four more years' life. People generally have more energy, a less restricted diet, and fewer complications with a kidney transplant than if they stay on conventional dialysis.

Some studies seem to suggest that the longer a patient is on dialysis before the transplant, the less time the kidney will last. It is not clear why this occurs, but it underscores the need for rapid referral to a transplant program. Ideally, a kidney transplant should be pre-emptive, i.e. take place before the patient begins dialysis.

At least four professional athletes have made a comeback to their sport after receiving a transplant: New Zealand rugby union player Jonah Lomu, German-Croatian Soccer Player Ivan Klasnić, and NBA basketballers Sean Elliott and Alonzo Mourning.

Statistics

Statistics by country, year and donor type

Country	Year	Cadaveric donor	Living donor	Total transplants
Canada	2000	724	388	1,112
France	2003	1,991	136	2,127
Italy	2003	1,489	135	1,624
Spain	2003	1,991	60	2,051
United Kingdom	2003	1,297	439	1,736
United States	2008	10,551	5,966	16,517
Pakistan - SIUT	2008		1,854	1,932

- Bill Thompson is the longest surviving American kidney recipient. Having received his kidney in 1966 at age 15, it has survived over 40 years

- Denice Lombard of Washington, D.C., received her father's kidney on August 30, 1967, aged 13 and is still alive and healthy forty years later.
- In Kenya, John Dan of Nairobi is the longest known surviving kidney recipient in East Africa. He received a kidney from his brother in 1984 and is still alive twenty six years later.

In addition to nationality, transplantation rates differ based on race, sex, and income. A study done with patients beginning long term dialysis showed that the sociodemographic barriers to renal transplantation present themselves even before patients are on the transplant list. For example, different groups express definite interest and complete pretransplant workup at different rates. Previous efforts to create fair transplantation policies had focused on patients currently on the transplantation waiting list.

In the US health system

A major barrier to individuals being accepted by a kidney transplant program in the United States is lack of adequate insurance. Transplant recipients must take immunosuppressive anti-rejection drugs for as long as the transplanted kidney functions. For the routine immunosuppressives Prograf, Cellcept and prednisone, these drugs cost US\$1,500 per month. In 1999 Congress passed a law that restricts Medicare from paying for more than three years for these drugs, unless the patient is otherwise Medicare eligible. Transplant programs may not transplant a patient unless the patient has a reasonable plan to pay for medication after the medicare expires, however, patients are almost never turned down for financial reasons alone. 50% of patients with end-stage renal disease only have Medicare coverage.

In March 2009 a bill was introduced in the Senate, S. 565 and in the House, H.R. 1458 that will extend Medicare coverage of the drugs for as long as the patient has a functioning transplant. This means that patients who have lost their jobs and insurance will not also lose their kidney and be forced back on dialysis. Dialysis is currently using up \$17 billion yearly of Medicare funds and total care of these patients amounts to over 10% of the entire Medicare budget.

Chapter 12

Urology

Urologist

Occupation

Names	Doctor, Medical Specialist
Type	Specialty
Activity sectors	Medicine

Description

Education required Doctor of Medicine

Fields of employment Hospitals, Clinics

Urology (from Greek *οὔρον* - *oûron*, "urine" and *-λογία*, *-logia* "study of") is the medical and surgical specialty that focuses on the urinary tracts of males and females, and on the reproductive system of males. Medical professionals specializing in the field of urology are called **urologists** and are trained to diagnose, treat, and manage patients with urological disorders. The organs covered by urology include the kidneys, adrenal glands, ureters, urinary bladder, urethra, and the male reproductive organs (testes, epididymis, vas deferens, seminal vesicles, prostate and penis). Urology is one of the most competitive specialties to enter for physicians.

In men, the urinary system overlaps with the reproductive system, and in women the urinary tract opens into the vulva. In both sexes, the urinary and reproductive tracts are close together, and disorders of one often affect the other. Urology combines management of medical (i.e. non-surgical) problems such as urinary tract infections and benign prostatic hyperplasia, as well as surgical problems such as the surgical management of cancers, the correction of congenital abnormalities, and correcting stress incontinence.

Urology is closely related to, and in some cases overlaps with, the medical fields of oncology, nephrology, gynecology, andrology, pediatric surgery, gastroenterology, and endocrinology.

Subdisciplines

As a discipline that involves the study of many organs and physiological systems, urology can be broken down into subfields. At larger centers and especially university hospitals, many urologists sub-specialize within a particular field of urology.

Endourology

Endourology is the branch of urology that deals with minimally invasive surgical procedures. As opposed to open surgery, endourology is performed using small **cameras** and instruments inserted into the urinary tract. Traditionally, transurethral surgery has been the cornerstone of endourology. Via the urethra, the complete urinary tract can be reached, enabling prostate surgery, surgery of tumors of the urothelium, stone surgery, and simple urethral and ureteral procedures.

Laparoscopy

Laparoscopy is a rapidly evolving branch of Urology and has replaced some open surgical procedures. Robotic assisted surgery of the prostate, kidney, and ureter has been expanding this field. Today, the majority of prostatectomies in the U.S. are carried out by robotic surgery. This has created controversy, however, as the machines are very expensive, require a dedicated surgical team, have high maintenance costs, and to date the only proven benefit of a robotic prostatectomy to an open one is less blood loss.

Urologic oncology

Urologic oncology concerns the surgical treatment of malignant genitourinary diseases such as cancer of the prostate, adrenal glands, bladder, kidneys, ureters, testicles and penis. The medical treatment of advanced genitourinary cancer is managed by either a Urologist or an Oncologist depending on the cancer.

Neurourology

Neurourology concerns nervous system control of the genitourinary system, and of conditions causing abnormal urination. Neurological diseases and disorders such as multiple sclerosis, Parkinson's disease, and spinal cord injury can disrupt the lower urinary tract and result in conditions such as urinary incontinence, detrusor overactivity, urinary retention, and detrusor sphincter dyssynergia. Urodynamic studies play an important diagnostic role in neurourology. Therapy for nervous system disorders includes clean intermittent self-catheterization of the bladder, anticholinergic drugs, injection of Botulinum toxin into the bladder wall and advanced and less commonly used therapies such as sacral neuromodulation. Less marked neurological abnormalities can cause urological disorders as well—for example, abnormalities of the sensory nervous system are thought by many researchers to play a role in disorders of painful or frequent urination (e.g. painful bladder syndrome, formerly known as interstitial cystitis).

Pediatric urology

Pediatric urology concerns urologic disorders in children. Such disorders include cryptorchism (undescended testes), congenital abnormalities of the genito-urinary tract, enuresis, underdeveloped genitalia (due to delayed growth or delayed puberty, often an endocrinological problem), and vesicoureteral reflux.

Andrology

Andrology focuses on the male reproductive system. It is mainly concerned with male infertility, erectile dysfunction and ejaculatory disorders. Since male sexuality is largely controlled by hormones, andrology overlaps with endocrinology. Surgery in this field includes fertilization procedures, vasectomy reversals, and the implantation of penile prostheses. Vasectomies may also be included here although most urologists perform this procedure.

Reconstructive urology

Reconstructive urology reestablishes functionality of the genito-urinary tract. Structures of the urethra or the ureter often require reconstructive surgery. Another frequent procedure is the reconstruction of the urinary bladder from small bowel in conjunction with cancer surgery. Cosmetic surgery such as penis enlargement is rarely done in urology.

Female urology

Female urology is a branch dealing with overactive bladder, pelvic organ prolapse, and urinary incontinence. Thorough knowledge of the female pelvic floor together with urodynamic skills are necessary to diagnose and treat these disorders. Depending on the cause of the individual problem a medical or surgical treatment can be the solution.

Chapter 13

Urogynecology

Urogynecologist

Occupation

Names	Doctor, Medical Specialist, Surgeon
Type	Gynecology, Urology, Specialty, Surgery
Activity sectors	Medicine, Surgery

Description

Competencies	Patient Care, Education, Research
Education required	Doctor of Medicine
Fields of employment	Hospitals, Clinics
Related jobs	Gynecologist, Urologist

Urogynecology is a surgical sub-specialty of urology and gynecology.

History

In 1893, Howard Kelly, a gynecologist and pioneering urogynecologist, invented an air cystoscope which was simply a handheld, hollow tube with a glass partition. When the American Surgical Society, later the American College of Surgeons, met in Baltimore in 1900, a contest was held between Howard Kelly and Hugh Hampton Young, who is often considered the father of modern urology. Using his air cystoscope, Kelly inserted ureteral catheters in a female patient in just 3 minutes. Young equaled this time in a male patient. So began the friendly competitive rivalry between gynecologists and urologists in the area of female urology and urogynecology. This friendly competition continued for decades. In modern times, the mutual interest of obstetricians, gynecologists, and urologists in pelvic floor problems in women has led to a more collaborative effort.

Education and training

Gynecologists who practice this sub-specialty are called urogynecologists and urologists who practice this sub-specialty are called female urologists. In the United States, urogynecologists have completed medical school and a four-year residency in obstetrics and gynecology and female urologists have completed medical school and a five-year residency in urology. These doctors become specialists with additional training and experience in the evaluation and treatment of conditions that affect the female pelvic organs, and the muscles and connective tissue that support the organs. The additional training focuses on the surgical and non-surgical treatment of non-cancerous gynecologic problems.

A few practitioners have completed a board-accredited fellowship in female pelvic medicine and reconstructive surgery after completing a residency in urology or obstetrics and gynecology. The first fellowship received accreditation in 1996. As of January 2010, there were 30 fellowship programs approved by both the American Board of Obstetrics and Gynecology and the American Board of Urology. These fellowships are three-years for obstetrician-gynecologists and two-years for urologists. Thus, the combined duration of training for female pelvic medicine and reconstructive surgery is seven years after medical school for both urologists and gynecologists. The International Urogynecology Journal publishes a listing of world-wide training programs.

Scope of practice

Urogynecology involves the diagnosis and treatment of urinary incontinence and female pelvic floor disorders. Incontinence and pelvic floor problems are remarkably common but many women are reluctant to receive help because of the stigma associated with these conditions. "There is no more distressing lesion than urinary incontinence-A constant dribbling of the repulsive urine soaking the clothes which cling wet and cold to the thighs, making the patient offensive to herself and her family and ostracizing her from society" Although countless women are bothered by a loss of bladder control, bowel symptoms, and pelvic discomfort they are often not aware that these problems have a name much less how common they really are. Pelvic floor conditions are more common than hypertension, depression, or diabetes. One in three adult women have hypertension; one in twenty adult women have depression; one in ten adult women have diabetes; and, more than one in two adult women suffer from pelvic floor dysfunction.

Some conditions treated in urogynecology practice include:

- Cystocele
- Enterocele
- Female genital prolapse
- Fecal incontinence
- Incontinence (fecal and urinary)
- Interstitial cystitis
- Lichen planus

- Lichen sclerosus
- Müllerian agenesis
- Overactive bladder
- Painful intercourse
- Pelvic organ prolapse
- Rectocele
- Rectovaginal fistula
- Recurrent urinary tract infections
- Urinary incontinence
- Urinary retention
- Vaginal agenesis
- Vaginal septum
- Vesicocutaneous fistula
- Vesicouterine fistula
- Vesicovaginal fistula
- Voiding difficulties

Diagnostic tests and procedures performed include:

- Cystourethroscopy
- Urodynamic testing
- Ultrasound

Specialty treatments available include:

- Abdominal reconstruction
- Behavioral modification
- Biofeedback
- Botulinum toxin injection
- Dietary modification
- Fascial grafts
- Laparoscopic reconstruction
- Medications
- Pelvic floor re-education
- Pessary (for prolapse and incontinence)
- Pubovaginal slings
- Relaxation techniques
- Robotic reconstruction
- Sacral nerve stimulation
- Urethral injections
- Urethral reconstruction
- Urge suppression drills
- Vaginal reconstruction

Chapter 14

Development of the Urinary and Reproductive Organs

The **development of the urinary and reproductive organs** as a part of the prenatal development, concerns the urinary system and sex organs. The latter is a part of the stages of sexual differentiation.

The urinary and reproductive organs are developed from the intermediate mesoderm. The permanent organs of the adult are preceded by a set of structures which are purely embryonic, and which with the exception of the ducts disappear almost entirely before the end of fetal life. These embryonic structures are on either side; the pronephros, the mesonephros and the metanephros of the kidney, and the Wolffian and Müllerian ducts of the sex organ. The pronephros disappears very early; the structural elements of the mesonephros mostly degenerate, but the gonad is developed in their place, with which the Wolffian duct remains as the duct in males, and the Müllerian as that of the female. Some of the tubules of the mesonephros form part of the permanent kidney.

Pronephros and Wolffian duct

Wolffian duct

In the outer part of the intermediate mesoderm, immediately under the ectoderm, in the region from the fifth cervical segment to the third thoracic segment, a series of short evaginations from each segment grows dorsally and extends caudally, fusing successively from before backward to form the pronephric duct. This continues to grow caudally until it opens into the ventral part of the cloaca; beyond the pronephros it is termed the Wolffian duct. Thus, the Wolffian duct is what remains of the pronephric duct after the atrophy of the pronephros.

Pronephros

The original evaginations form a series of transverse tubules each of which communicates by means of a funnel-shaped ciliated opening with the abdominal cavity, and in the course of each duct a glomerulus also is developed. A secondary glomerulus is formed ventral to each of these, and the complete group constitutes the pronephros. In humans, the pronephros is just rudimentary, and undergoes rapid atrophy and disappears.

Wolffian duct

Mesonephros

On the medial side of the Wolffian duct, from the sixth cervical to the third lumbar segments, a series of tubules, the Wolffian tubules, develops. They increase in number by outgrowths from the original tubules. They change from solid masses of cells to instead become hollowed in the center. One end grows toward and finally opens into the Wolffian duct, the other dilates and is invaginated by a tuft of capillary bloodvessels to form a glomerulus. The tubules collectively constitute the mesonephros.


The mesonephros persists and form the permanent kidneys in fishes and amphibians, but in reptiles, birds, and mammals, it atrophies and for the most part disappears rapidly as the permanent kidney (metanephros) develops beginning during the sixth or seventh week, so that by the beginning of the fifth month only the ducts and a few of the tubules of the mesonephros remain.

Development in male

In the male the Wolffian duct persists, and forms for example the epididymis, the ductus deferens, the ejaculatory duct, seminal vesicle and efferent ducts.

In the female, on the other hand, the Wolffian bodies and ducts atrophy, leaving behind only remnants in the adult, involving e.g. the development of the suspensory ligament of the ovary.

The Müllerian Duct



A.—Diagram of the primitive urogenital organs in the embryo previous to sexual distinction. The common genital cord is labeled with gc.

- * 3. Ureter.
- * 4. Urinary bladder.
- * 5. Urachus.
- * cl. Cloaca.
- * cp. Elevation which becomes clitoris or penis.
- * i. Lower part of the intestine.
- * ls. Fold of integument from which the labia majora or scrotum are formed.
- * m, m. Right and left Müllerian ducts uniting together and running with the Wolffian ducts in gc, the common genital cord.
- * ot. The gonadal ridge from which either the ovary or testis is formed.
- * ug. Sinus urogenitalis.
- * W. Left Wolffian body.
- * w, w. Right and left Wolffian ducts.

Shortly after the formation of the Wolffian ducts a second pair of ducts is developed; these are the Müllerian ducts. Each arises on the lateral aspect of the corresponding Wolffian duct as a tubular invagination of the cells lining the abdominal cavity. The orifice of the invagination remains open, and undergoes enlargement and modification to form the abdominal ostium of the fallopian tube. The ducts pass backward lateral to the Wolffian ducts, but toward the posterior end of the embryo they cross to the medial side of these ducts, and thus come to lie side by side between and behind the latter—the four ducts forming what is termed the *common genital cord*, to distinguish it from the *genital cords of the germinal epithelium* seen later. The Müllerian ducts end in an epithelial elevation, the Müllerian eminence, on the ventral part of the cloaca between the orifices of the Wolffian ducts. At a later stage the eminence opens in the middle, connecting the Müllerian ducts with the cloaca.

Atrophy in males

In the male the Müllerian ducts atrophy, but traces of their anterior ends are represented by the appendices testis (hydatids of Morgagni of the male), while their terminal fused portions form the utriculus in the floor of the prostatic urethra.

Development in females

In the female the Müllerian ducts persist and undergo further development. The portions which lie in the *genital cord* fuse to form the uterus and vagina. This fusion of the Müllerian ducts begins in the third month, and the septum formed by their fused medial walls disappears from below upward.

The parts outside this cord remain separate, and each forms the corresponding Fallopian tube. The ostium of the fallopian tube remains from the anterior extremity of the original tubular invagination from the abdominal cavity.

About the fifth month a ring-like constriction marks the position of the cervix of the uterus, and after the sixth month the walls of the uterus begin to thicken. For a time the

vagina is represented by a solid rod of epithelial cells. A ring-like outgrowth of this epithelium occurs at the lower end of the uterus and marks the future vaginal fornix. At about the fifth or sixth month the lumen of the vagina is produced by the breaking down of the central cells of the epithelium. The hymen represents the remains of the Müllerian eminence.

Gonads

The gonads are the precursors of the testes in males and ovaries in females. They initially develop from the mesothelial layer of the peritoneum.

Ovaries

The ovary is differentiated into a central part, the medulla of ovary, covered by a surface layer, the germinal epithelium. The immature ova originate from cells from the dorsal endoderm of the yolk sac. Once they have reached the gonadal ridge they are called oogonia. Development proceeds and the oogonia become fully surrounded by a layer of connective tissue cells (pre-granulosa cells) In this way, the rudiments of the ovarian follicles are formed. The embryological origin of granulosa cells, on the other hand, remains controversial. Just as in the male, there is a gubernaculum in the female, which pulls it downward, albeit not as much as in males. The gubernaculum later becomes the proper ovarian ligament and the round ligament of the uterus.

Testes

The periphery of the testes are converted into the tunica albuginea. Cords of the central mass run together and form a network which becomes the rete testis, and another network, which develops the seminiferous tubules. Via the rete testis, the seminiferous tubules become connected with outgrowths from the mesonephros, which form the efferent ducts of the testis.

In short, the descent of the testes consists of the opening of a connection from the testis to its final location at the anterior abdominal wall, followed by the development of the gubernaculum, which subsequently pulls and translocates the testis down into the developing scrotum. Ultimately, the passageway closes behind the testis. A failure in this process causes indirect inguinal hernia.

Metanephros and definitive kidney

The metanephros is the definite, permanent, but yet immature kidney. It arises from two directions. On one hand, the precursor of the ureter buds from the Wolffian duct, while on the other hand, the precursor of the renal tubules develop from the metanephrogenic blastema. The ureteric bud subsequently grows into the latter mass, forming the parts of the nephron. Other changes include e.g. the translocation of the ureteric opening directly into the cloaca.

Ureteric bud

The rudiments of the permanent kidneys make their appearance about the end of the first or the beginning of the second month. Each kidney originates as an ureteric bud from the caudal end of the Wolffian duct, which, in turn, originates from intermediate mesoderm. The ureteric bud starts close to where the Wolffian duct opens into the cloaca, and grows dorsalward and rostralward along the posterior abdominal wall, where its blind extremity expands and subsequently divides into several buds, which form the rudiments of the renal pelvis and renal calyces; by continued growth and subdivision it gives rise to the collecting duct system of the kidney. The other, more superficial, portion of the diverticulum, on the other hand, becomes the ureter.


Metanephrogenic blastema

The renal corpuscles and renal tubules, in contrast, are developed from the metanephrogenic blastema instead of from the ureteric bud. The metanephrogenic blastema is moulded over the growing end of the latter, and becomes a part of the metanephros in this way. The renal tubules of the metanephros, unlike those of the pronephros and mesonephros, do not open into the Wolffian duct. Instead, the tubules rapidly elongate to form the parts of the nephron: the proximal tubules, the loops of Henle and the distal convoluted tubules. These last join and establish communications with the collecting duct system derived from the ultimate ramifications of the ureteric bud. In the other end, the renal tubules give rise to Bowman's capsules and glomeruli.

Other changes

The mesoderm around the tubules becomes condensed to form the connective tissue of the kidney. The ureter opens at first into the hind-end of the Wolffian duct; after the sixth week it separates from the Wolffian duct, and opens independently into the part of the cloaca which ultimately becomes the urinary bladder. The renal tubules become arranged into renal pyramids, and the lobulated condition of the kidneys exists for some time after birth, while traces of it may be found even in the adult. The kidney of the ox and many other animals, on the other hand, remains lobulated throughout life.

The Urinary Bladder



Tail end of human embryo thirty-two to thirty-three days old. The entodermal cloaca is visible at center left, labeled in green

The urinary bladder is formed partly from the entodermal cloaca and partly from the ends of the Wolffian ducts. In other words, the allantois takes no share in its formation.

After the separation of the rectum from the dorsal part of the cloaca, the ventral part becomes the primary urogenital sinus. The urogenital sinus, in turn, divides into the superficial definitive urogenital sinus and the deeper anterior vesico-urethral portion.


Definitive urogenital sinus

The definitive urogenital sinus consists of a caudal phallic portion and an intermediate narrow channel, the pelvic portion.

Vesico-urethral portion

The vesico-urethral portion is the deepest portion, continuous with the allantois. It absorbs the ends of the Wolffian ducts and the associated ends of the renal diverticula, and these give rise to the trigone of urinary bladder and part of the prostatic urethra. The remainder of the vesico-urethral portion forms the body of the bladder and part of the prostatic urethra; its apex is prolonged to the umbilicus as a narrow canal, the urachus, which later is obliterated and becomes the median umbilical ligament of the adult.

External genitalia




Development of external genitalia. A: common development. C,E: male development. B,D, F: female development

Until about the ninth week of gestational age, the external genitalia of males and females look the same, and follow a common development. This includes the development of a genital tubercle and a membrane dorsally to it, covering the developing urogenital opening, and the development of labioscrotal folds.

Even after differentiation can be seen between the sexes, some stages are common, e.g. the disappearing of the membrane. On the other hand, sex-dependent development include further protrusion of the genital tubercle in the male to form the penis. Furthermore, the labioscrotal folds evolve into the scrotum in males, while they evolve into labia in females.

Diagram of internal differentiation



Diagrams to show the development of male and female generative organs from a common type.

A.—Diagram of the primitive urogenital organs in the embryo previous to sexual distinction.

- 3. Ureter.
- 4. Urinary bladder.
- 5. Urachus.
- cl. Cloaca.
- cp. Elevation which becomes clitoris or penis.
- i. Lower part of the intestine.
- ls. Fold of integument from which the labia majora or scrotum are formed.
- m, m. Right and left Müllerian ducts uniting together and running with the Wolffian ducts in gc, the genital cord.
- ot. The genital ridge from which either the ovary or testis is formed.
- ug. Sinus urogenitalis.

- W. Left Wolffian body.
- w, w. Right and left Wolffian ducts.

B.—Diagram of the female type of sexual organs.

- C. Greater vestibular gland, and immediately above it the urethra.
- cc. Corpus cavernosum clitoridis.
- dG. Remains of the left Wolffian duct, such as give rise to the duct of Gärtner, represented by dotted lines; that of the right side is marked w.
- f. The abdominal opening of the left uterine tube.
- g. Round ligament, corresponding to gubernaculum.
- h. Situation of the hymen.
- i. Lower part of the intestine.
- l. Labium major.
- n. Labium minus.
- o. The left ovary.
- po. Epoophoron.
- sc. Corpus cavernosum urethrae.
- u. Uterus. The uterine tube of the right side is marked m.
- v. Vulva.
- va. Vagina.
- W. Scattered remains of Wolffian tubes near it (paroöphoron of Waldeyer).


C.—Diagram of the male type of sexual organs.

- C. Bulbo-urethral gland of one side.
- cp. Corpora cavernosa penis cut short.
- e. Caput epididymis.
- g. The gubernaculum.
- i. Lower part of the intestine.
- m. Müllerian duct, the upper part of which remains as the hydatid of Morgagni; the lower part, represented by a dotted line descending to the prostatic utricle, constitutes the occasionally existing cornu and tube of the uterus masculinus.
- pr. The prostate.
- s. Scrotum.
- sp. Corpus cavernosum urethrae.
- t. Testis in the place of its original formation.
- t', together with the dotted lines above, indicates the direction in which the testis and epididymis descend from the abdomen into the scrotum.
- vd. Ductus deferens.
- vh. Ductus aberrans.
- vs. The vesicula seminalis.
- W. Scattered remains of the Wolffian body, constituting the organ of Giralde's, or the paradidymis of Waldeyer.

Chapter 15

Bladder Cancer

Bladder cancer



Histopathology of urothelial carcinoma of the urinary bladder.

Transurethral biopsy. H&E stain.

ICD-10 C67., C67.9

ICD-9 188, 188.9

OMIM 109800

DiseasesDB 1427

eMedicine radio/711 med/2344 med/3022

MeSH D001749

Bladder cancer refers to any of several types of malignant growths of the urinary bladder. It is a disease in which abnormal cells multiply without control in the bladder. The bladder is a hollow, muscular organ that stores urine; it is located in the pelvis. The most common type of bladder cancer begins in cells lining the inside of the bladder and is called transitional cell carcinoma (sometimes urothelial cell carcinoma).

Signs and symptoms


Bladder cancer characteristically causes blood in the urine; this may be visible to the naked eye (gross hematuria) or detectable only by microscope (microscopic hematuria). Other possible symptoms include pain during urination, frequent urination (polyuria) or feeling the need to urinate without results. These signs and symptoms are not specific to bladder cancer, and are also caused by non-cancerous conditions, including prostate infections and cystitis. Kidney cancer also can cause hematuria.

Causes

Tobacco smoking is the main known contributor to urinary bladder cancer: in most populations, smoking is associated with over half of bladder cancer cases in men and one-third of cases among women. There is a linear relationship between smoking and risk, and quitting smoking reduces the risk. Passive smoking has not been proven to be involved. In a 10-year study involving almost 48,000 men, researchers found that men who drank 1.5L of water a day had a significantly reduced incidence of bladder cancer when compared with men who drank less than 240mL (around 1 cup) per day. The authors proposed that bladder cancer might partly be caused by the bladder directly contacting carcinogens that are excreted in urine, although this has not yet been confirmed in other studies. Thirty percent of bladder tumors probably result from occupational exposure in the workplace to carcinogens such as benzidine. 2-Naphthylamine, which is found in cigarette smoke, has also been shown to increase bladder cancer risk. Occupations at risk are bus drivers, rubber workers, motor mechanics, leather workers, blacksmiths, machine setters and mechanics. Hairdressers are thought to be at risk as well because of their frequent exposure to permanent hair dyes. A 2008 study commissioned by the World Health Organisation concluded that "specific fruit and vegetables may act to reduce the risk of bladder cancer." Fruit and yellow-orange vegetables, particularly carrots and selenium, are probably associated with a moderately reduced risk of bladder cancer. Citrus fruits and cruciferous vegetables were also identified as having a possible protective effect.

It has been suggested that mutations at HRAS, KRAS2, RB1, and FGFR3 may be associated in some cases.

Diagnosis



Bladder tumor in FDG PET due to the high physiological FDG-concentration in the bladder, furosemide was supplied together with 200 MBq FDG. The uptake cranial to the lesion is a physiological uptake in the colon.

The gold standard for diagnosing bladder cancer is biopsy obtained during cystoscopy. Sometimes it is an incidental finding during cystoscopy. Urine cytology can be obtained in voided urine or at the time of the cystoscopy ("bladder washing"). Cytology is very specific (a positive result is highly indicative of bladder cancer) but suffers from low sensitivity (inability of a negative result to reliably exclude bladder cancer). There are newer urine bound markers for the diagnosis of bladder cancer. These markers are not currently used routinely in clinical practice due to absence of clear professional guidelines. They are much more expensive as well.

The diagnosing of bladder cancer can also be done with a Hexvix guided fluorescence cystoscopy (Hexvix®), as an adjunct to conventional white-light cystoscopy. This procedure improves the detection of bladder cancer and reduces the rate of early tumour recurrence, compared with white-light cystoscopy alone. Hexvix cystoscopy detects more cancer and reduce recurrency. Hexvix is marketed in USA under the brand name Cysview

Many patients with a history, signs, and symptoms suspicious for bladder cancer are referred to a urologist or other physician trained in cystoscopy, a procedure in which a flexible tube bearing a camera and various instruments is introduced into the bladder through the urethra. Suspicious lesions may be biopsied and sent for pathologic analysis.

Pathological classification

90% of bladder cancers are Transitional cell carcinoma. The other 10% are squamous cell carcinoma, adenocarcinoma, sarcoma, small cell carcinoma and secondary deposits from cancers elsewhere in the body.

Carcinoma in situ (CIS) invariably consists of cytologically high grade tumour cells.

Staging


The following stages are used to classify the location, size, and spread of the cancer, according to the TNM (tumor, lymph node, and metastasis) staging system:

- **Stage 0:** Cancer cells are found only on the inner lining of the bladder (This stage is also often called **Stage Ta**).
- **Stage I:** Cancer cells have proliferated to the layer beyond the inner lining of the urinary bladder but not to the muscles of the urinary bladder.
- **Stage II:** Cancer cells have proliferated to the muscles in the bladder wall but not to the fatty tissue that surrounds the urinary bladder.
- **Stage III:** Cancer cells have proliferated to the fatty tissue surrounding the urinary bladder and to the prostate gland, vagina, or uterus, but not to the lymph nodes or other organs.
- **Stage IV:** Cancer cells have proliferated to the lymph nodes, pelvic or abdominal wall, and/or other organs.
- **Recurrent:** Cancer has recurred in the urinary bladder or in another nearby organ after having been treated.

Screening

As of 2010 there is insufficient evidence to determine if screening for bladder cancer in people without symptoms is effective or not.

Treatment



Flow chart of the Bladder Cancer Treatment Guide

The treatment of bladder cancer depends on how deep the tumor invades into the bladder wall. Superficial tumors (those not entering the muscle layer) can be "shaved off" using an electrocautery device attached to a cystoscope. Immunotherapy in the form of BCG instillation is also used to treat and prevent the recurrence of superficial tumors.

BCG immunotherapy is effective in up to 2/3 of the cases at this stage. Instillations of chemotherapy, such as valrubicin (Valstar) into the bladder can also be used to treat BCG-refractory CIS disease when cystectomy is not an option. Urocidin is phase III trials for this.

Patients whose tumors recurred after treatment with BCG are more difficult to treat. Many physicians recommend Cystectomy for these patients. This recommendation is in accordance with the official guidelines of the European Association of Urologists (EAU).

and the American Urological Association (AUA) However, many patient refuse to undergo this life changing operation, and prefer to try novel conservative treatment options before opting to this last radical resort. Device assisted chemotherapy is such one group of novel technologies used to treat superficial bladder cancer. These technologies use different mechanisms to facilitate the absorption and action of a chemotherapy drug instilled directly into the bladder. Another technology uses an electrical current to enhance drug absorption. Another technology, Thermo-chemotherapy, uses radio-frequency energy to directly heat the bladder wall. The heat and chemotherapy show a synergistic effect, enhancing each other's capacity to kill tumor cells. This technology was studied by different investigators.


Untreated, superficial tumors may gradually begin to infiltrate the muscular wall of the bladder. Tumors that infiltrate the bladder require more radical surgery where part or all of the bladder is removed (a cystectomy) and the urinary stream is diverted. In some cases, skilled surgeons can create a substitute bladder (a neobladder) from a segment of intestinal tissue, but this largely depends upon patient preference, age of patient, renal function, and the site of the disease.

A combination of radiation and chemotherapy can also be used to treat invasive disease. It has not yet been determined how the effectiveness of this form of treatment compares to that of radical ablative surgery.

There is weak observational evidence from one very small study (84) to suggest that the concurrent use of statins is associated with failure of BCG immunotherapy.


Photodynamic diagnosis may improve surgical outcome on bladder cancer.

Epidemiology



Age-standardized death from bladder cancer per 100,000 inhabitants in 2004.

- no data
- less than 1.5



In the United States, bladder cancer is the fourth most common type of cancer in men and the ninth most common cancer in women. More than 50,000 men and 16,000 women are diagnosed with bladder cancer each year. Smoking can only partially explain this higher incidence. One other reason is that the androgen receptor, which is much more active in men than in women, plays a major part in the development of the cancer.

Chapter 16

Interstitial Cystitis

Bladder pain syndrome/interstitial cystitis

ICD-10	N30.1
ICD-9	595.1
DiseasesDB	30832
MedlinePlus	000477
eMedicine	med/2866
MeSH	D018856

Interstitial cystitis or **Bladder pain syndrome/interstitial cystitis** (commonly abbreviated to "BPS/IC") is a urinary bladder disease of unknown cause characterised by pain associated with urination (dysuria), urinary frequency (as often as every 10 minutes), urgency, and pressure in the bladder and/or pelvis. Sometimes referred to as I.C., the disease is a visceral pain syndrome with a profound impact on quality of life. Pain that worsened with a certain food or drink and/or worsened with bladder filling and/or improved with urination was in one study reported by 97% of patients. Patients may also experience nocturia, pelvic floor dysfunction and tension (thus making it difficult to start their urine stream), pain with sexual intercourse, and discomfort and difficulty driving, traveling or working. Research has claimed that the quality of life of some IC patients is equivalent to those with end stage renal failure. A 2000 Harvard study also concluded, 'the impact of interstitial cystitis on quality of life is severe and debilitating'. A survey conducted by the Urban Institute of Washington showed that among interstitial cystitis sufferers:

- 40 per cent were unable to work
- 27 per cent were unable to have sex due to pain
- 27 per cent had marriage breakdown
- 55 per cent contemplated suicide
- 12 per cent had actually attempted suicide.

It is not unusual for patients to have been misdiagnosed with a variety of other conditions, including: overactive bladder, urethritis, urethral syndrome, trigonitis, prostatitis and other generic terms used to describe frequency/urgency symptoms in the urinary tract.

BPS/IC affects men and women of all cultures, socioeconomic backgrounds, and ages. Although the disease previously was believed to be a condition of menopausal women, growing numbers of men and women are being diagnosed in their twenties and younger. BPS/IC is not a rare condition, however BPS/IC is more common in females than in men. Early research suggested that BPS/IC prevalence ranged from 1 in 100,000 to 5.1 in 1,000 of the general population. Up to 12% of women may have early symptoms of BPS/IC.

Nomenclature

Originally called *interstitial cystitis*, the name for this disorder changed to *Bladder pain syndrome/interstitial cystitis* in the period 2002-2010. In 2007, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) began using the umbrella term **Urologic Chronic Pelvic Pain Syndromes (UCPPS)** to refer to pain syndromes associated with the bladder (i.e. Bladder pain syndrome/interstitial cystitis, BPS/IC) and the prostate gland (i.e. chronic prostatitis/chronic pelvic pain syndrome, CP/CPSP).

In 2008, terms currently in use in addition to BPS/IC include *painful bladder syndrome*, *bladder pain syndrome* and *hypersensitive bladder syndrome*, alone and in a variety of combinations. These different terms are being used in different parts of the world.

The term "interstitial cystitis" is the primary term used in ICD-10 and MeSH.

Causes

The cause of BPS/IC is unknown, though several theories have been put forward (these include autoimmune, psychological, neurologic, allergic and genetic). Regardless of the origin, it is clear that the majority of BPS/IC patients struggle with a damaged urothelium, or bladder lining. When the surface glycosaminoglycan (GAG) layer is damaged (via a urinary tract infection (UTI), excessive consumption of coffee or sodas, traumatic injury, etc.), urinary chemicals can "leak" into surrounding tissues, causing pain, inflammation, and urinary symptoms. Oral medications like Elmiron and medications that are placed directly into the bladder via a catheter sometimes work to repair and rebuild this damaged/wounded lining, allowing for a reduction in symptoms.

Stress

In murine (rat) models, stress can produce inflammation in the bladder. Chronic psychological stress significantly enhanced bladder nociceptive responses only in high-anxiety rats supports a critical role of genetics, stress and anxiety as exacerbating factors

in IC and other chronic pelvic pain conditions. Numerous studies have noted the link between IC, anxiety, stress, hyperresponsiveness, and panic.

Genes

Some genetic subtypes, in some patients, have been linked to the disorder.

- An antiproliferative factor secreted by the bladders of BPS/IC patients which inhibits bladder cell proliferation, thus possibly causing the missing bladder lining.
- PAND, at gene map locus 13q22-q32, is associated with a constellation of disorders (a "pleiotropic syndrome") including BPS/IC and other bladder and kidney problems, thyroid diseases, serious headaches/migraines, panic disorder, and mitral valve prolapse.

The presence of endometriosis has a stronger association with typical IC findings on cystoscopy including glomerulations, ulcers, and reduced bladder capacity.

Symptoms

The symptoms of BPS/IC are often misdiagnosed as a "common" bladder infection (cystitis) or a UTI. However BPS/IC has not been shown to be caused by a bacterial infection, and the mis-prescribed treatment of antibiotics is ineffective. The symptoms of BPS/IC may also initially be attributed to prostatitis and epididymitis (in men) and endometriosis and uterine fibroids (in women).

The most common symptom of BPS/IC is pain, which is found in 100% of patients, frequency (82% of patients) and nocturia (62%).

In general, symptoms are:

- Painful urination
 - Pain that is worsened with bladder filling and/or improved with urination.
 - Pain that is worsened with a certain food or drink.
 - Some patients report dysuria (burning sensation in the urethra when urinating).
- Urinary frequency (as often as every 10 minutes), urgency, and pressure in the bladder and/or pelvis.
- Some patients report waking at night to urinate, hesitancy (needing to wait for the stream to begin), pain with sexual intercourse, and discomfort and difficulty driving, travelling or working.

During cystoscopy, 5 to 10% of patients are found to have Hunner's ulcers. Far more patients may experience a very mild form of BPS/IC, in which they have no visible wounds in their bladder, yet struggle with symptoms of pain, frequency and/or urgency.

Still other patients may have discomfort only in their urethra, while others struggle with pain in the entire pelvis.

Diagnosis

Diagnosis has been greatly simplified in recent years with the development of two new methodologies. The *Pelvic Pain Urgency/Frequency (PUF) Patient Survey*, created by C. Lowell Parsons, is a short questionnaire that will help doctors identify if pelvic pain could be coming from the bladder. The *KCl test*, also known as the *potassium sensitivity test*, uses a mild potassium solution to test the integrity of the bladder wall. Though the latter is not specific for BPS/IC, it has been determined to be helpful in predicting the use of compounds, such as pentosan polysulphate, which are designed to help repair the GAG layer. The previous gold standard test for BPS/IC was the use of hydrodistention with cystoscopy. Researchers, however, determined that this visual examination of the bladder wall after stretching the bladder was not specific for BPS/IC and that the test, itself, can contribute to the development of small glomerulations (that is, petechial hemorrhages) often found in BPS/IC. Thus, a diagnosis of BPS/IC is one of exclusion, as well as a review of clinical symptoms.

In 2006, the ESSIC society proposed more rigorous and demanding diagnostic methods with specific classification criteria so that it cannot be confused with other, similar conditions. Specifically, they require that a patient must have pain associated with the bladder, accompanied by one other urinary symptom. Thus, a patient with just frequency or urgency would be excluded from a diagnosis. Secondly, they strongly encourage the exclusion of confusable diseases through an extensive and expensive series of tests including (A) a medical history and physical exam, (B) a dipstick urinalysis, various urine cultures, and a serum PSA in men over 40, (C) flowmetry and post-void residual urine volume by ultrasound scanning and (D) cystoscopy. A diagnosis of BPS/IC would be confirmed with a hydrodistention during cystoscopy with biopsy.

They also propose a ranking system based upon the physical findings in the bladder. Patients would receive a numeric and letter based score based upon the severity of their disease as found during the hydrodistention. A score of 1-3 would relate to the severity of the disease and a rating of A-C represents biopsy findings. Thus, a patient with 1A would have very mild symptoms and disease while a patient with 3C would have the worst available symptoms.

In 2009, Japanese researchers identified a urinary marker called phenylacetylglutamine that could be used for early diagnosis.

Treatment

Pelvic floor treatments

Work by Wise and Anderson has shown that urologic pelvic pain syndromes, such as BPS/IC and CP/CPPS, may have no initial trigger other than anxiety, often with an

element of Obsessive Compulsive Disorder or other anxiety-spectrum problem. This is theorized to leave the pelvic area in a sensitized condition resulting in a loop of muscle tension and heightened neurological feedback (neural wind-up). This is a form of myofascial pain syndrome. Current protocols largely focus on stretches to release overtensed muscles in the pelvic or anal area (commonly referred to as trigger points), physical therapy to the area, and progressive relaxation therapy to reduce causative stress.

Most major BPS/IC clinics now evaluate the pelvic floor and/or refer patients directly to a physical therapist for a prompt treatment of pelvic floor muscle tension or weakness. Chronic pelvic floor tension can cause pain in the bladder and/or pelvis, which is often described by women as a burning sensation, particularly in the vagina. Men with pelvic floor tension experience referred pain, particularly at the tip of their penis. In 9 out of 10 BPS/IC patients struggling with painful sexual relations, muscle tension is the primary cause of that pain and discomfort. Tender trigger points —small, tight, hyperirritable bundles of muscle— may also be found in the pelvic floor.

Pelvic floor dysfunction is a fairly new area of specialty for physical therapists world wide. The goal of therapy is to relax and lengthen the pelvic floor muscles, rather than to tighten and/or strengthen them as is the goal of therapy for patients with incontinence. Thus, traditional exercises such as Kegels, can be helpful as they strengthen the muscles, however they can provoke pain and additional muscle tension. A specially trained physical therapist can provide direct, hands on, evaluation of the muscles, both externally and internally. While weekly therapy is certainly valuable, most providers also suggest an aggressive self-care regimen at home to help combat muscle tension, such as daily muscle relaxation audiotapes, stress reduction and anxiety management on a daily basis. Anxiety is often found in patients with painful conditions and can subconsciously trigger muscle tension.

Thiele massage

Transvaginal manual therapy of the pelvic floor musculature (Thiele massage) has shown promise in relieving the pain associated with Interstitial cystitis in at least one open, clinical pilot study.

Medication

As recently as a decade ago, treatments available were limited to the use of astringent instillations, such as chlorpactin (oxychlorosene) or silver nitrate, designed to kill "infection" and/or strip off the bladder lining. In 2005, our understanding of BPS/IC has improved dramatically and these therapies are now no longer done. Rather, BPS/IC therapy is typically multi-modal, including the use of a bladder coating, an antihistamine to help control mast cell activity and a low dose antidepressant to fight neurogenic inflammation.

Pentosan polysulfate

Oral pentosan polysulfate (Elmiron) is believed to provide a protective coating in the bladder, but studies show it is not statistically significant compared to placebo. However, some studies have found that a minority of patients do respond to pentosan polysulfate.

Amitriptyline

Amitriptyline can reduce symptoms in patients with BPS/IC. Patient overall satisfaction with the therapeutic result of amitriptyline was excellent or good in 46%.

Duloxetine

The antidepressant duloxetine was found to be ineffective as a treatment.

Bladder instillations

DMSO, a wood pulp extract, is the only approved bladder instillation for BPS/IC yet it is much less frequently used in urology clinics. Research studies presented at recent conferences of the American Urological Association by C. Subah Packer have demonstrated that the FDA approved dosage of a 50% solution of DMSO had the potential of creating irreversible muscle contraction. However, a lesser solution of 25% was found to be reversible. Long term use is questionable, at best, particularly given the fact that the method of action of DMSO is not fully understood.

Rescue instillations

More recently, the use of a "rescue instillation" composed of Elmiron or heparin, Cystistat, lidocaine and sodium bicarbonate, has generated considerable excitement in the BPS/IC community because it is the first therapeutic intervention that can be used to reduce a flare of symptoms. Published studies report a 90% effectiveness in reducing symptoms.

Sometimes these rescue instillations are given on a regular basis for treatment. It is important to note that this is off-label use for both Elmiron and heparin, as neither medicine has been approved to be used this way.

Bladder coatings

Other bladder coating therapies include Cystistat (sodium hyaluronate) and Uracyst (chondroitin). They are believed to replace the deficient GAG layer on the bladder wall. Like most other intravesical bladder treatments, this treatment may require the patient to lie for 20 – 40 minutes, turning over every ten minutes, to allow the chemical to 'soak in' and give a good coating, before it is passed out with the urine.

Cystistat is not currently available in the United States or Canada, though testing has recently started in Canada. Testing has also begun for Uracyst in both Canada and the United States.

Diet

In 2007, a study done at Long Island University reported that over 90 percent of interstitial cystitis patients experience an increase in symptoms when they consume certain foods and beverages, especially coffee, tea, soda, alcoholic beverages, citrus fruits and juices, artificial sweeteners and hot pepper.

The challenge with diet triggers is that they vary from person to person: the best way for a person to discover his or her own triggers is to use an elimination diet. The foundation of therapy is a modification of diet to help patients avoid those foods which can further irritate the damaged bladder wall.

Anecdotal evidence has linked gluten intolerance to UCPPS symptoms. Studies are lacking in this area.

The mechanism by which dietary modification benefits patients with IC is unclear. Researchers hypothesize that integration of neural signals from pelvic organs mediates the effects of diet on symptoms of IC:

“ In animal models, pelvic inflammation is subject to crosstalk, so an inflammatory stimulus in one pelvic organ evokes a response in an independent organ. Recent data show that the colon can modulate bladder-associated pelvic pain in mice. As pelvic organs are innervated through shared circuitry, perceived pelvic pain might occur when spatial summation of individual pelvic inputs exceeds a threshold. Through this mechanism, a noxious dietary stimulus, which otherwise does not exceed the pain threshold in a normal individual, may substantially exacerbate pain in a patient with bladder symptoms. Repeated painful stimuli over time further contribute to symptoms by a process of temporal summation, resulting in enhanced responsiveness through central sensitization. Thus, pelvic organ crosstalk might modulate symptoms of pelvic pain by spatial and temporal summation. ”

Bladder distension

Bladder distension (a procedure which stretches the bladder capacity, done under general anaesthesia) has shown some success in reducing urinary frequency and giving pain relief to patients. However, many experts still cannot understand precisely *how* this can cause pain relief. Recent studies showing that pressure on pelvic trigger points can relieve symptoms may be connected. Unfortunately, the relief achieved by bladder distensions is only temporary (weeks or months) and consequently, it is not really viable as a long-term treatment for BPS/IC.

Surgery

Surgical interventions are rarely used for BPS/IC. Surgical intervention is very unpredictable for BPS/IC, and is considered a treatment of last resort when all other treatment modalities have failed and pain is severe. Some patients who opt for surgical intervention continue to experience pain after surgery. Surgical interventions for BPS/IC include transurethral fulguration and resection of ulcers, using electricity/laser; bladder denervation, where some of the nerves to the bladder are cut (Modified Ingelman-Sundberg Procedure); bladder augmentation; bladder removal (cystectomy); electrical nerve stimulation, similar to TENS, where an electrical unit is implanted in the body and provides continuous or intermittent electrical pulses to the affected areas (Interstim); spinal cord stimulation (SCS), where an electrical unit is implanted that provides electrical stimulation to the spinal cord, interfering with pain reception to the brain (ANS/Advanced Neuromodulation Systems spinal Cord Stimulator); and the implantation of the intrathecal pain pump, where very small amounts of medication, like morphine sulfate, dilaudid, or baclophen are released into the cerebrospinal fluid via a catheter stemming from the small electrical pump, requiring only about 1/100 to 1/300 the amount of medication needed orally for the same therapeutic benefit, but with significantly fewer side effects.

Pain control

Pain control is usually necessary in the BPS/IC treatment plan. The pain of BPS/IC has been rated equivalent to cancer pain and may lead to central sensitization if untreated.

Medication

The use of a variety of traditional pain medications, including opiates and synthetic opioids like tramadol, is often necessary to treat the varying degrees of pain. Even children with BPS/IC should be appropriately addressed regarding pelvic pain, and receive necessary treatment to manage it.

Neuromodulation

Neuromodulation can be successful in treating BPS/IC symptoms, including pain. Electronic pain-killing options include TENS. PTNS stimulators have also been used, with varying degrees of success. Percutaneous sacral nerve root stimulation (PNS) was able to produce statistically significant improvements in several parameters, including pain.

Acupuncture

A 2002 review study reported that acupuncture alleviates pain associated with BPS/IC as part of multimodal treatment. While a 1987 study showed that 11 of 14 (78%) patients had a >50% reduction in pain, another study (published in 1993) found no beneficial effect. A 2008 review found that although there are hardly any controlled studies on

alternative medicine and BPS/IC, "rather good results have been obtained" when acupuncture is combined with other treatments.

Biofeedback

Biofeedback, a relaxation technique aimed at helping people control functions of the autonomous nervous system, has shown some benefit in controlling pain associated with BPS/IC as part of a multimodal approach that may also include medication or hydrodistention of the bladder.


Links to other conditions

Some people with BPS/IC suffer from anxiety disorder, and other conditions that may have the same etiology as BPS/IC. These include: irritable bowel syndrome (IBS), fibromyalgia, chronic fatigue syndrome, endometriosis, vulvodynia, and chemical sensitivities. Men with BPS/IC are frequently diagnosed as having chronic nonbacterial prostatitis, and there is an extensive overlap of symptoms and treatment between the two conditions, leading researchers to posit that the conditions share the same etiology and pathology.

Chapter 17

Prostate Cancer

Prostate cancer



Micrograph of prostate adenocarcinoma, acinar type, the most common type of prostate cancer. Gleason pattern 4. Needle biopsy. H&E stain.

ICD-10	C61.
ICD-9	185
OMIM	176807
DiseasesDB	10780
MedlinePlus	000380
eMedicine	radio/574
MeSH	D011471

Prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostate cancers. The cancer cells may metastasize (spread) from the prostate

to other parts of the body, particularly the bones and lymph nodes. Prostate cancer may cause pain, difficulty in urinating, problems during sexual intercourse, or erectile dysfunction. Other symptoms can potentially develop during later stages of the disease.


Rates of detection of prostate cancers vary widely across the world, with South and East Asia detecting less frequently than in Europe, and especially the United States. Prostate cancer tends to develop in men over the age of fifty and although it is one of the most prevalent types of cancer in men, many never have symptoms, undergo no therapy, and eventually die of other causes. This is because cancer of the prostate is, in most cases, slow-growing, symptom-free, and since men with the condition are older they often die of causes unrelated to the prostate cancer, such as heart/circulatory disease, pneumonia, other unconnected cancers, or old age. About 2/3 of cases are slow growing, the other third more aggressive and fast developing.

Many factors, including genetics and diet, have been implicated in the development of prostate cancer. The presence of prostate cancer may be indicated by symptoms, physical examination, prostate-specific antigen (PSA), or biopsy. The PSA test increases cancer detection but does not decrease mortality. Suspected prostate cancer is typically confirmed by taking a biopsy of the prostate and examining it under a microscope. Further tests, such as CT scans and bone scans, may be performed to determine whether prostate cancer has spread.


Treatment options for prostate cancer with intent to cure are primarily surgery, radiation therapy, and proton therapy. Other treatments, such as hormonal therapy, chemotherapy, cryosurgery, and high intensity focused ultrasound (HIFU) also exist, depending on the clinical scenario and desired outcome.

The age and underlying health of the man, the extent of metastasis, appearance under the microscope, and response of the cancer to initial treatment are important in determining the outcome of the disease. The decision whether or not to treat localized prostate cancer (a tumor that is contained within the prostate) with curative intent is a patient trade-off between the expected beneficial and harmful effects in terms of patient survival and quality of life.

Overview



This shows the prostate and nearby organs.



This shows the inside of the prostate, urethra, rectum, and bladder.

The prostate is a part of the male reproductive system that helps make and store seminal fluid. In adult men, a typical prostate is about three centimeters long and weighs about twenty grams. It is located in the pelvis, under the urinary bladder and in front of the rectum. The prostate surrounds part of the urethra, the tube that carries urine from the bladder during urination and semen during ejaculation. Because of its location, prostate diseases often affect urination, ejaculation, and rarely defecation. The prostate contains many small glands which make about twenty percent of the fluid constituting semen. In prostate cancer, the cells of these prostate glands mutate into cancer cells. The prostate glands require male hormones, known as androgens, to work properly. Androgens include testosterone, which is made in the testes; dehydroepiandrosterone, made in the adrenal glands; and dihydrotestosterone, which is converted from testosterone within the prostate itself. Androgens are also responsible for secondary sex characteristics such as facial hair and increased muscle mass.

Classification

An important part of evaluating prostate cancer is determining the stage, or how far the cancer has spread. Knowing the stage helps define prognosis and is useful when selecting therapies. The most common system is the four-stage TNM system (abbreviated from Tumor/Nodes/Metastases). Its components include the size of the tumor, the number of involved lymph nodes, and the presence of any other metastases.

The most important distinction made by any staging system is whether or not the cancer is still confined to the prostate. In the TNM system, clinical T1 and T2 cancers are found only in the prostate, while T3 and T4 cancers have spread elsewhere. Several tests can be used to look for evidence of spread. These include computed tomography to evaluate spread within the pelvis, bone scans to look for spread to the bones, and endorectal coil magnetic resonance imaging to closely evaluate the prostatic capsule and the seminal vesicles. Bone scans should reveal osteoblastic appearance due to *increased* bone density in the areas of bone metastasis—opposite to what is found in many other cancers that metastasize.

After a prostate biopsy, a pathologist looks at the samples under a microscope. If cancer is present, the pathologist reports the grade of the tumor. The grade tells how much the tumor tissue differs from normal prostate tissue and suggests how fast the tumor is likely to grow. The Gleason system is used to grade prostate tumors from 2 to 10, where a Gleason score of 10 indicates the most abnormalities. The pathologist assigns a number from 1 to 5 for the most common pattern observed under the microscope, then does the same for the second-most-common pattern. The sum of these two numbers is the Gleason score. The Whitmore-Jewett stage is another method sometimes used.

Signs and symptoms

Early prostate cancer usually causes no symptoms. Often it is diagnosed during the workup for an elevated PSA noticed during a routine checkup.

Sometimes, however, prostate cancer does cause symptoms, often similar to those of diseases such as benign prostatic hyperplasia. These include frequent urination, nocturia (increased urination at night), difficulty starting and maintaining a steady stream of urine, hematuria (blood in the urine), and dysuria (painful urination).

Prostate cancer is associated with urinary dysfunction as the prostate gland surrounds the prostatic urethra. Changes within the gland, therefore, directly affect urinary function. Because the *vas deferens* deposits seminal fluid into the prostatic urethra, and secretions from the prostate gland itself are included in semen content, prostate cancer may also cause problems with sexual function and performance, such as difficulty achieving erection or painful ejaculation.

Advanced prostate cancer can spread to other parts of the body, possibly causing additional symptoms. The most common symptom is bone pain, often in the vertebrae

(bones of the spine), pelvis, or ribs. Spread of cancer into other bones such as the femur is usually to the proximal part of the bone. Prostate cancer in the spine can also compress the spinal cord, causing leg weakness and urinary and fecal incontinence.

Causes

The specific causes of prostate cancer remain unknown. The primary risk factors are age and family history. Prostate cancer is very uncommon in men younger than 45, but becomes more common with advancing age. The average age at the time of diagnosis is 70. However, many men never know they have prostate cancer. Autopsy studies of Chinese, German, Israeli, Jamaican, Swedish, and Ugandan men who died of other causes have found prostate cancer in thirty percent of men in their 50s, and in eighty percent of men in their 70s. Men who have first-degree family members with prostate cancer appear to have double the risk of getting the disease compared to men without prostate cancer in the family. This risk appears to be greater for men with an affected brother than for men with an affected father. In the United States in 2005, there were an estimated 230,000 new cases of prostate cancer and 30,000 deaths due to prostate cancer. Men with high blood pressure are more likely to develop prostate cancer. A 2010 study found that prostate basal cells were the most common site of origin for prostate cancers.

Genetic

Genetic background may contribute to prostate cancer risk, as suggested by associations with race, family, and specific gene variants. Men with one first-degree relative with prostate cancer have a twofold higher risk, and those with two first-degree relatives have a fivefold greater risk of developing prostate cancer compared with men with no family history. In the United States, prostate cancer more commonly affects black men than white or Hispanic men, and is also more deadly in black men. In contrast, the incidence and mortality rates for Hispanic men are one third lower than for non-Hispanic whites. Men who have a brother or father with prostate cancer have twice the risk of developing prostate cancer. Studies of twins in Scandinavia suggest that forty percent of prostate cancer risk can be explained by inherited factors.

No single gene is responsible for prostate cancer; many different genes have been implicated. Mutations in *BRCA1* and *BRCA2*, important risk factors for ovarian cancer and breast cancer in women, have also been implicated in prostate cancer. Other linked genes include the Hereditary Prostate cancer gene 1 (*HPC1*), the androgen receptor, and the vitamin D receptor. *TMPRSS2-ETS* gene family fusion, specifically *TMPRSS2-ERG* or *TMPRSS2-ETV1/4* promotes cancer cell growth.

Loss of cancer suppressor genes, early in the prostatic carcinogenesis, have been localized to chromosomes *8p*, *10q*, *13q*, and *16q*. P53 mutations in the primary prostate cancer are relatively low and are more frequently seen in metastatic settings, hence, p53 mutations are late event in pathology of prostate cancer. Other tumor suppressor genes that are thought to play a role in prostate cancer include PTEN (gene) and KAI1. "Up to

70 percent of men with prostate cancer have lost one copy of the PTEN gene at the time of diagnosis" Relative frequency of loss of E-cadherin and CD44 has also been observed.

Diet

Evidence from epidemiological studies supports a possible protective role in reducing prostate cancer for dietary Vitamin B6, selenium, vitamin E, lycopene, and soy foods. A study in 2007 cast doubt on the effectiveness of lycopene (found in tomatoes) in reducing the risk of prostate cancer. Lower blood levels of vitamin D may increase the risk of developing prostate cancer. This may be linked to lower exposure to ultraviolet (UV) light, since UV light exposure can increase vitamin D in the body.

Studies comparing men who live in areas with high levels of selenium to men in areas with low levels suggest that this mineral protects against prostate cancer. Selenium is believed to reduce the risk of developing prostate cancer because it keeps cells from proliferating or dying off in a rapid or unusual way. An analysis in 2002 of the Nutritional Prevention of Cancer Trial revealed that the men who took selenium supplements daily were half as likely to be diagnosed with prostate cancer. These findings have been confirmed in most observational studies. However, in 2008, the Selenium and Vitamin E Cancer Prevention Trial (SELECT) indicated that neither selenium nor vitamin E, alone or in combination, was effective for the primary prevention of prostate cancer. Whether or not selenium helps prevent prostate cancer, researchers at the Dana-Farber Cancer Institute in Boston found that higher selenium levels in the blood may worsen prostate cancer in many men who already have the disease.

Green tea may be protective (due to its catechins content), although the most comprehensive clinical study indicates that it has no protective effect. Other holistic methods are also studied.

Research published in the Journal of the National Cancer Institute suggests that taking multivitamins more than seven times a week can increase the risks of contracting the disease. This research was unable to highlight the exact vitamins responsible for this increase (almost double), although they suggest that vitamin A, vitamin E and beta-carotene may lie at its heart. It is advised that those taking multivitamins never exceed the stated daily dose on the label.

A 2007 study published in the Journal of the National Cancer Institute found that men eating cauliflower, broccoli, or one of the other cruciferous vegetables, more than once a week were 40% less likely to develop prostate cancer than men who rarely ate those vegetables. The phytochemicals indole-3-carbinol and diindolylmethane, found in cruciferous vegetables, has antiandrogenic and immune modulating properties.

Many doctors prescribe supplements to prostate cancer patients but currently the efficacy of nutrient supplements is still unknown. Supplements may not be as beneficial to prostate health as micronutrients obtained naturally from the diet.

Folic acid supplements have recently been linked to an increase in risk of developing prostate cancer. A ten-year research study led by University of Southern California researchers showed that men who took daily folic acid supplements of 1 mg were three times more likely to be diagnosed with prostate cancer than men who took a placebo. Folate plays a complex role in prostate cancer and folic acid supplements have a different effect on prostate cancer than folate naturally found in foods. The supplement form, folic acid, is more bioavailable in the body compared with dietary sources of folate. Folate hydrolase activity is associated with prostate-specific antigen.

A small Swedish study of 254 subjects, with a median age of 64, and a follow up of 5 years suggested that folate status is not protective against prostate cancer, however, and like folic acid may even result in a 3 fold increase in early prostate cancer development and risk. Supplements and multivitamins, alcohol and drug consumption, GI disorders, and folate bioavailability were not analyzed in this study.

High alcohol intake may increase the risk of prostate cancer and interfere with folate metabolism. Low folate intake and high alcohol intake may increase the risk of prostate cancer to a greater extent than the sole effect of either one by itself. A case control study consisting of 137 veterans addressed this hypothesis and the results were that high folate intake was related to a 79% lower risk of developing prostate cancer and there was no association between alcohol consumption by itself and prostate cancer risk. Folate's effect however was only significant when coupled with low alcohol intake. There is a significant decrease in risk of prostate cancer with increasing dietary folate intake but this association only remains in individuals with low levels of alcohol consumption. There was no association found in this study between folic acid supplements and risk of prostate cancer.

The prostate gland has a high concentration of zinc so zinc may play a role in prostate cancer. Researchers studied the relationship between zinc supplement intake of 100 mg/day and the risk of prostate cancer in 46 974 US men over a 14 year period and reported in 2003 that long term zinc supplement of over 100 mg/day intake seemed to be associated with approximately double the risk of developing prostate cancer. Greater intake of milk, calcium, or dairy calcium has been consistently associated with an elevated risk of prostate cancer in several studies

Medication exposure

There are also some links between prostate cancer and medications, medical procedures, and medical conditions. Use of the cholesterol-lowering drugs known as the statins may also decrease prostate cancer risk.

Infection or inflammation of the prostate (prostatitis) may increase the chance for prostate cancer while another study shows infection may help prevent prostate cancer by increasing blood to the area. In particular, infection with the sexually transmitted infections chlamydia, gonorrhea, or syphilis seems to increase risk. Finally, obesity and elevated blood levels of testosterone may increase the risk for prostate cancer. There is an


association between vasectomy and prostate cancer however more research is needed to determine if this is a causative relationship.

Research released in May 2007, found that US war veterans who had been exposed to Agent Orange had a 48% increased risk of prostate cancer recurrence following surgery.

Viral

In 2006, researchers associated a previously unknown retrovirus, Xenotropic MuLV-related virus or XMRV, with human prostate tumors. Subsequent reports on the virus have been contradictory. A group of US researchers found XMRV protein expression in human prostate tumors, while German scientists failed to find XMRV-specific antibodies or XMRV-specific nucleic acid sequences in prostate cancer samples.

Pathophysiology



When normal cells are damaged beyond repair, they are eliminated by apoptosis. Cancer cells avoid apoptosis and continue to multiply in an unregulated manner.

Prostate cancer is classified as an adenocarcinoma, or glandular cancer, that begins when normal semen-secreting prostate gland cells mutate into cancer cells. The region of prostate gland where the adenocarcinoma is most common is the peripheral zone. Initially, small clumps of cancer cells remain confined to otherwise normal prostate glands, a condition known as carcinoma in situ or prostatic intraepithelial neoplasia (PIN). Although there is no proof that PIN is a cancer precursor, it is closely associated

with cancer. Over time, these cancer cells begin to multiply and spread to the surrounding prostate tissue (the stroma) forming a tumor. Eventually, the tumor may grow large enough to invade nearby organs such as the seminal vesicles or the rectum, or the tumor cells may develop the ability to travel in the bloodstream and lymphatic system. Prostate cancer is considered a malignant tumor because it is a mass of cells that can invade other parts of the body. This invasion of other organs is called metastasis. Prostate cancer most commonly metastasizes to the bones, lymph nodes, and may invade rectum, bladder and lower ureters after local progression.

The prostate is a zinc accumulating, citrate producing organ. The protein ZIP1 is responsible for the active transport of zinc into prostate cells. One of zinc's important roles is to change the metabolism of the cell in order to produce citrate, an important component of semen. The process of zinc accumulation, alteration of metabolism, and citrate production is energy inefficient, and prostate cells sacrifice enormous amounts of energy (ATP) in order to accomplish this task. Prostate cancer cells are generally devoid of zinc. This allows prostate cancer cells to save energy not making citrate, and utilize the new abundance of energy to grow and spread. The absence of zinc is thought to occur via a silencing of the gene that produces the transporter protein ZIP1. ZIP1 is now called a tumor suppressor gene product for the gene SLC39A1. The cause of the epigenetic silencing is unknown. Strategies which transport zinc into transformed prostate cells effectively eliminate these cells in animals. Zinc inhibits NF- κ B pathways, is anti-proliferative, and induces apoptosis in abnormal cells. Unfortunately, oral ingestion of zinc is ineffective since high concentrations of zinc into prostate cells is not possible without the active transporter, ZIP1.

RUNX2 is a transcription factor that prevents cancer cells from undergoing apoptosis thereby contributing to the development of prostate cancer.


The PI3k/Akt signaling cascade works with the transforming growth factor beta/SMAD signaling cascade to ensure prostate cancer cell survival and protection against apoptosis. X-linked inhibitor of apoptosis (XIAP) is hypothesized to promote prostate cancer cell survival and growth and is a target of research because if this inhibitor can be shut down then the apoptosis cascade can carry on its function in preventing cancer cell proliferation. Macrophage inhibitory cytokine-1 (MIC-1) stimulates the focal adhesion kinase (FAK) signaling pathway which leads to prostate cancer cell growth and survival.

The androgen receptor helps prostate cancer cells to survive and is a target for many anti cancer research studies; so far, inhibiting the androgen receptor has only proven to be effective in mouse studies. Prostate specific membrane antigen (PSMA) stimulates the development of prostate cancer by increasing folate levels for the cancer cells to use to survive and grow; PSMA increases available folates for use by hydrolyzing glutamated folates.

Diagnosis

The only test that can fully confirm the diagnosis of prostate cancer is a biopsy, the removal of small pieces of the prostate for microscopic examination. However, prior to a biopsy, several other tools may be used to gather more information about the prostate and the urinary tract. Digital rectal examination may allow a doctor to detect prostate abnormalities. Cystoscopy shows the urinary tract from inside the bladder, using a thin, flexible camera tube inserted down the urethra. Transrectal ultrasonography creates a picture of the prostate using sound waves from a probe in the rectum.

Biopsy



Micrograph showing a prostate cancer (conventional adenocarcinoma) with perineural invasion. H&E stain.

If cancer is suspected, a biopsy is offered expediently. During a biopsy a urologist or radiologist obtains tissue samples from the prostate via the rectum. A biopsy gun inserts and removes special hollow-core needles (usually three to six on each side of the prostate) in less than a second. Prostate biopsies are routinely done on an outpatient basis and rarely require hospitalization. Fifty-five percent of men report discomfort during prostate biopsy.

Gleason score

The tissue samples are then examined under a microscope to determine whether cancer cells are present, and to evaluate the microscopic features (or Gleason score) of any cancer found. Prostate specific membrane antigen is a transmembrane carboxypeptidase and exhibits folate hydrolase activity. This protein is overexpressed in prostate cancer tissues and is associated with a higher Gleason score.

Tumor markers

Tissue samples can be stained for the presence of PSA and other tumor markers in order to determine the origin of malignant cells that have metastasized.

Small cell carcinoma is a very rare (1%) type of prostate cancer that cannot be diagnosed using the PSA. As of 2009 researchers are trying to determine the best way to screen for this type of prostate cancer because it is a relatively unknown and rare type of prostate cancer but very serious and quick to spread to other parts of the body. Possible methods include chromatographic separation methods by mass spectrometry, or protein capturing by immunoassays or immunized antibodies. The test method will involve quantifying the amount of the biomarker PCI, with reference to the Gleason Score. Not only is this test quick, it is also sensitive. It can detect patients in the diagnostic grey zone, particularly those with a serum free to total Prostate Specific Antigen ratio of 10-20%.

The oncoprotein BCL-2, has been associated with the development of androgen-independent prostate cancer due to its high levels of expression in androgen-independent tumours in advanced stages of the pathology. The upregulation of BCL-2 after androgen ablation in prostate carcinoma cell lines and in a castrated-male rat model further established a connection between BCL-2 expression and prostate cancer progression.

The expression of Ki-67 by immunohistochemistry may be a significant predictor of patient outcome for men with prostate cancer.

Under investigation

At present, an active area of research involves non-invasive methods of prostate tumor detection. Adenoviruses modified to transfect tumor cells with harmless yet distinct genes (such as luciferase) have proven capable of early detection. So far, however, this area of research has been tested only in animal and LNCaP cell models.

PCA3

Another potential non-invasive method of early prostate tumor detection is through a molecular test that detects the presence of cell-associated PCA3 mRNA in urine. PCA3 mRNA is expressed almost exclusively by prostate cells and has been shown to be highly over-expressed in prostate cancer cells. PCA3 is not a replacement for PSA but an additional tool to help decide whether, in men suspected of having prostate cancer, a

biopsy is really needed. The higher the expression of PCA3 in urine, the greater the likelihood of a positive biopsy, i.e., the presence of cancer cells in the prostate.

Early prostate cancer antigen-2

It was reported in April 2007 that a new blood test for early prostate cancer antigen-2 (EPCA-2) that may alert men if they have prostate cancer and how aggressive it will be is being researched.

Thrombophlebitis is associated with an increased risk of prostate cancer and may be a good way for physicians to remind themselves to screen patients with thrombophlebitis for prostate cancer as well since these two are closely linked.

Prostate mapping

Prostate mapping is a method of diagnosis that may be accurate in determining the precise location and aggressiveness of a tumor. It uses a combination of multi-sequence MRI imaging techniques and a template-guided biopsy system, and involves taking multiple biopsies through the skin that lies in front of the rectum rather than through the rectum itself. The procedure is carried out under general anesthetic.

Prostasomes

Epithelial cells of the prostate secrete prostasomes as well as PSA. Prostasomes are membrane-surrounded, prostate-derived organelles that appear extracellularly, and one of their physiological functions is to protect the sperm from attacks by the female immune system. Cancerous prostate cells continue to synthesize and secrete prostasomes, and may be shielded against immunological attacks by these prostasomes. Research of several aspects of prostasomal involvement in prostate cancer has been performed.

Screening

Prostate cancer screening is an attempt to find unsuspected cancers, and may lead to more specific follow-up tests such as a biopsy, with cell samples taken for closer study. Options include the digital rectal exam (DRE) and the prostate-specific antigen (PSA) blood test. A 2010 analysis concluded that routine screening with either a DRE or PSA is not supported by the evidence as there is no mortality benefit from screening.

Modern screening tests have found cancers that might never have developed into serious disease, and that "the slight reduction of risk by surgically removing the prostate or treating it with radiation may not outweigh the substantial side effects of these treatments," an opinion also shared by the CDC.

Prevention

A comprehensive worldwide report Food, Nutrition, Physical Activity and the Prevention of Cancer: a Global Perspective compiled by the World Cancer Research Fund and the American Institute for Cancer Research reports a significant relation between lifestyle (including food consumption) and cancer prevention. Other research also supports this finding. Exercise and diet may help prevent prostate cancer to the same extent as medications such as alpha-blockers and 5-alpha-reductase inhibitors.

Two medications which block the conversion of testosterone to dihydrotestosterone, finasteride and dutasteride, have also shown some promise. The use of these medications for primary prevention is still in the testing phase, and they are not widely used for this purpose. A 2008 study found that finasteride reduces the incidence of prostate cancer by 30%, without any increase in the risk of High-Grade prostate cancer. In the original study it turns out that the smaller prostate caused by finasteride means that a doctor is more likely to hit upon cancer nests and more likely to find aggressive-looking cells.

Compared to placebo treatment, taking 5-alpha-reductase inhibitors (5-ARIs) can reduce a man's risk of being diagnosed with prostate cancer from around 5–9% to around 4-6% during up to 7 years of treatment, according to a Cochrane Review of studies.

Ejaculation frequency

More frequent ejaculation also may decrease a man's risk of prostate cancer. One study showed that men who ejaculated 3-5 times a week at the age of 15-19 had a decreased rate of prostate cancer when they are old, though other studies have shown no benefit. The results contradict those of previous studies, which have suggested that having had many sexual partners, or a high frequency of sexual activity, increases the risk of prostate cancer by up to 40 percent. A key difference may be that these earlier studies defined sexual activity as sexual intercourse, whereas this study focused on the number of ejaculations, whether or not intercourse was involved. Another study completed in 2004 reported that "Most categories of ejaculation frequency were unrelated to risk of prostate cancer. However, high ejaculation frequency was related to decreased risk of total prostate cancer." The report abstract concluded, "Our results suggest that ejaculation frequency is not related to increased risk of prostate cancer."

Diet

Oils and fatty acids

polyunsaturated fatty acids (PUFAs) increased prostate tumor growth, and has sped up histopathological progression, and decreased survival, while the omega-3 fatty acids, in the same situation, had the opposite, beneficial effect.

Men with high serum linoleic acid, but not palmitic, can reduce the risk of prostate cancer by taking tocopherol supplementation.

Men with elevated levels of long-chain omega-3 fatty acids (EPA and DHA) had lowered incidence.

A long-term study reports that "blood levels of trans fatty acids, in particular trans fats resulting from the hydrogenation of vegetable oils, are associated with an increased prostate cancer risk."

Some researchers have indicated that serum myristic acid and palmitic acid and dietary myristic and palmitic saturated fatty acids and serum palmitic combined with alpha-tocopherol supplementation are associated with increased risk of prostate cancer in a dose-dependent manner. These associations may, however, reflect differences in intake or metabolism of these fatty acids between the precancer cases and controls, rather than being an actual cause.

Other

Vegetarian: The American Dietetic Association and Dieticians of Canada report a decreased incidence of prostate cancer for those following a vegetarian diet.

Low-carb : In lab tests on mice, prostate tumors grow slower with a no-carbohydrate diet.

Coffee: A preliminary study found a correlation between coffee consumption and a lower risk of aggressive prostate cancer.

Management

Treatment for prostate cancer may involve active surveillance (monitoring for tumor progress or symptoms), surgery (i.e. radical prostatectomy), radiation therapy including brachytherapy (prostate brachytherapy) and external beam radiation therapy, High-intensity focused ultrasound (HIFU), chemotherapy, oral chemotherapeutic drugs (Temozolomide/TMZ), cryosurgery, hormonal therapy, or some combination. William J. Catalona, MD: regarding Active Surveillance, "Watchful Waiting or for some patients, Wishful Waiting: Can delay prompt treatment of life-threatening tumors, it would require repeated biopsies that often make subsequent nerve-sparing surgery more difficult and it causes many patients anxiety about living with untreated cancer, thus diminishing their quality of life." These men may have already been chemically castrated and impotent.

Which option is best depends on the stage of the disease, the Gleason score, and the PSA level. Other important factors are the man's age, his general health, and his feelings about potential treatments and their possible side-effects. Because all treatments can have significant side-effects, such as erectile dysfunction and urinary incontinence, treatment discussions often focus on balancing the goals of therapy with the risks of lifestyle alterations. Prostate cancer patients are strongly recommended to work closely with their physicians and use a combination of the treatment options when managing their prostate cancer.

The selection of treatment options may be a complex decision involving many factors. For example, radical prostatectomy after primary radiation failure is a very technically challenging surgery and may not be an option, while salvage radiation therapy after surgical failure may have many complications. This may enter into the treatment decision.

If the cancer has spread beyond the prostate, treatment options significantly change, so most doctors that treat prostate cancer use a variety of nomograms to predict the probability of spread. Treatment by watchful waiting/active surveillance, external beam radiation therapy, brachytherapy, cryosurgery, HIFU, and surgery are, in general, offered to men whose cancer remains within the prostate. Hormonal therapy and chemotherapy are often reserved for disease that has spread beyond the prostate. However, there are exceptions: radiation therapy may be used for some advanced tumors, and hormonal therapy is used for some early stage tumors. Cryotherapy (the process of freezing the tumor), hormonal therapy, and chemotherapy may also be offered if initial treatment fails and the cancer progresses.

Hormone-refractory prostate cancer

Most hormone dependent cancers become refractory (independent) after one to three years and resume growth despite hormone therapy.

Docetaxel has been used for HRPC with a median survival benefit of 2 to 3 months.

A combination of bevacizumab(Avastin), taxotere, thalidomide and prednisone appears effective in the treatment of hormone-refractory prostate cancer.

Provenge is also effective (better than placebo) in the treatment of hormone-refractory prostate cancer, as is Cabazitaxel.

MDV3100 is in phase III trials for HRPC (chemo-naive and post-chemo patient populations).

Abiraterone completed a phase 3 trial for HRPC patients who have failed chemotherapy in 2010. Results were overwhelmingly positive. Johnson & Johnson has filed an application with the FDA to have abiraterone approved for use in this patient population. Approval is expected sometime in 2011.

Prognosis

Prostate cancer rates are higher and prognosis poorer in developed countries than the rest of the world. Many of the risk factors for prostate cancer are more prevalent in the developed world, including longer life expectancy and diets high in red meat (People that consume larger amounts of meat and dairy also tend to consume fewer portions of fruits and vegetables. It is not currently clear whether both of these factors, or just one of them, contribute to the occurrence of prostate cancer.) Also, where there is more access to

screening programs, there is a higher detection rate. Prostate cancer is the ninth-most-common cancer in the world, but is the number-one non-skin cancer in United States men. Prostate cancer affected eighteen percent of American men and caused death in three percent in 2005. In Japan, death from prostate cancer was one-fifth to one-half the rates in the United States and Europe in the 1990s. In India in the 1990s, half of the people with prostate cancer confined to the prostate died within ten years. African-American men have 50–60 times more prostate cancer and prostate cancer deaths than men in Shanghai, China. In Nigeria, two percent of men develop prostate cancer and 64% of them are dead after two years.

In patients that undergo treatment, the most important clinical prognostic indicators of disease outcome are stage, pre-therapy PSA level and Gleason score. In general, the higher the grade and the stage the poorer the prognosis. Nomograms can be used to calculate the estimated risk of the individual patient. The predictions are based on the experience of large groups of patients suffering from cancers at various stages.

In 1941, Charles Huggins reported that androgen ablation therapy causes regression of primary and metastatic androgen-dependent prostate cancer. Androgen ablation therapy causes remission in 80-90% of patients undergoing therapy, resulting in a median progression-free survival of 12 to 33 months. After remission, an androgen-independent phenotype typically emerges, wherein the median overall survival is 23–37 months from the time of initiation of androgen ablation therapy. The actual mechanism contributes to the progression of prostate cancer is not clear and may vary between individual patient. A few possible mechanisms have been proposed.


Classification systems

Many prostate cancers are not destined to be lethal, and most men will ultimately die from causes other than of the disease. Decisions about treatment type and timing may, therefore, be informed by an estimation of the risk that the tumor will ultimately recur after treatment and/or progress to metastases and mortality. Several tools are available to help predict outcomes such as pathologic stage and recurrence after surgery or radiation therapy. Most combine stage, grade, and PSA level, and some also add the number or percent of biopsy cores positive, age, and/or other information.


- The *D'Amico classification* stratifies men by low, intermediate, or high risk based on stage, grade, and PSA. It is used widely in clinical practice and research settings. The major downside to the 3-level system is that it does not account for multiple adverse parameters (e.g., high Gleason score *and* high PSA) in stratifying patients.
- The Partin tables predict pathologic outcomes (margin status, extraprostatic extension, and seminal vesicle invasion) based on the same 3 variables, and are published as lookup tables.

- The *Kattan nomograms* predict recurrence after surgery and/or radiation therapy, based on data available either at time of diagnosis or after surgery. The nomograms can be calculated using paper graphs, or using software available on a website or for handheld computers. The Kattan score represents the likelihood of remaining free of disease at a given time interval following treatment.
- The UCSF *Cancer of the Prostate Risk Assessment (CAPRA) score* predicts both pathologic status and recurrence after surgery. It offers comparable accuracy as the Kattan preoperative nomogram, and can be calculated without paper tables or a calculator. Points are assigned based on PSA, Grade, stage, age, and percent of cores positive; the sum yields a 0–10 score, with every 2 points representing roughly a doubling of risk of recurrence. The CAPRA score was derived from community-based data in the CaPSURE database. It has been validated among over 10,000 prostatectomy patients, including patients from CaPSURE; the SEARCH registry, representing data from several Veterans Administration and active military medical centers; a multi-institutional cohort in Germany; and the prostatectomy cohort at Johns Hopkins University. More recently, it has been shown to predict metastasis and mortality following prostatectomy, radiation therapy, watchful waiting, or androgen deprivation therapy.

Epidemiology



Age-standardized death from prostate cancer per 100,000 inhabitants in 2004.



- 32-36
- 36-40
- 40-44
- more than 44

Rates of prostate cancer vary widely across the world. Although the rates vary widely between countries, it is least common in South and East Asia, more common in Europe, and most common in the United States. The average annual incidence rate of prostate cancer between 1988 and 1992 among Chinese men in the United States was 15 times higher than that of their counterparts living in Shanghai and Tianjin. However, these high rates may be affected by increasing rates of detection. Many suggest that prostate cancer may be under reported, yet BPH incidence in China and Japan is similar to rates in Western countries.,

Prostate cancer develops primarily in men over fifty. It is the most common type of cancer in men in the United States, with 186,000 new cases in 2008 and 28,600 deaths. It is the second leading cause of cancer death in U.S. men after lung cancer. In the United Kingdom it is also the second most common cause of cancer death after lung cancer, where around 35,000 cases are diagnosed every year and of which around 10,000 die of it. Many factors, including genetics and diet, have been implicated in the development of prostate cancer. The Prostate Cancer Prevention Trial found that finasteride reduces the incidence of prostate cancer rate by 30%. There had been a controversy about this also increasing the risk of more aggressive cancers, but more recent research showed this may not be the case.

History

Although the prostate was first described by Venetian anatomist Niccolò Massa in 1536, and illustrated by Flemish anatomist Andreas Vesalius in 1538, prostate cancer was not identified until 1853. Prostate cancer was initially considered a rare disease, probably because of shorter life expectancies and poorer detection methods in the 19th century. The first treatments of prostate cancer were surgeries to relieve urinary obstruction. Removal of the entire gland (radical perineal prostatectomy) was first performed in 1904 by Hugh H. Young at Johns Hopkins Hospital. Surgical removal of the testes (orchietomy) to treat prostate cancer was first performed in the 1890s, but with limited success. Transurethral resection of the prostate (TURP) replaced radical prostatectomy for symptomatic relief of obstruction in the middle of the 20th century because it could better preserve penile erectile function. Radical retropubic prostatectomy was developed in 1983 by Patrick Walsh. This surgical approach allowed for removal of the prostate and lymph nodes with maintenance of penile function.

In 1941, Charles B. Huggins published studies in which he used estrogen to oppose testosterone production in men with metastatic prostate cancer. This discovery of "chemical castration" won Huggins the 1966 Nobel Prize in Physiology or Medicine. The role of the hormone GnRH in reproduction was determined by Andrzej W. Schally and

Roger Guillemin, who both won the 1977 Nobel Prize in Physiology or Medicine for this work.

Receptor agonists, such as leuprolide and goserelin, were subsequently developed and used to treat prostate cancer.

Radiation therapy for prostate cancer was first developed in the early 20th century and initially consisted of intraprostatic radium implants. External beam radiation became more popular as stronger radiation sources became available in the middle of the 20th century. Brachytherapy with implanted seeds was first described in 1983.

Systemic chemotherapy for prostate cancer was first studied in the 1970s. The initial regimen of cyclophosphamide and 5-fluorouracil was quickly joined by multiple regimens using a host of other systemic chemotherapy drugs.

On 30 July 2010 Owen Witte M.D. et al. of UCLA published a series of studies in *Science* during which they had introduced viruses known to cause cancerous mutation in prostate cells: AKT, ERG, and AR into isolated samples of basal and luminal cells and grafted the treated tissue into mice. After 16 weeks, none of the luminal samples had undergone malignant mutation, while the basal samples had mutated into prostate-like tubules which had then developed malignancy and formed cancerous tumors, which appeared identical to human samples under magnification. This led to the conclusion that the prostate basal cell may be the most likely "site of origin" of prostate cancer.

Research

Androgen at a concentration of 10-fold higher than the physiological concentration has also been shown to cause growth suppression and reversion of androgen-independent prostate cancer xenografts or androgen-independent prostate tumors derived in vivo model to an androgen-stimulated phenotype in athymic mice. These observation suggest the possibility to use androgen to treat the development of relapsed androgen-independent prostate tumors in patients.

Oral infusion of green tea catechins, a potential alternative therapy for prostate cancer by natural compounds, has been shown to inhibit the development, progression, and metastasis as well in autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) model, which spontaneously develops prostate cancer.

The insulin-like growth factor signaling axis is thought to play a key role in the progression of prostate carcinoma. It consists of two ligands (IGF-1 and IGF-2), two receptors (IGF-IR and IGF-IIR) and six related high-affinity IGF-binding proteins (IGFBP 1-6). Altered expression of IGF axis members has been implicated in the development of many different types of cancers, including prostate.

A genistein derivative KBU2046 is under investigation for prostate cancer.


The Color of Prostate Cancer Awareness is Light Blue.

Prostate cancer models

Scientists have established a few prostate cancer cell lines to investigate the mechanism involved in the progression of prostate cancer. LNCaP, PC-3 (PC3), and DU-145 (DU145) are commonly used prostate cancer cell lines. The LNCaP cancer cell line was established from a human lymph node metastatic lesion of prostatic adenocarcinoma. PC-3 and DU-145 cells were established from human prostatic adenocarcinoma metastatic to bone and to brain, respectively. LNCaP cells express androgen receptor (AR); however, PC-3 and DU-145 cells express very little or no AR. AR, an androgen-activated transcription factor, belongs to the steroid nuclear receptor family. Development of the prostate is dependent on androgen signaling mediated through AR, and AR is also important during the development of prostate cancer. The proliferation of LNCaP cells is androgen-dependent but the proliferation of PC-3 and DU-145 cells is androgen-insensitive. Elevation of AR expression is often observed in advanced prostate tumors in patients. Some androgen-independent LNCaP sublines have been developed from the ATCC androgen-dependent LNCaP cells after androgen deprivation for study of prostate cancer progression. These androgen-independent LNCaP cells have elevated AR expression and express prostate specific antigen upon androgen treatment. The paradox is that androgens inhibit the proliferation of these androgen-independent prostate cancer cells.

Chapter 18

Testicular Cancer



7.4 x 5.5-cm seminoma in a radical orchiectomy specimen.

ICD-10	C62.
ICD-9	186.9
OMIM	273300

DiseasesDB 12966

eMedicine med/2250 med/863

MeSH D013736

Testicular cancer is cancer that develops in the testicles, a part of the male reproductive system.

In the United States, between 7,500 and 8,000 diagnoses of testicular cancer are made each year. Over his lifetime, a man's risk of testicular cancer is roughly 1 in 250 (0.4%). It is most common among males aged 15–40 years. Testicular cancer has one of the highest cure rates of all cancers: in excess of 90 percent; essentially 100 percent if it has not metastasized. Even for the relatively few cases in which malignant cancer has spread widely, chemotherapy offers a cure rate of at least 85 percent today. Not all lumps on the testicles are tumors, and not all tumors are malignant; there are many other conditions such as testicular microlithiasis, epididymal cysts, appendix testis (hydatid of Morgagni), and so on which may be painful but are non-cancerous.

Classification

Although testicular cancer can be derived from any cell type found in the testicles, more than 95% of testicular cancers are germ cell tumors. Most of the remaining 5% are sex cord-gonadal stromal tumours derived from Leydig cells or Sertoli cells. Correct diagnosis is necessary to ensure the most effective and least harmful treatment. To some extent, this can be done via blood tests for tumor markers, but definitive diagnosis requires examination of the histology of a specimen by a pathologist.

Most pathologists use the World Health Organization Classification system for testicular tumours:

- **Germ cell tumours**
 - *Precursor lesions*
 - Intratubular germ cell neoplasia
 - Unclassified type (carcinoma in situ)
 - Specified types
 - *Tumours of one histologic type (pure forms)*
 - Seminoma
 - Variant - Seminoma with syncytiotrophoblastic cells

- Spermatocytic seminoma
- Variant - spermatocytic seminoma with sarcoma
- Embryonal carcinoma
- Yolk sac tumour
- Trophoblastic tumours
- Choriocarcinoma
- Variant - monophasic choriocarcinoma
- Placental site trophoblastic tumour
- Cystic trophoblastic tumour
- Teratoma
- Variant - Dermoid cyst
- Variant - Epidermoid cyst
- Variant - Monodermal teratoma (Carcinoid, Primitive neuroectodermal tumour (PNET), Nephroblastoma-like tumor, others).
- Variant - Teratomic with somatic-type malignancy
- *Tumours of more than one histologic type (mixed forms)*
- Embryonal carcinoma and teratoma
- Teratoma and seminoma
- Choriocarcinoma and teratoma.embryonal carcinoma
- Others
- **Sex cord/Gonadal stromal tumours**
 - Leydig cell tumour
 - Sertoli cell tumour
 - Lipid rich variant
 - Sclerosing variant
 - Large cell calcifying variant
 - Intratubular sertoli cell neoplasia in Peutz-Jeghers syndrome
 - Granulosa cell tumour
 - Adult type
 - Juvenile type
 - Thecoma Fibroma Group

- Thecoma
- Fibroma

- Sex cord/gonadal stromal tumour - incompletely differentiated
- Sex cord/gonadal stromal tumour - mixed types

- **Mixed Germ Cell and Sex Cord/Gonadal Stromal Tumours**
 - Gonadoblastoma
 - Germ cell-sex cord/gonadal stromal tumour, unclassified

- **Miscellaneous tumours of the testis**
 - Carcinoid
 - Tumours of ovarian epithelial types
 - Serous tumour of borderline malignancy
 - Serous carcinoma
 - Well differentiated endometrioid tumour
 - Mucinous cystadenoma
 - Mucinous cystadenocarcinoma
 - Brenner tumour
 - Nephroblastoma
 - Paraganglioma

- **Haematopoietic tumours**
- **Tumours of collecting ducts and rete**
 - Adenoma
 - Carcinoma

- **Tumours of the paratesticular structures**
 - Adenomatoid tumour
 - Malignant mesothelioma
 - Benign mesothelioma
 - Adenocarcinoma of the epididymis
 - Papillary cystadenoma of the epididymis
 - Melanotic neuroectodermal tumour
 - Desmoplastic small round cell tumour

- **Mesenchymal tumours of the spermatic cord and testicular adnexae**
 - Lipoma
 - Liposarcoma

- Rhabdomyosarcoma
 - Aggressive angiomyxoma
 - Angiomyofibroblastoma-like tumour
 - Fibromatosis
 - Fibroma
 - Solitary fibrous tumour
 - Others
- **Secondary tumours of the testis**

Signs and symptoms

A testicular mass can often be palpated. The U.S. Preventive Services Task Force (USPSTF) recommends against routine screening for testicular cancer in asymptomatic adolescent and adults, which means that men should not perform routine testicular self-exams. This practice was encouraged in the past, but current scientific evidence suggests that screening for testicular cancer does not lead to decreased morbidity and mortality. However, the American Cancer Society suggests that some men should examine their testicles monthly, especially if they have a family history of cancer.

Symptoms may include one or more of the following:


- a lump in one testis which may or may not be painful
- sharp pain or a dull ache in the lower abdomen or scrotum
- a feeling often described as "heaviness" in the scrotum
- breast enlargement (gynecomastia) from hormonal effects of β -hCG
- low back pain (lumbago) tumor spread to the lymph nodes along the back
- shortness of breath (dyspnea), cough or coughing up blood (hemoptysis) from metastatic spread to the lungs
- a lump in the neck due to metastases to the lymph nodes

The nature of any palpated lump in the scrotum is evaluated by scrotal ultrasound, which can determine exact location, size, and some characteristics of the lump, such as cystic vs solid, uniform vs heterogeneous, sharply circumscribed or poorly defined. The extent of the disease is evaluated by CT scans, which are used to locate metastases. Blood tests are also used to identify and measure tumor markers that are specific to testicular cancer. AFP alpha feto protein, Beta-HCG, and LDH are the typical markers used to identify testicular cancer. The diagnosis is made by performing an inguinal orchiectomy, surgical excision of the entire testis along with attached structures epididymis and spermatic cord; the resected specimen is evaluated by a pathologist. A biopsy should not be performed, as it raises the risk of migrating cancer cells into the scrotum. The reason why inguinal orchiectomy is the preferred method is that the lymphatic system of the scrotum links to the lower extremities and that of the testicle links to the retroperitoneum. A transscrotal biopsy or orchiectomy will potentially leave cancer cells in the scrotum and create two vectors for cancer spread, while in an inguinal orchiectomy only the retroperitoneal route exists.

Pathophysiology

Most testicular germ cell tumors have too many chromosomes, and most often they are triploid to tetraploid. An isochromosome 12p (the short arm of chromosome 12 on both sides of the same centromere) is present in about 80 % of the testicular cancers, and also the other cancers usually have extra material from this chromosome arm through other mechanisms of genomic amplification.

Diagnosis



Micrograph (high magnification) of a seminoma. H&E stain.

The cardinal diagnostic finding in the patient with testis cancer is a mass in the substance of the testis. Unilateral enlargement of the testis with or without pain in the adolescent or young adult male should raise concern for testis cancer.

An incorrect diagnosis is made at the initial examination in up to 25% of patients with testicular tumors and may result in delay in treatment or a suboptimal approach (scrotal incision) for exploration.

- Epididymitis or epididymoorchitis
- Hematocele

- Varicocele

The differential diagnosis of testicular cancer requires examining the histology of tissue obtained from an inguinal orchiectomy specimen. Orchiectomy, rather than transcrotal biopsy, is preferred to reduce the risk of spill and thus the risk of metastasis, in the event that the tumor is malignant. For orchiectomy, an inguinal surgical approach is preferred.

Staging

After removal, a testicular tumor is staged by a pathologist according to the TNM Classification of Malignant Tumors as published in the AJCC Cancer Staging Manual. Testicular cancer is categorized as being in one of three stages (which have subclassifications). The size of the tumor in the testis is irrelevant to staging. In broad terms, testicular cancer is staged as follows:

- Stage 1: the cancer remains localized to the testis.
- Stage 2: the cancer involves the testis and metastasis to retroperitoneal and/or Paraaortic lymph nodes (lymph nodes below the diaphragm).
- Stage 3: the cancer involves the testis and metastasis beyond the retroperitoneal and Paraaortic lymph nodes. Stage 3 is further subdivided into non-bulky stage 3 and bulky stage 3.
- Stage 4: if there is liver and/or lung secondaries

Management

Before 1970, men with recurrent testicular cancer were destined to have rapid progression and death from disseminated disease. Currently, although 7000 to 8000 new cases of testicular cancer occur in the United States yearly, only 400 men are expected to die of the disease. Much of this improvement is due to advances in adjuvant therapy.

Due to the risk of subsequent metastasis, post-surgical adjuvant therapy may be offered to the patient following orchiectomy. The type of adjuvant therapy depends largely on the histology of the tumor and the stage of progression at the time of surgery. These two factors contribute to the risk of recurrence, including metastasis. Adjuvant treatments may involve chemotherapy, radiotherapy or careful surveillance by frequent CT scans and blood tests by oncologists.

The three basic types of treatment are surgery, radiation therapy, and chemotherapy.

Surgery is performed by urologists; radiation therapy is administered by radiation oncologists; and chemotherapy is the work of medical oncologists. In most patients with testicular cancer, the disease is cured readily with minimal long-term morbidity.

Surgery

Orchiectomy

While it may be possible, in some cases, to remove testicular cancer tumors from a testis while leaving the testis functional, this is almost never done, as the affected testicle usually contains pre-cancerous cells spread throughout the entire testicle. Thus removing the tumor alone without additional treatment greatly increases the risk that another cancer will form in that testicle. Since only one testis is typically required to maintain fertility, hormone production, and other male functions, the afflicted testis is almost always removed completely in a procedure called inguinal orchiectomy. (The testicle is almost never removed through the scrotum; an incision is made beneath the belt line in the inguinal area.) In the UK, the procedure is known as a **radical orchidectomy**.

Retroperitoneal Lymph Node Dissection (RPLND)

In the case of nonseminomas that appear to be stage I, surgery may be done on the retroperitoneal/Para-aortic lymph nodes (in a separate operation) to accurately determine whether the cancer is in stage I or stage II and to reduce the risk that malignant testicular cancer cells that may have metastasized to lymph nodes in the lower abdomen. This surgery is called Retroperitoneal Lymph Node Dissection (RPLND). However, this approach, while standard in many places, especially the United States, is out of favor due to costs and the high level of expertise required to perform the surgery. The urologist may take extra care in the case of males who have not fathered children, to preserve the nerves involved in ejaculation.

Many patients are instead choosing surveillance, where no further surgery is performed unless tests indicate that the cancer has returned. This approach maintains a high cure rate because of the growing accuracy of surveillance techniques.

Lymph node surgery may also be performed after chemotherapy to remove masses left behind, particularly in the cases of advanced initial cancer or large nonseminomas.

Radiation therapy

Radiation may be used to treat stage 2 seminoma cancers, or as adjuvant (preventative) therapy in the case of stage 1 seminomas, to minimize the likelihood that tiny, non-detectable tumors exist and will spread (in the inguinal and para-aortic lymph nodes). Radiation is never used as a primary therapy for nonseminoma.

Chemotherapy

As an adjuvant treatment, use of chemotherapy as an alternative to radiation therapy in the treatment of seminoma is increasing, because radiation therapy appears to have more significant long-term side effects (for example, internal scarring, increased risks of secondary malignancies, etc.). Two doses, or occasionally a single dose of carboplatin,

typically delivered three weeks apart, is proving to be a successful adjuvant treatment, with recurrence rates in the same ranges as those of radiotherapy. However, very long term data on the efficacy of adjuvant carboplatin in this setting does not exist. Since seminoma can recur decades after the primary tumor is removed, patients receiving adjuvant chemotherapy should remain vigilant and not assume they are cured 5 years after treatment. The concept of carboplatin as a single-dose therapy was developed by Tim Oliver, Professor of Medical Oncology at Barts and The London School of Medicine and Dentistry.

Chemotherapy is the standard treatment for non-seminoma when the cancer has spread to other parts of the body (that is, stage 2B or 3). The standard chemotherapy protocol is three, or sometimes four, rounds of Bleomycin-Etoposide-Cisplatin (BEP). This treatment was developed by Dr. Lawrence Einhorn at Indiana University. An alternative, equally effective treatment involves the use of four cycles of Etoposide-Cisplatin (EP).

While treatment success depends on the stage, the average survival rate after five years is around 95%, and stage 1 cancers cases (if monitored properly) have essentially a 100% survival rate (which is why prompt action, when testicular cancer is a possibility, is extremely important).

Prognosis

In the *New England Journal of Medicine*, treatment of testicular cancer has been called one of the success stories of modern medicine, with sustained response to treatment in more than 90% of cases, regardless of stage. Because of advances in chemotherapy, cure rates now approach 85% overall, with better than 95% for localized disease and 80% for metastatic disease—the best response by any solid tumor.

Surveillance

For many patients with stage I cancer, adjuvant (preventative) therapy following surgery may not be appropriate and patients will undergo surveillance instead. The form this surveillance takes, e.g. the type and frequency of investigations and the length time it should continue, will depend on the type of cancer (non-seminoma or seminoma), but the aim is to avoid unnecessary treatments in the many patients who are cured by their surgery, and ensure that any relapses with metastases (secondary cancers) are detected early and cured. This approach ensures that chemotherapy and or radiotherapy is only given to the patients that need it. The number of patients ultimately cured is the same using surveillance as post-operative “adjuvant” treatments, but the patients have to be prepared to follow a prolonged series of visits and tests.

For both non-seminomas and seminomas, surveillance tests generally include physical examination, blood tests for tumour markers, chest x-rays and CT scanning. However, the requirements of a surveillance programme differ according to the type of disease since, for seminoma patients, relapses can occur later and blood tests are not as good at indicating relapse.

CT scans are performed on the abdomen (and sometimes the pelvis) and also the chest in some hospitals. Chest x-rays are increasingly preferred for the lungs as they give sufficient detail combined with a lower false-positive rate and significantly smaller radiation dose than CT.

The frequency of CT scans during surveillance should ensure that relapses are detected at an early stage whilst minimising the radiation exposure.

For patients treated for stage I non-seminoma, a randomised trial (Medical Research Council TE08) showed that, when combined with the standard surveillance tests described above, 2 CT scans at 3 and 12 months were as good as 5 over 2 years in detecting relapse at an early stage.

For patients treated for stage I seminoma who choose surveillance rather than undergoing adjuvant therapy, there have been no randomised trials to determine the optimum frequency of scans and visits, and the schedules vary very widely across the world, and within individual countries. In the UK there is an ongoing clinical trial called TRISST.. This is assessing how often scans should take place and whether magnetic resonance imaging (MRI) can be used instead of CT scans. MRI is being investigated because it does not expose the patient to radiation and so, if it is shown to be as good at detecting relapses, it may be preferable to CT. It is possible that one or more centres in Canada may join the trial in the next year or so.

For more advanced stages of testicular cancer, and for those cases in which radiation therapy or chemotherapy was administered, the extent of monitoring (tests) after treatment will vary on the basis of the circumstances, but normally should be done for five years in uncomplicated cases and for longer in those with higher risks of relapse.

Fertility

A man with one remaining testis can lead a normal life, because the remaining testis takes up the burden of testosterone production and will generally have adequate fertility. However, it is worth the (minor) expense of measuring hormone levels before removal of a testicle, and sperm banking may be appropriate for younger men who still plan to have children, since fertility may be lessened by removal of one testicle, and can be severely affected if extensive chemotherapy and/or radiotherapy is done.

Less than five percent of those who have testicular cancer will have it again in the remaining testis. A man who loses both testicles will normally have to take hormone supplements (in particular, testosterone, which is created in the testicles), and will be infertile, but can lead an otherwise normal life.

Epidemiology

Testicular cancer is most common among Caucasian men and rare among men of African descent. Testicular cancer is uncommon in Asia and Africa. Worldwide incidence has

doubled since the 1960s, with the highest rates of prevalence in Scandinavia, Germany, and New Zealand.

Incidence among African Americans doubled from 1988 to 2001 with a bias towards seminoma. The lack of significant increase in the incidence of early-stage testicular cancer during this timeframe suggests that the overall increase was not due to heightened awareness of the disease.

Although testicular cancer is most common among men aged 15–40 years, it has three peaks: infancy through the age of four as teratomas and yolk sac tumors, ages 25–40 years as post-pubertal seminomas and nonseminomas, and from age 60 as spermatocytic seminomas.

Germ cell tumors of the testis are the most common cancer in young men between the ages of 15 and 35 years.


A major risk factor for the development of testis cancer is cryptorchidism (undescended testicles). It is generally believed that the presence of a tumor contributes to cryptorchidism; when cryptorchidism occurs in conjunction with a tumor then the tumor tends to be large. Other risk factors include inguinal hernia, mumps orchitis. Physical activity is associated with decreased risk and sedentary lifestyle is associated with increased risk. Early onset of male characteristics is associated with increased risk. These may reflect endogenous or environmental hormones.

In other animals

Testicular tumors occur also in animals. In horses, these include interstitial cell tumors and teratomas. Typically, the former are found in older stallions (affected stallions may become extremely vicious, suggesting excessive production of androgen), and the latter are found in young horses and are large.

Chapter 19

Hypospadias



Example of penis with hypospadias

ICD-10	Q54.
ICD-9	752.61, 752.6
DiseasesDB	29907
MedlinePlus	001286
eMedicine	ped/1136

Hypospadias is a birth defect of the urethra in the male that involves an abnormally placed urinary meatus (the opening, or male external urethral orifice). Instead of opening at the tip of the glans of the penis, a hypospadiac urethra opens anywhere along a line (the *urethral groove*) running from the tip along the underside (ventral aspect) of the shaft to the junction of the penis and scrotum or perineum. A distal hypospadias may be

suspected even in an uncircumcised boy from an abnormally formed foreskin and downward tilt of the glans.

The urethral meatus opens on the glans penis in about 50–75% of cases; these are categorized as *first degree* hypospadias. *Second degree* (when the urethra opens on the shaft), and *third degree* (when the urethra opens on the perineum) occur in up to 20 and 30% of cases respectively. The more severe degrees are more likely to be associated with chordee, in which the phallus is incompletely separated from the perineum or is still tethered downwards by connective tissue, or with undescended testes (cryptorchidism).

Signs and symptoms



Australian man showing signs of hypospadias, including a bifid penis

Hypospadias is a male birth defect in which the opening of the tube that carries urine from the body (urethra) develops abnormally, usually on the underside of the penis. The opening can occur anywhere from just below the end of the penis to the scrotum. A form of hypospadias in which the genitals are abnormally positioned can also develop in females.

Associated birth defects

Mild hypospadias most often occurs as an isolated birth defect without detectable abnormality of the remainder of the reproductive or endocrine system. However, a minority of infants, especially those with more severe degrees of hypospadias will have additional structural anomalies of the genitourinary tract. Up to 10% of boys with hypospadias have at least one undescended testis, and a similar number have an inguinal hernia. An enlarged prostatic utricle is common when the hypospadias is severe (scrotal or perineal), and can predispose to urinary tract infections, pseudo-incontinence, or even stone formation.

Epispadias

A much rarer and unrelated type of urethral malformation is an **epispadias**. This is not a problem of the urethral groove or meatus, but a failure of midline penile fusion much earlier in embryogenesis. An isolated opening of the dorsal ("top") side of the penis is rare, and most of these children have much more severe defects, involving a small and

bifid phallus with bladder exstrophy or more severely, cloacal exstrophy involving the entire perineum. The cause of this defect of early embryogenesis is unknown but does not involve androgens.

Cause

In most cases, the cause of this birth defect is not fully understood. Treatment with hormones such as progesterone during pregnancy may increase the risk of hypospadias. Certain hormonal fluctuations, such as failure of the fetal testes to produce enough testosterone or the failure of the body to respond to testosterone, increase the risk of hypospadias and other genetic problems. Sometimes hypospadias is inherited.

There also may be an increased risk of hypospadias in infant males born to women of an advanced age or those who used in vitro fertilization (IVF) to conceive. The connection to IVF may be due to the mother's exposure to progesterone, a natural hormone, or to progestin, a synthetic form of progesterone, administered during the IVF process.

Prenatal testosterone, converted in the genital skin to dihydrotestosterone, causes migration of skin fibroblasts to fully enclose the urethral groove in fetal males, normally resulting in an enclosed penile urethra by the second trimester of pregnancy. Failure of adequate prenatal androgen effect is therefore thought to be involved in many cases, making severe hypospadias a very mild form of intersex (under-virilization of a genetic male). Since postnatal androgen deficiency can only be demonstrated in a minority of cases, it has been proposed that transient deficiency of testosterone can occur during critical periods of fetal genital development, due to elevation of anti-müllerian hormone or more subtle degrees of pituitary-gonadal dysfunction. More recently, abnormalities of transcription factors have been proposed.

In animals, several teratogenic drugs or chemicals can cause hypospadias by interfering with androgen action in the embryo. Speculation that environmental agents—endocrine disruptors—might be interfering with human hormone systems has not been proven. The agents that have caused hypospadias in a small number of boys have been maternal use of synthetic progestins and finasteride in the first two trimesters of pregnancy. In 2008, it was suggested that maternal use of diethylstilbestrol, a synthetic estrogen, resulted in a 20-fold increase in prevalence of hypospadias although a followup study showed the risk, though present, to be much lesser.

In a minority of cases a postnatal deficiency of, or reduced sensitivity to, androgens (testosterone and dihydrotestosterone) can be demonstrated. These are often associated with a chordee, and in severe cases a residual perineal urogenital opening and small phallus. This combination of birth defects is referred to as pseudovaginal perineoscrotal hypospadias and is part of the spectrum of ambiguous genitalia. Treatment with testosterone postnatally does not close the urethra.

Genetic factors are likely involved in at least some cases, as there is about a 7% familial recurrence risk. A 2010 Article found a 2.5 times increase in the condition for boys with a specific genetic defect that was carried on the X (maternally contributed sex) chromosome.

Rare iatrogenic urethral injuries similar to hypospadias after procedures such as surgery, catheterization, or circumcision have been reported.

Treatment



An erect penis with hypospadias

First degree hypospadias are primarily a cosmetic defect and have little effect on function except for direction of the urinary stream. If uncorrected, a second or third degree hypospadias can make male urination messy, necessitate that it be performed sitting, impair delivery of semen into the vagina (possibly creating problems with fertility), or interfere with erections. In developed countries, most hypospadias are surgically repaired in infancy. Surgical repair of first and second degree hypospadias is nearly always successful in one procedure, usually performed in the first year of life by a pediatric urologist or a plastic surgeon.

When the hypospadias is third degree, or there are associated birth defects such as chordee or cryptorchidism, the best management can be a more complicated decision. A karyotype and endocrine evaluation should be performed to detect intersex conditions or hormone deficiencies. If the penis is small, testosterone or human chorionic gonadotropin (hCG) injections may be given to enlarge it prior to surgery.

Surgical repair of severe hypospadias may require multiple procedures and mucosal grafting. Preputial skin is often used for grafting and circumcision should be avoided prior to repair. In a minority of patients with severe hypospadias surgery produces unsatisfactory results, such as scarring, curvature, or formation of urethral fistulas, diverticula, or strictures. A fistula is an unwanted opening through the skin along the course of the urethra, and can result in urinary leakage or an abnormal stream. A diverticulum is an "outpocketing" of the lining of the urethra which interferes with urinary flow and may result in post-urination leakage. A stricture is a narrowing of the urethra severe enough to obstruct flow. Reduced complication rates even for third degree repair (e.g., fistula rates below 5%) have been reported in recent years from centers with the most experience, and surgical repair is now performed for the vast majority of infants with hypospadias.

Because of the difficulties and lower success rates of surgical repair of the most severe degrees of under virilization, some of these genetically male but severely undervirilized infants have been assigned and raised as girls, with feminizing surgical reconstruction. Opinion has shifted against this approach in the last decade because adult sexual function as a female has often been poor, and development of a male gender identity despite female sex assignment and rearing, has occurred in some XY children after reassignment for a more severe type of genital birth defect, cloacal exstrophy.

Epidemiology

Hypospadias are among the most common birth defects of the male genitalia (second to cryptorchidism), but widely varying incidences have been reported from different countries, from as low as 1 in 4000 to as high as 1 in 125 boys.

The incidence of hypospadias around the world has been increasing in recent decades. In the United States, two surveillance studies reported that the incidence had increased from about 1 in 500 total births (1 in 250 boys) in the 1970s to 1 in 250 total births (1 in 125 boys) in the 1990s. Although a slight worldwide increase in hypospadias was reported in the 1980s, studies in different countries and regions have yielded conflicting results and some registries have reported decreases.

Chapter 20

Vasectomy

Vasectomy	
Background	
Birth control type	Sterilization
First use	1899 (experiments from 1785)
Failure rates (first year)	
Perfect use	<0.1%
Typical use	0.15%, "Vas-Clip" nearly 1%
Usage	
Duration effect	Permanent
Reversibility	Possible, but expensive and low success rate.
User reminders	2 consecutive negative semen specimens required to verify infertility.
Clinic review	All
Advantages and disadvantages	
STD protection	No
Benefits	No need for general anesthesia. Lower cost than tubal ligation for women.
Risks	Temporary local inflammation or swelling

of the testes. Long-term genital pain (PVPS).

Vasectomy is a surgical procedure in which the vasa deferentia of a man are severed, and sometimes tied or sealed.

Procedure

Usually done in an outpatient setting, a traditional vasectomy involves numbing of the scrotum with local anesthetic after which one or two small incisions are made, allowing a surgeon to gain access to the vas deferens of each testicle. The vasa deferentia are cut and sometimes sealed by ligating, cauterizing, or clamping.

Variations

Variations in how a vasectomy is performed can be employed in attempts to increase success rates, reduce healing times, lower chances of infection, and decrease the risk of post-vasectomy pain syndrome (PVPS). The primary goal however is always the same, preventing sperm from entering into a man's ejaculate.

With conventional vasectomy, the surgeon uses a scalpel to make a small incision on each side of the scrotum, allowing access to each vas deferens. The vas deferens is severed, and usually a small piece removed. It is then tied-off and/or cauterized to make the seal. The surgeon and/or patient may elect to forgo some of the "traditional" methods in favor of newer variations as described below.

1. A No-Scalpel vasectomy, also known as a "key-hole" vasectomy, in which a sharp hemostat, rather than a scalpel, is used to puncture the scrotum. It may reduce healing times as well as lower the chance of, but not eliminate, infection from incision. Usually, there are no stitches needed when using the No-Scalpel method.
2. In an "open-ended" vasectomy, the testicular end of the vas deferens is not sealed, which allows continued streaming of sperm into the scrotum. This method may avoid build-up of pressure in the epididymis. Testicular pain from "back-pressure" may also be reduced using this method.
3. A "Vas-Clip" vasectomy does not require cutting the vas deferens, but rather uses a clip to squeeze shut the flow of sperm. This method may facilitate a better chance/outlook for reversal, as well as reduced post-procedure pain.

To help prevent re canalization of the vas deferens, the patient may opt for Fascial Interposition. Fascial Interposition is the positioning of the producing end of the vas deferens to the outside of the fascia. The Fascia is a fibrous protective sheath that surrounds the vas deferens. By sewing one end of the vas deferens to the outside of this sheath while leaving the other end inside, this makes it difficult if not impossible for reattaching or re canalization of the vas deferens.

Biological implications

Vasectomy essentially ensures that the patient will be sterile after surgery. The procedure is regarded by the medical profession as permanent because vasectomy reversal is costly and often does not restore the pre-vasectomy condition. Men with vasectomies have a very small chance of making a woman pregnant, but they will still have exactly the same risk of contracting and spreading sexually transmitted diseases.

After vasectomy, the testes remain in the scrotum where Leydig cells continue to produce testosterone and other male hormones that continue to be secreted into the blood stream. One study found that sexual desire after vasectomy was diminished in 6% of vasectomized men, whereas other studies find higher rates of diminished sexual desire, for example nearly 20%.

When the vasectomy is complete, sperm cannot exit the body through the penis. Sperm are still produced by the testicles, but they are broken down and absorbed by the body. Much fluid content is absorbed by membranes in the epididymis, and much solid content is broken down by the responding macrophages and re-absorbed via the blood stream. Sperm is matured in the epididymis for about a month once it leaves the testicles. After vasectomy, the membranes must increase in size to absorb and store more fluid; this triggering of the immune system causes more macrophages to be recruited to break down and re-absorb more solid content. Within one year after vasectomy, sixty to seventy percent of vasectomized men develop antisperm antibodies. In some cases, vasitis nodosa, a benign proliferation of the ductular epithelium, can also result. The buildup of sperm increases pressure in the vas deferens and epididymis. The entry of the sperm into the scrotum causes sperm granulomas to be formed by the body to contain and absorb the sperm which the body treats as a foreign substance.

Effectiveness as birth control

The Royal College of Obstetricians and Gynaecologists state there is a generally agreed upon rate of failure of about 1 in 2000 vasectomies which is considerably better than tubal ligations for which there is one failure in every 200 to 300 cases. Early failure rates, i.e. pregnancy within a few months after vasectomy typically result from having unprotected intercourse too soon after the procedure. Late failure, i.e. pregnancy after recanalization of the vasa deferentia, has been documented. A 2005 systematic review of 28 studies described a total of 183 failures or recanalizations from approximately 43,642 vasectomy patients (0.4%), and 20 studies in the same review described 60 pregnancies after 92,184 vasectomies (0.07%).

Most physicians and surgeons who perform vasectomies recommend one (sometimes two) post-procedural semen specimens to verify a successful vasectomy, however many men fail to return for verification tests citing inconvenience, embarrassment, death, or change in partner. In January 2008 the FDA cleared a home test called SpermCheck Vasectomy that allows patients to perform postvasectomy confirmation tests themselves, however compliance for postvasectomy semen analysis in general remains low.

Sexual intercourse may be resumed in about a week. However, pregnancy is still possible as long as the sperm count is above zero. Another method of birth control must be used until a follow-up sperm count test two months after the vasectomy, or after 10 to 20 ejaculations over a shorter period of time, can be performed.

Complications of vasectomy



A post-vasectomy scrotum, showing typical post-operative bruising, incision stitches and a shaved scrotum

Short-term complications include temporary bruising and bleeding, known as hematoma. The primary long-term complication is a permanent pain condition, post-vasectomy pain syndrome. Animal and human data indicate that vasectomy does not increase atherosclerosis and that increases in circulating immune complexes after vasectomy are transient. Furthermore, the weight of the evidence regarding prostate and testicular cancer suggests that men with vasectomy are not at increased risk of these cancers.

Post-vasectomy pain syndrome

Post-vasectomy pain syndrome (PVPS) is a chronic and sometimes debilitating condition that may develop immediately or several years after vasectomy. One survey cites studies that estimate incidence at one case every ten to thirty vasectomies. The pain can be constant orchialgia or epididymal pain, or it can be pain that occurs only at particular times such as with intercourse, ejaculation, or physical exertion.

Vasectomy reversal

Although men considering vasectomies should not think of them as reversible, and most men and their partners are satisfied with the operation, there is a surgical procedure to reverse vasectomies using vasovasostomy (a form of microsurgery first performed by Earl Owen in 1971). Vasovasostomy is effective at achieving pregnancy in only 50%-70% of cases, and it is costly, with total out-of-pocket costs in the United States often upwards of \$10,000. The rate of pregnancy depends on such factors as the method used for the vasectomy and the length of time that has passed since the vasectomy was performed. The reversal procedures are frequently impermanent, with occlusion of the vas recurring two or more years after the operation. After reversal, sperm counts are usually much lower than pre-vasectomy levels. There is evidence that men who have had a vasectomy may produce more abnormal sperm, which would explain why even a

mechanically successful reversal does not always restore fertility. The higher rates of aneuploidy and diploidy in the sperm cells of men who have undergone vasectomy reversal may lead to a higher rate of birth defects.

Conceiving after vasectomy

In order to allow a possibility of reproduction via artificial insemination after vasectomy, some men opt for cryostorage of sperm before sterilization.

It is also possible to conceive via IVF after a vasectomy. In a vasectomized man, sperm can be aspirated from the testicles or the epididymis, and while there is not enough for successful artificial insemination, there is enough to fertilize an ovum by ICSI. This avoids the problem of anti-sperm antibodies and may result in a faster pregnancy. IVF may be less costly per cycle than reversal in some healthcare systems, but a single IVF cycle is often insufficient for conception. Disadvantages include the need for procedures on the woman, and the standard potential side-effects of IVF for both the mother and the child.

As in other cases of male infertility, conception can take place with donor sperm.

History

The first recorded vasectomy was performed on a dog in 1823. A short time after that, R. Harrison of London performed the first human vasectomy, however the surgery was not done for sterilization purposes, but to bring about atrophy of the prostate. Vasectomy began to be regarded as a method of birth control during the Second World War. The first vasectomy program on a national scale was launched in 1954 in India.

Availability and legal status

In the UK vasectomy is often available free of charge through the National Health Service upon referral by one's GP. However, some PCTs do not fund the procedure. There are private clinics, such as Marie Stopes International, who perform the operation with short waiting times.

Vasectomy is also covered in Australia, Canada and Mexico.

In Costa Rica, vasectomy is covered by the Caja Costarricense del Seguro Social (Costa Rica's national insurance).

In 2006 Argentina approved vasectomy in public health service.

Under the laws of Paraguay vasectomy, like tubal ligation, is considered a mutilation, and the surgeon could be prosecuted. However the surgery remains available to those who seek it, the surgeons covering themselves by having the patient and his spouse sign a form of consent, thus making them accessories before the fact.

In Poland any surgical procedure leading to sterility is illegal with penalty of up to 10 years imprisonment for the surgeon.

Chapter 21

Vasectomy Reversal

Vasectomy reversal is a term used for surgical procedures that reconnect the male reproductive tract after interruption by a vasectomy. Two procedures are possible at the time of vasectomy reversal: vasovasostomy (vas deferens to vas deferens connection) and vasoepididymostomy (epididymis to vas deferens connection). Although vasectomy is considered a permanent form of contraception, advances in microsurgery have improved the success of vasectomy reversal procedures. The procedures remain technically demanding and expensive, and usually do not restore the pre-vasectomy condition.

History

Technical advances in vasectomy reversal mirror those in microsurgery over the past 100 years. As a discipline, microsurgery was first performed by Carl Nylen in Sweden for middle ear surgery in 1910, but grew most rapidly as a discipline in the 20th century stimulated by its success in microvascular reconstruction of war-injured soldiers. The first microsurgical vasectomy reversal was performed by Earl Owen in 1971.

Prevalence

Vasectomy is a common method of contraception worldwide, with an estimated 40-60 million individuals having the procedure and 5-10% of couples choosing it as a birth control method. In the U.S., about 5% of men who have had a vasectomy will change their minds and have a vasectomy reversal afterwards. The most common reason for a reversal is remarriage and a desire for more children. Other men in long-standing relationships have changed their minds and would like more children. There are occasional unfortunate individuals who have lost children and want to have more children. Vasectomy reversals are also performed in attempts to relieve post-vasectomy pain syndrome.

Biological considerations

Sperm are produced in the male sex gland or testicle. From there they travel through tubes (efferent tubules), exit the testes and enter a “storage site” or epididymis. The epididymis is a single, 18-foot-long (5.5 m), tightly coiled, small tube, within which sperm mature to the point where they can move, swim and fertilize eggs. Testicular sperm are not able to fertilize eggs naturally (but can if they are injected directly into the

egg in the laboratory), as the ability to fertilize eggs is developed slowly over several months of storage in the epididymis. From the epididymis, a 14-inch, 3 mm-thick muscular tube called the vas deferens carries the sperm to the urethra near the base of the penis. The urethra then carries the sperm through the penis during ejaculation. A vasectomy interrupts sperm flow within the vas deferens. After a vasectomy, the testes still make sperm, but because the exit is blocked, the sperm die and eventually are reabsorbed by the body.

A problem in the delicate tubes of epididymis can develop over time after vasectomy. The longer the time since the vasectomy, the greater the “back-pressure” behind the vasectomy. This “back-pressure” may cause a “blowout” in the delicate epididymal tubule, the weakest point in the system. The blowout may or may not cause symptoms, but will probably scar the epididymal tubule, thus blocking sperm flow at second point. To summarize, with time, a man with a vasectomy can develop a second obstruction deeper in the reproductive tract that can make the vasectomy more difficult to reverse. Having the skill to detect and fix this problem during vasectomy reversal is the essence of a skilled surgeon. If the surgeon simply reconnects the two freshened ends of the vas deferens without examining for a second, deeper obstruction, then the procedure can fail, as sperm-containing fluids are still unable to flow to the place of the connection. In this case, the vas deferens must be connected to the epididymis in front of the second blockage, to bypass both blockages and allow the sperm to reenter the urethra in the ejaculate. Since the epididymal tubule is much smaller (0.3 mm diameter) than the vas deferens (3 mm diameter, 10-fold larger), epididymal surgery is far more complicated and precise than the simple vas deferens-to-vas deferens connection.

Procedure

Preparation

A general or regional anesthetic is most commonly used, as this offers the least interruption by patient movement for microsurgery. Local anesthesia, with or without sedation, can also be used. The procedure is generally done on a “come and go” basis. The actual operating time can range from 1–4 hours, depending on the anatomical complexity, skill of the surgeon and the kind of procedure performed.

Assessing biology

After anesthesia and scrubbing the scrotum with soap and water, the vas deferens is exposed through a small, 1-2 cm incision in the upper scrotum on each side. The vas deferens is cut sharply in half, both above and below the vasectomy site. A special bipolar microcautery is used to judiciously control any bleeding. One end of the vas deferens, termed the abdominal end, is inspected and flushed with salt solution to ensure that it is not blocked as it courses from the scrotum to the prostate (a “saline vasogram”). If a blockage is suspect above the vasectomy site, then this must be dealt with as well, if sperm is to return to the ejaculate after surgery. The testicle end of the vas deferens is then compressed and inspected for fluid. This fluid is examined with a microscope for

color, consistency and for sperm. This information is used to decide whether or not a secondary epididymal obstruction is present (see Table below).

Grade	Vasal Fluid Findings	Procedure Suggested
1	Normal appearing sperm with motility	Vasovasostomy
2	Mostly normal appearing, nonmotile	Vasovasostomy
3	Mostly sperm heads without tails, nonmotile	Vasovasostomy
4	Only sperm heads	Vasovasostomy
5	No sperm, creamy fluid	Vasoepididymostomy
6	No fluid	Vasoepididymostomy
7	Clear fluid, no sperm	It depends

If sperm are found at the testis end of the vas deferens, then it is assumed that a secondary epididymal obstruction has not occurred and a vas deferens-to-vas deferens reconnection (vasovasostomy) is planned. If sperm are not found, then an epididymis to vas deferens connection (vasoepididymostomy) is needed to restore sperm flow. Other, more subtle findings that can be observed in the fluid—including the presence of sperm fragments and clear, good quality fluid without any sperm—require surgical decision-making to successfully treat.

Vasovasostomy

For a vasovasostomy, two microsurgical approaches are most commonly used. Neither has proven superior to the other. What has been shown to be important, however, is that the surgeon use optical magnification to perform the vasectomy reversal. One approach is the modified 1-layer vasovasostomy and the other is a formal, 2-layer vasovasostomy.

Vasoepididymostomy

A vasoepididymostomy involves a connection of the vas deferens to the epididymis. This is necessary when there is no sperm present in the vas deferens.

Success Rates

Success rates: patency

With vasectomy reversal surgery, there are two typical measures of success: patency rate, or return of some moving sperm to the ejaculate after vasectomy reversal, and pregnancy rates. In a recently published report 95% of men with a vasovasostomy had motile sperm in the ejaculate within 1 year after vasectomy reversal. Interestingly, almost 80% of these men achieved sperm motility within 3 months of vasectomy reversal. The case for vasoepididymostomy is different. Fewer men will eventually achieve motile sperm counts and the time to achieve motile sperm counts is longer.

What has also been published is that:

- The age of the patient at the time of vasectomy reversal does not appear to matter. Using different age cut-offs, including <35, 36-45, and > 45 years old, no differences in patency rates were detected in a recent vasectomy reversal series.
- The patency rates after vasovasostomy appear equivalent when performed in the straight or convoluted segments of the vas deferens

Another issue to consider is the likelihood of vasoepididymostomy at the time of vasectomy reversal, as this technique is generally associated with lower patency and pregnancy rates than vasovasostomy. Web-based, computer models and calculations have been proposed and published that described the chance of needing an vasoepididymostomy at reversal surgery.

Success rates: pregnancy

The outcome of pregnancy rate after vasectomy reversal depends not only on the patency rate, but also on known or unknown female factor issues. Pregnancy rates range widely in published series, anywhere from 30-76%, and depend on many factors. Some of these include female age, female reproductive potential, female uterine and ovulatory issues. There are also male specific reasons for variations in pregnancy rates, including antisperm antibodies and epididymal dysfunction and other reasons listed below. However, in general, pregnancy rates with vasovasostomy are higher than those with vasoepididymostomy.

Failure and complications

Failure

The current measure of success in vasectomy reversal surgery is achievement of a pregnancy. There are several reasons why a vasectomy reversal may fail to achieve this:

1. A pregnancy involves two partners. Although the count and quality of sperm may be sufficiently high after vasectomy reversal surgery, female fertility factors may play an indirect role in pregnancy success. If the female partner's age is >35 years old, the couple should consider a female factor evaluation to determine if they have adequate reproductive potential before a vasectomy reversal is undertaken. This evaluation can be done by a gynecologist and should include a cycle day 3 FSH and estradiol levels, an assessment of menstrual cycle regularity, and a hysterosalpingogram to evaluate for fibroids.
2. Approximately 50%-80% of men who have had vasectomies develop a reaction against their own sperm (i.e., antisperm antibodies). High levels of these proteins directed against sperm may impair fertility, either by making it hard for sperm to swim to the egg or by interrupting the way the sperm must interact with the egg. Sperm-bound antibodies are usually assessed >6 months after the vasectomy

- reversal if no pregnancy has ensued. Treatment options include steroid treatment, intrauterine insemination (IUI) and in vitro fertilization (IVF) techniques.
3. Occasionally, scar tissue develops at the site where the vas deferens is reconnected, causing a blockage. Depending on the physician, this occurs in 5-10% of vasovasostomies and up to 35% of vasoepididymostomies. Depending on when it occurs, it may be treated with anti-inflammatory medication or could necessitate repeat vasectomy reversal surgery.
 4. If an epididymal blowout has occurred and is not discovered at the time of vasectomy reversal surgery, the vasectomy reversal will probably fail. In this case, a vasoepididymostomy would need to be performed.
 5. When the vas deferens has been blocked for a long time, the epididymis is adversely affected by elevated pressure. As sperm are nurtured to maturity within the normal epididymis, sperm counts may be sufficiently high to achieve a pregnancy, but sperm movement may be poor. Antioxidants, vitamins (A, C and E), or other supplements are recommended by some centers after vasectomy reversal for this reason. Some patients gradually recover from this epididymal dysfunction. Those patients whose sperm continue to have problems may require IVF to achieve a pregnancy.

Complications

In general, vasectomy reversal is a safe procedure and complication rates are low. There are small chances of infection or bleeding, the latter of which can result in a hematoma or blood clot in the scrotum that needs surgical drainage. If there is significant scar tissue encountered during the vasectomy reversal, fluid other than blood (seroma) can also accumulate in a small number of cases. Painful granulomas, caused by leaking sperm, can develop near the surgical site in some cases. Very rare complications include compartment syndrome or deep venous thrombosis from prolonged positioning, testis atrophy due to damaged blood supply, and reactions to anesthesia.

Choosing a surgeon

Beware of surgeons and websites that claim they are the best at vasectomy reversal, without offering real evidence that this is true. Also, beware of vasectomy reversal procedures that seem too inexpensive. A more important way to shop is to look for “value” in a procedure, as value incorporates “quality” with cost and is expressed as quality/cost. In fact, the issue of the quality of the vasectomy reversal is just as important as cost. However, it is also true that determining the quality of a vasectomy reversal surgeon is not easy to do. Some questions to consider asking the vasectomy reversal surgeon you are considering:

- Is an operating microscope used for the reversal procedure?
- Has the surgeon been formally trained in urologic microsurgery and vasectomy reversal?
- Does the surgeon quote personal success rates or that of others for the vasectomy reversals?

- Has the surgeon published their vasectomy reversal success rates?
- How does the surgeon define patency rate (“moving” sperm or “any” sperm) after vasectomy reversal?
- How many vasectomy reversal procedures does the surgeon perform annually?
- Is the surgeon comfortable with vasoepididymostomy or must they refer the patient to a more experienced surgeon for another if vasovasostomy is not applicable?
- Will they plan to bank sperm at the time of the vasectomy reversal procedure (which can save the patient from having another procedure to retrieve sperm if the reversal fails)?

Alternatives: assisted reproduction

Assisted reproduction uses “test tube baby” technology (also called in vitro fertilization, IVF) for the female partner along with sperm retrieval techniques for the male partner to help build a family. This technology, including intracytoplasmic sperm injection (ICSI), has been available since 1992 and became available as an alternative to vasectomy reversal soon after. This alternative should be discussed with couples during a consultation for vasectomy reversal.

Published research attempts to identify the issues that matter most as couples decide between IVF-ICSI and vasectomy reversal, two very different approaches to family building. This research has generally taken the form of cost-effectiveness or cost-benefit analyses and decision analyses and Markov modeling. Since it is difficult to perform randomized, blinded prospective trials on couples in this situation, analytic modeling can help uncover what variables affect outcomes the most. From this body of work, it has been observed that vasectomy reversal can be the most cost effective way to build a family if: (a) the female partner is reproductively healthy, and (b) the surgeon can achieve good vasectomy reversal outcomes. If the surgeon can achieve high “patency” rates (moving sperm in the ejaculate) after vasectomy reversal, then vasectomy reversal is competitive with IVF-ICSI. In the special instance of couples with advanced maternal age (defined as a female partner > 38 years old), case series’ have reported that pregnancy rates with vasectomy reversal are competitive with IVF-ICSI. When Markov modeling was applied to probe the issue of pregnancy rates after reversal surgery in more depth, the results revealed that female reproductive health is far more important than: (a) the age of the vasectomy, (b) the age of the man, or (c) the vasectomy reversal patency rate. Ultimately the decision to pursue a vasectomy reversal is a personal one for each couple.

Alternatives: how to choose

Sometimes it is not clear to couples who want children whether they should do a vasectomy reversal or pursue assisted reproduction. There are several questions for couples to ask themselves.

1. *How long ago was the vasectomy performed?* An older vasectomy, especially those more than 20–25 years, may make vasectomy reversal less likely to work.
2. *How many children do we want?* Sperm retrieval and IVF-ICSI may be a better fit for the couple who wants only one child, as it generally results in both fresh embryos and frozen embryos that can make conceiving one child very reasonable.
3. *Are we comfortable with dealing with birth control issues again?* Birth control may be required again after vasectomy reversal.
4. *How long are we willing to wait for a child?* The average time to pregnancy after vasectomy reversal ranges from 9–14 months.
5. *What will each approach cost us?* Most insurance companies do not cover the cost of vasectomy reversal. However, sometimes insurance companies cover the cost (partially or fully) for IVF-ICSI.
6. *Are we comfortable with assisted reproductive technology? Or, how do we feel about children conceived with the help of technology?*

Patient expectations

Every patient who is considering vasectomy reversal should undergo a screening visit before the procedure to learn as much as possible about his current fertility potential. At this visit, the patient can decide whether he is a good candidate for vasectomy reversal and assess if it is right for him. Issues to be discussed at this visit include:

- Female partner's history of past pregnancies
- Male's medical and surgical history
- Complications during or after the vasectomy
- Female partner's age, menstrual cycle and fertility
- Brief physical examination to assess male reproductive tract anatomy
- A review of the vasectomy reversal procedure, its nature, benefits and risks, and complications
- Alternatives to vasectomy reversal
- Freezing of sperm at the time of vasectomy reversal
- Questions about the surgery, the success rates, and recovery
- Analysis of hormones such as testosterone or FSH in selected cases to better determine whether sperm production is normal

Immediately before the procedure, the following information is important for patients:

- They should eat normally the night before the vasectomy reversal, but follow the directions that anesthesia recommends for the morning of the reversal. If no specific directions are given, all food and drink should be withheld after midnight and on the morning of the surgery.
- Stop taking aspirin, or any medications containing ibuprofen (Advil, Motrin, Aleve), at least 10 days prior to vasectomy reversal, as these medications have a side effect that can reduce platelet function and therefore lower blood clotting ability.
- Be prepared to be driven home or to a hotel after the vasectomy reversal

After the procedure, patients should perform the following tasks:

- Remove dressings from inside the athletic supporter in 48 hours; continue with the scrotal support for 1 week. Shower once the dressings are removed.
- Apply frequent ice packs (or frozen peas, any brand) to the scrotum the evening after the vasectomy reversal and the day after that for 24 hours to reduce swelling.
- Take prescribed pain medication as directed.
- Resume a normal, well-balanced diet upon returning home or to the hotel. Drink lots of fluids.
- Normal, non-vigorous activity can be restarted after 48 hours or when feeling better. Activities that cause discomfort should be stopped for the time being. Heavy activities such as jogging and weight lifting can be resumed in 2 to 4 weeks depending on the particular procedure.
- Refrain from sexual intercourse for 2 weeks to 4 weeks depending on the procedure and the surgeon's recommendations.
- The semen is checked for sperm at 4-6 weeks and monthly semen analyses are then obtained for about 4-6 months or until the semen quality stabilizes.
- You may experience discomfort after the vasectomy reversal. Symptoms that may not require a doctor's attention are: (a) light bruising and discoloration of the scrotal skin and base of penis. This will take one week to go away. b) limited scrotal swelling (a grapefruit is too large); (c) small amounts of thin, clear, pinkish fluid may drain from the incision for a few days after reversal surgery. Keep the area clean and dry and it will stop.
- If you received general anesthesia, a sore throat, nausea, constipation, and general "body ache" may occur. These problems should resolve within 48 hours.
- Consider calling a provider for the following issues: (a) wound infection as suggested by a fever, a warm, swollen, red and painful incision area, with pus draining from the site. Antibiotics are necessary to treat this. (b) scrotal hematoma as suggested by extreme discoloration (black and blue) of the skin and continuing scrotal enlargement from bleeding underneath. This can cause throbbing pain and a bulging of the wound. If the scrotum continues to hurt more and continues to enlarge after 72 hours, then it may need to be drained.

Chapter 22

Intersex Surgery

Intersex surgery is one of several terms referring to surgery performed to correct birth defects or early injuries of the genitalia, primarily for the purposes of making the appearance more normal and to reduce the likelihood of future problems. The recent history of intersex surgery has been characterized by controversy after publicized reports that surgery failed to achieve the desired outcomes in many cases. Timing of surgery (infancy, adolescence or adult age) has also been controversial.

Intersex surgery is a form of genital reconstructive surgery, which also includes surgery performed for the purpose of transforming normal adult genitalia of one sex to that of the other (discussed elsewhere as sex reassignment surgery).

Purposes of genital reconstructive surgery

The goals of surgery vary with the type of abnormality but usually include one or more of the following:

1. to improve the potential for fertility
2. to provide an outlet for menstruation
3. to prevent or reduce urinary tract infections or obstruction
4. to reduce risk of cancer in abnormal gonads.
5. to close open wounds or exposed internal organs
6. to improve urinary or fecal continence.
7. to alleviate parental distress over the atypical genital appearance.
8. to make the appearance more normal for the person's sex of rearing
9. to reduce effects of abnormal genitalia on psychosexual development and gender identity
10. to improve the potential for adult sexual relationships

Types of surgery

Genital reconstructive surgery can be divided into ***masculinizing surgical procedures*** intended to make the genitalia more like those of typical males, and ***feminizing surgical procedures*** intended to make the genitalia more like those of typical females.

- There are several techniques or approaches for each procedure.

- Some of the variations of procedure are needed for varying degrees of severity of the abnormalities.
- Some of the different techniques have been devised to reduce complications associated with earlier techniques.
- Techniques and procedure have evolved over the last 60 years. Some have been considered obsolete for decades.
- Some children need a combination of procedures.
 - For example, a severely undervirilized boy with a pseudovaginal perineoscrotal hypospadias may have midline urogenital closure, third degree hypospadias repair, chordee release and phalloplasty, and orchiopexy performed. A severely virilized girl with congenital adrenal hyperplasia (CAH) may undergo both a clitoral reduction and a vaginoplasty.

Masculinizing surgical procedures

Orchiopexy and hypospadias repair are the most common types of genital corrective surgery performed in infant boys, but most of these boys have no other abnormalities and are not considered to have an intersex condition. Undervirilized boys typically have at least one of these two procedures performed in addition to others described below.

Types of undervirilization and malformation for which some type of masculinizing surgery has been performed most often in the last 50 years are:

- the configuration of ambiguous genitalia referred to as pseudovaginal perineoscrotal hypospadias (PPSH)
 - the Reifenstein type of partial androgen insensitivity syndrome
 - gonadal dysgenesis disorders such as mixed gonadal dysgenesis and testicular dysgenesis
 - idiopathic (specific cause not determined)
- birth defects of male genitalia
 - bladder exstrophy and epispadias spectrum
 - chordee (simple or as part of undervirilization)
 - micropenis
 - concealed penis

The disorders above comprised over 90% of reported surgical series from North America and Europe. In a few parts of the world 5-alpha-reductase deficiency or defects of testosterone synthesis, or even rarer forms of intersex account for a significant portion of cases but these are rare in North America and Europe. Masculinizing surgery for completely virilized genetic females with CAH is even rarer.

Orchiopexy for repair of undescended testes (cryptorchidism) is the second most common surgery performed on infant male genitalia (after circumcision). The surgeon moves one or both testes, with blood vessels, from an abdominal or inguinal position to the scrotum. If the inguinal canal is open it must be closed to prevent hernia.

Potential problems: Maintaining the blood supply is the major challenge. If vessels cannot be stretched into the scrotum, or are separated and cannot be reconnected, a testis will die and atrophy.

Hypospadias repair is a relatively simple single procedure if the hypospadias is first or second degree (urethral opening on glans or shaft respectively) and the penis is otherwise normal. Repair of a third degree hypospadias (urethral opening on perineum or in urogenital opening) is more challenging, may be done in stages, and has a significant rate of complications and unsatisfactory outcomes. (Glassberg, 1999)

Potential problems: For severe hypospadias (3rd degree, on perineum) constructing a urethral tube the length of the phallus is not always successful, leaving an opening (a "fistula") proximal to the intended urethral opening. Sometimes a second operation is successful, but some boys and men have been left with chronic problems with fistulas, scarring and contractures that make urination or erections uncomfortable.

Urogenital closure describes closure of any midline opening at the base of the penis. In severe undervirilization a boy may have a "pseudovaginal pouch" or a single urogenital opening in the midline of the perineum.

Potential problems: The most complicated aspect of closure involves moving the urethra to the phallus if it is not already there (i.e., repairing a perineal hypospadias). Fistulas and scarring are the main risks.

Gonadectomy (also referred to as "orchietomy") refers to removal of the gonads. This is done in three circumstances. (1) If the gonads are dysgenetic testes or streak gonads and at least some of the boy's cells have a Y chromosome, the gonads or streaks must be removed because they are nonfunctional but have a relatively high risk of developing gonadoblastoma. (2) In rare instances when an XX child with completely virilizing congenital adrenal hyperplasia (Prader stage 5) is being raised as a male, the ovaries must be removed before puberty to prevent breast development and/or menstruation. (3) Gonadectomy would be needed for the equally rare instance of a child with true hermaphrodite virilized enough to raise as male: any ovary or ovotestis would need to be removed. (Manuel, 1976)

Potential problems: Gonadectomy involves little risk beyond that of any abdominal surgery.

Chordee release refers to cutting of ventral penile skin and connective tissue to free and straighten the penis. A mild chordee, manifest as a well-formed penis "bent" downward by subcutaneous connective tissue, may be an isolated birth defect easily repaired by releasing some of the inelastic connective tissue on the ventral side of the shaft. In a complete chordee the phallus is "tethered" downward to the perineum by skin. A more severe chordee is often accompanied by a hypospadias and sometimes by severe undervirilization: a perineal "pseudovaginal pouch" and bifid ("split") scrotum with an

undersized penis. This combination, referred to as pseudovaginal perineoscrotal hypospadias, is in the spectrum of ambiguous genitalia due to a number of conditions.

Potential problems: Scarring and contracture are occasional complications, but most unsatisfactory outcomes occur when a severe hypospadias needs to be repaired as well. Long-term complications can include fistulas between colon or upper rectum and skin or other cavities, or between urethra and perineum.

Cloacal repair is among the most complex of the surgeries described here. Bladder exstrophy or more severe cloacal exstrophy refers to a major birth defect involving inadequate closure and incomplete midline fusion of multiple pelvic and perineal organs as well as the front of the pelvis and lower abdominal wall. The penis and scrotum are often widely bifid (the two embryonic parts unjoined). The penis often cannot be salvaged, although the testes can be retained. Repair may involve closure of the bladder, closure of the anterior abdominal wall, colostomy (temporary or permanent) with reconstruction of the rectum. If the halves of the phallus cannot be joined, they may be removed. The smallest defect in this spectrum is an epispadias. Surgical repair for this is primarily a phalloplasty. (Schober, 2002)

Potential problems: Surgery for the more severe degrees of cloacal exstrophy is extensive and usually multistage. A variety of potential problems and complications can occur, including need for long-term colostomy or vesicostomy. In many cases a functional penis cannot be created. Scarring is often extensive and the lower torso severely disfigured even with fairly good outcomes.

Phalloplasty is a general term for any reconstruction of the penis itself, especially for more unusual types of injuries, deformities, or birth defects. The principal difficulty is that erectile tissue is not easily constructed and this limits the surgeon's ability to make more than minor size changes. Construction of a narrow tube lined with mucosa (a urethra) is a similar challenge.

Potential problems: Minor revisions of the skin are rarely followed by problems. More complicated reconstruction may result in scarring and contracture, which can distort the shape or curvature of the penis, or interfere with erections or make them painful.

Hysterectomy is removal of a uterus. It is rare that a uterus or mullerian duct derivatives would need to be removed from a child being raised as a boy. The most common scenario is accidental discovery of persistent mullerian derivatives or a small uterus during abdominal surgery of a normal boy for cryptorchidism, appendectomy, or bowel disease. Removal would not involve genital surgery. A rarer indication would be that of a completely virilized XX child with congenital adrenal hyperplasia (Prader stage 5) being raised as a male; ovaries and uterus must be removed to prevent breast development and menstruation by early adolescence.

Potential problems: Risks are simply those of abdominal surgery.

Testicular prostheses are saline-filled plastic ovoids implanted in the scrotum. They have no function except to provide the appearance and feel of testes. Several sizes are available, but most are implanted in adolescence to avoid repeated procedures to implant larger sizes at puberty. Prostheses made of silastic are no longer available due to safety and perception-of-safety concerns.

Potential problems: Foreign body reactions, rarely with infection or erosion of scrotal skin, are minimal but constitute the most significant complication.

Penile augmentation surgery is surgery intended to enlarge a small penis. Early attempts in the 1950s and 1960s involved constructing a tube of non-erectile flesh extending a small penis but the penis did not function. In recent years a small number of urologists have been offering an augmentation procedure that involves moving outward some of the buried components of the corpora so that the penis protrudes more. The girth is augmented with transplantation of the patient's fat. This procedure is designed to preserve erectile and sexual function without surgically altering the urethra. This type of surgery is not performed on children and primarily produces a small increase in the size of a normal penis, but would be less likely to produce a major functional change in a severe micropenis.

Potential problems: Reabsorption of the fat is common. Scarring resulting in interference with erectile function is less likely but more damaging.

Concealed penis is the term used to describe a normal penis buried in suprapubic fat. In most cases, when the fat is depressed with the fingers, the penis is seen to be of normal size. This is common in overweight boys before the penile growth of puberty. Surgical techniques have been devised to improve it. (Casale, 1999)

Potential problems: The most common difficulty is recurrence with further weight gain. Scarring can occur.

Feminizing surgical procedures

In the last 50 years, the following procedures were most commonly performed for the following intersex conditions and birth defects in order to make the genitalia more like those of normal females:

- virilization due to congenital adrenal hyperplasia
- malformations of genitalia in genetic females
 - urogenital sinus malformation
 - cloacal exstrophy
- conditions involving severe undervirilization or malformations of genetic males, or infants with mixed genetic sex, to be assigned and raised as girls
 - gonadal dysgenesis (various forms)
 - partial and complete androgen insensitivity syndrome
 - micropenis

- cloacal and bladder exstrophy

There are rarer causes of virilization of genetic females or undervirilization of genetic males, as well as some less easily categorized types of intersex conditions or other malformations of the genitalia. In the last decade, feminizing surgery to support reassignment of genetic males with non-ambiguous micropenis has been largely discontinued, and surgical reassignment of genetic males with exstrophy or other severe malformations or injuries is diminishing.

Clitorectomy describes amputation or removal of most of the clitoris, including glans, erectile tissue, and nerves. This procedure was the most common clitoral surgery performed prior to 1970, but was largely abandoned by 1980 because it usually resulted in loss of clitoral sensation.

Potential problems: The primary effect of this surgery, not surprisingly, is a drastic reduction in ability to experience orgasm. The appearance is not very normal. Regrowth of unwanted erectile tissue has sometimes presented problems.

Clitoroplasty, like phalloplasty, is a term that encompasses any surgical reconstruction of the clitoris, such as removal of the corpora. Clitoral recession and reduction can both be referred to as clitoroplasty.

Potential problems: Major complications can include scarring, contractures, loss of sensation, loss of capacity for orgasm, and unsatisfactory appearance.

Clitoral recession involves the repositioning of the erectile body and glans of the clitoris farther back under the symphysis pubis and/or skin of the preputium and mons. This was commonly done from the 1970s through the 1980s to reduce protrusion without sacrificing sensation. Outcomes were often unsatisfactory, and it fell into disfavor in the last 15 years. (Rangecroft, 2001)

Potential problems: Unfortunately the subsequent sensations were not always pleasant, and erection could be painful. Adults who had a clitoral recession in early childhood often report reduced capacity for enjoyment of sexual intercourse, though similar women who had not had surgery also report a high rate of sexual dysfunction. (Minto, 2003)

Clitoral reduction was developed in the 1980s to reduce size without reducing function. Lateral wedges of the erectile tissue of the clitoris are removed to reduce the size and protrusion. The neurovascular tissue is carefully spared to preserve function and sensation. Nerve stimulation and sensory responses are now often performed during the surgery to confirm function of the sensory nerves. (Chase, 1996; Rangecroft, 2001)

Potential problems: The degree to which the goal of preserving sexual sensations is attained is a subject of controversy. Many of the children who have had the newer versions of this procedure have not yet become adults.

Vaginoplasty, the construction or reconstruction of a vagina, can be fairly simple or quite complex, depending on the initial anatomy. If a normal internal uterus, cervix and upper vagina (the mullerian derivatives) exist, and the outer virilization is modest, surgery involves separating the fused labia and widening the vaginal introitus. With greater degrees of virilization, the major challenge of the procedure is to provide a passage connecting the outer vaginal opening to the cervix which will stay wide enough to allow coitus. XY girls or women with partial androgen insensitivity syndrome will have a blind vaginal pouch of varying degrees of depth. Sometimes this can be dilated to a usable depth. Sometimes surgery is performed to deepen it.

The most challenging surgery with the highest complication rate is construction of an entirely new vagina (a "neovagina"). The most common instance of this is when a child will be assigned and raised as a female despite complete virilization, as with Prader 5 CAH, or (in the past) when a genetic male infant with a severely defective penis was reassigned as a female. One method is to use a segment of colon, which provides a lubricated mucosal surface as a substitute for the vaginal mucosa. Another is to line the new vagina with a skin graft. (Creighton, 2001; Rink, 1998; Schnitzer, 2001)

Potential problems: Stenosis (narrowing) of the constructed vagina is the most common long-term complication and the chief reason that a revision may be required when a girl is older. When a neovagina is made from a segment of bowel, it tends to leak mucus; when made with a skin graft, lubrication is necessary. Less common complications include fistulas, uncomfortable scarring, and problems with urinary continence. (Alizai, 1999; Lobe, 1987; Minto, 2003)

Gonadectomy refers to removal of the gonads. If the gonads are dysgenetic testes or streak gonads and at least some of the cells have a Y chromosome, the gonads or streaks must be removed because they are nonfunctional but have a relatively high risk of developing gonadoblastoma. If the gonads are relatively "normal" testes, but the child is to be assigned and raised as female, (e.g., for intersex conditions with severe undervirilization, or major malformations involving an absent or unsalvageable penis) they must be removed before puberty to prevent virilization from rising testosterone. Testes in androgen insensitivity are a special case: if there is any degree of responsiveness to testosterone, they should be removed before puberty. On the other hand, if androgen insensitivity is complete, the testes may be left to produce estradiol (via testosterone) to induce breast development, but there is a slowly increasing risk of cancer in adult life. Streak gonads without a Y chromosome cell line need not be removed but will not function. Finally, the gonads in true hermaphroditism must be directly examined; abnormal gonads with Y line or potential testicular function should be removed but in rare instances a surgeon may try to preserve the ovarian part of an ovotestis. (Manuel, 1976)

Potential problems: Gonadectomy involves little risk beyond that of any abdominal surgery.

Cloacal exstrophy and bladder exstrophy repair is needed regardless of the sex of assignment or rearing. Simple bladder exstrophy in a genetic female does not usually involve the vagina. Cloacal exstrophy in a genetic female usually requires major surgical reconstruction of the entire perineum, including bladder, clitoris, symphysis pubis, and both the vaginal introitus and urethra. However, the uterus and ovaries are normally formed. Severe bladder exstrophy or cloacal exstrophy in genetic males often renders the phallus widely split, small, and unsalvageable. The scrotum is also widely split, though testes themselves are usually normal. From the 1960s until the last decade, many of these infants were assigned and raised as females, with fashioning of a vagina and gonadectomy as part of the perineal reconstruction. (Schober, 2002)

Potential problems: Surgery for the more severe degrees of cloacal exstrophy is extensive and usually multistage. A variety of potential problems and complications can occur, including need for long-term colostomy or vesicostomy. Creating a functional urethra is difficult and poor healing, with scarring, stricture, or fistula can require a vesicostomy to prevent urinary incontinence. Construction of a functional anal sphincter can be equally difficult when this has been disrupted as well. Functional problems can warrant a temporary or long-term colostomy. The added challenge for the most severely affected genetic females, and for genetic males who are being raised as females, is construction of a neovagina. Scarring is extensive and the lower torso disfigured even with the best outcomes. Finally, it has become apparent in recent years that some genetic males (without intersex conditions) who are reassigned and raised as females have not developed a female gender identity and have sought reassignment back to male. (Reiner, 2004)

Controversies and unsettled questions

Management practices for several types of intersex conditions and other abnormalities and injuries of the genitalia have evolved over the last 50 years. In the last decade several of the surgical practices have become the subject of public and professional controversy.

Is functional outcome better when surgery is performed in infancy, in adolescence, or adulthood, for vaginoplasty for markedly virilized females (e.g., from congenital adrenal hyperplasia, mixed gonadal dysgenesis, or partial androgen insensitivity)?

- Argued or putative advantages of infant surgery
 - Tissue is more elastic and heals better according to many surgeons.
 - Genital surgery performed before the age of memory is less emotionally traumatic.
 - Surgery in infancy avoids asking adolescent to make a decision that is stressful and difficult even for adults.
 - Assuming infant surgery is successful, there is no barrier to engaging in normal sexual activities, and less distortion of psychosexual identity.
- Argued or putative advantages of surgery in adolescence or later
 - If outcome is less than satisfactory, early surgery leaves a person wondering if she would have been better off without it.

- Any surgery not absolutely necessary for physical health should be postponed until the person is old enough to give informed consent; parents should not be empowered to make medical decisions for their children.
- Genital surgery should be handled differently than other birth defect surgery; this is the one type of surgery that parents should not be empowered to make decisions about because they will be under social pressure to make "bad" decisions.
- By mid-adolescence or later, a woman may decide that her abnormal genitalia do not need to be changed.
- Infant vaginoplasties should not be done because most women who have had them performed report some degree of difficulty with sexual function; even though we have no evidence that adult sexual function will be better if surgery is deferred, the outcomes couldn't be worse than they currently are after infant surgery.

Do any advantages of infant clitoral reduction surgery outweigh the potential disadvantages of reduced or distorted sexual sensation? Clitoral reduction is rarely done except in combination with vaginoplasty when substantial virilization is present.

- How much weight should be given to the cosmetic argument that there is value in making it more normal looking?

Should parents have the same ethical and legal right to consent on behalf of their child to genital surgery as to consent to other reconstructive surgery (e.g., cleft lip repair or birth mark removal) for largely psychosocial purposes?

- The high court in Colombia has ruled no, and some advocacy groups in the US and elsewhere agree (, comparing this type of surgery to genital mutilation(intactivism).

How can we minimize gender identity problems? Is it valid to assume in cases of ambiguous genitalia that the magnitude of the "innate" tendency to develop a specific gender identity is usually similar to the degree of genital virilization? Should we abandon completely the idea that an unambiguous XY child with an irreparably defective penis might be better off raised as a girl?

- Medical professionals have traditionally considered the worst outcomes after genital reconstruction in infancy to occur when the person develops a gender identity discordant with the sex assigned as an infant. Most of the cases in which a child or adult has voluntarily changed sex and rejected sex of assignment and rearing have occurred in partially or completely virilized genetic males who were reassigned and raised as females. This is the management practice that has been most thoroughly undermined in the last decade, as a result of a small number of spontaneous self-reassignments back to male in a number of genetic males who had been raised as female because of birth defects of the penis which did not involve undervirilization (e.g., exstrophy or traumatic loss).

- Reducing the likelihood of a gender "mismatch" is also a claimed advantage of deferring reconstructive surgery until the patient is old enough to assess gender identity with confidence.
- However, support groups tend to identify intense feelings of shame and betrayal as the worst outcomes of a philosophy of management that focuses on normalizing the child's anatomy. Many individuals who have developed a discordant gender identity and rejected the sex assigned during infancy have done quite well after transition (Reiner 2004, Consortium 2006,). Gender identity may not be the most important variable to consider in caring for children with intersex conditions.

Within the last decade, some people have raised the question of whether surgery to correct abnormal genitalia should be done at all, especially for purposes of changing appearance. Opponents of all "corrective surgery" on abnormal genitalia suggest we should be attempting to change social opinion regarding the desirability of having genitalia that look more average, rather than performing surgery to try to make them more like other peoples'.

Historical background, supporting arguments, and changing practice standards are treated in more detail in History of intersex surgery, and in some of the following references (Creighton, 2001).